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Abstract 
Rhinoviruses (RV) cause the common cold and are major precipitants of asthma 
exacerbations. The underlying mechanisms of RV-induced airways disease are unclear. IL-15 
is a proinflammatory cytokine produced during viral infections and plays a key role in the 
regulation of NK cells. Using mouse models of RV infection and RV-induced asthma 
exacerbation we examined the role of IL-15 and its importance for NK cell responses during 
RV infections in allergic and non-allergic airways. We demonstrate RV-induced IL-15 
upregulation in the airway and lungs of BALB/c mice at day 1 after infection and 
accumulation of NK cells in the airway and lungs at days 1-2 and 2-4 respectively. The NK 
cells exhibited an activated phenotype characterised by upregulated CD69, IFN-γ and 
GranzymeB expression. Blocking IL-15 upon intranasal administration of an IL-15 neutralising 
antibody inhibited the NK cell response to RV infection, which was associated with deficient 
IFN-γ production and increased expression of Th2 mediators. IL-15Rα knockout mice lack NK 
cells and also demonstrated deficient IFN-γ and increased Th2 responses to RV infection; 
these mice also exhibited deficient CD8+ T cell responses and an increased viral load. Similar 
results were observed in RV infected IFNAR1 ko mice, which was associated with deficient IL-
15 upregulation. We suggest that RV-induced IL-15 is mediated by type I interferon signalling, 
and is necessary for NK cell responses and early IFN-γ production during RV-1B infection, 
which drives development of appropriate Th1 antiviral responses. In the absence of this 
pathway, Th2 responses result and are associated with impaired antiviral immunity. To 
examine the interaction between allergen driven Th2 immunity and RV infection, we 
employed a RV-induced asthma exacerbation model. Unexpectedly, RV infected allergen 
challenged mice, despite having increased viral load, demonstrated increased IL-15 
expression and NK cell responses, revealing a novel interaction between allergic responses 
and antiviral immunity.   
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RANTES Regulated upon activation, normal T cell expressed, and 
secreted/CCL5 
RIG-1 Retinoic acid inducible gene-1 
RNA   Ribonucleic acid 
RNaseL   Endoribonuclease L 
RPMI   Roswell Park Memorial Institute 
RSV   Respiratory syncytial virus 
RT-PCR   Reverse transcription polymerase chain reaction 
RV   Rhinovirus 
SEM   Standard error of the mean 
Ss   Single stranded 
TARC   Thymus and activated-regulated chemokines /CCL17 
Tc1/2   Cytotoxic T lymphocyte type 1/2 
T cell   T lymphocyte 
TCID50   Tissue culture infective dose 
Th1/2   T helper lymphocyte type 1/2 
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TLR   Toll like receptor 
TMB   Tetramethyl benzidine chromogen 
TNF   Tumour necrosis factor 
TSLP   Thymic stromal lymphopoietin 
UV   Ultraviolet 
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1. Chapter 1: Introduction 
1.1. Human Rhinoviruses 
1.1.1. Epidemiology 
Human rhinoviruses (RVs) are the most frequent cause of the common cold and were first 
isolated and cultured in 1953 from nasal secretions [1]. Viral respiratory tract infections are 
amongst the most frequent illnesses in humans, and epidemiological studies conducted in 
the 1960s found RVs to be the causative agent of >60% of all upper respiratory tract 
infections with cold symptoms [1, 2]. Other aetiological agents of the common cold include 
respiratory syncytial virus (RSV), influenza viruses A and B, parainfluenza viruses, coronavirus, 
adenovirus, Chlamydophila pneumoniae and Streptococcus pneumoniae [3]. 
 
In the 1990s, reverse transcriptase PCR (PCR) greatly improved diagnosis and detection of 
RVs, due to increased sensitivity and specificity in comparison to cell culture techniques 
previously used, demonstrating higher detection rates than earlier epidemiological studies. 
Transmission of RVs occurs primarily via contaminated surfaces and inhalation of aerosolized 
particles [4, 5]. On average, it has been observed that adults are infected with RVs 2-3 times 
per year, and 6-12 times per year in pre-school aged children [6, 7]. Additionally, the rate of 
symptomatic infection is seen to decrease with age, possibly attributed to development of 
immune memory and production of protective serum neutralising antibodies [8], though this 
may be an artefact of observing higher transmission rates in children [9]. RV infections occur 
all year round; in temperate climates the frequency peaks during early autumn and spring, 
during which RV infections are the dominant respiratory infection [8]. The peak in tropical 
areas coincides with the start of the rainy season [10].   
 
More significant to the medical and economic burden caused by RV infections is the 
discovery of its contribution to development of asthma exacerbations in the late 1990s. RV 
infections in infants have been linked with development of an asthmatic phenotype. These 
inflictions are estimated to result in ~30 billion US dollars per year in health care costs and 
lost productivity [11].  
 
1.1.2. Classification 
RVs belong to the Picornaviridae family, literally translated as ‘small RNA viruses’, and are 
classified within the genus of enteroviruses. Initially, species definition was based on partial 
genome sequence analysis (of genes VP2 and VP4) that identified two species – A and B, and 
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sequence analysis of recent RV isolates have detected a third species – C. In 2009, 
Palmenberg et al. [12] completed sequencing of all classical RV genomes, greatly improving 
characterisation of HRV-A, HRV-B and the recently identified HRV-C species. Within species A 
and B, ~100 serotypes have been identified, which fall into 2 categories based on the 
receptor used for host cell entry: ‘minor group’ RVs (~10%) utilise the low-density 
lipoprotein receptor (LDL-R) and ‘major group’ RVs (~90%) bind the intracellular adhesion 
molecule 1 (ICAM-1) [13-15].  
 
1.1.3. Structure & Life Cycle 
RVs are small, ~20-30nm in size, non-enveloped viruses. The capsid entails an icosahedral 
shell of 60 protomers, consisting of 4 capsid proteins VP1-VP4 that are organised such that a 
deep canyon exists within the protomer [16]. X-ray crystallographic analyses have identified 
these canyons as ICAM-1 binding sites for virus attachment and entry of host cells [17, 18]. 
The shell encapsidates an ~7kb single stranded RNA genome containing a single open 
reading frame, which yields 4 structural capsid proteins and 7 non-structural proteins [19]. 
Functions of some non-structural proteins remain to be fully elucidated, but are suggested 
to interfere with host cellular functions including transcription and translation [20].  
 
Upon receptor binding, RV is internalised via receptor-mediated endocytosis and uncoating 
occurs in the endosome allowing transfer of viral RNA into the cytoplasm. The positive-sense 
genomic RNA is immediately translated to produce a polypeptide that is cleaved by viral 
proteases 2A and 2C (included in the polypeptide), generating VP1-4, an RNA dependant 
RNA polymerase and a small viral protein (Vpg) – the later 2 proteins act to replicate the 
RNA genome [2]. Progeny genomes are encapsulated by the structural proteins, and the 
mature virions are released by cell lysis. The growth cycle of RVs is 5-7 hours, and released 
progeny virions are detectable by 12h post-infection (p.i.) after experimental inoculation in 
humans [21]; virus titres peak at days 2-3 p.i. and virus shedding continues until total 
elimination, which can take up to 3 weeks p.i. in otherwise healthy individuals [22-25]. 
 
1.1.4. Disease Pathogenesis & Clinical Features 
RVs primarily infect epithelial cells of the upper respiratory tract, specifically the nasal 
mucosa and nasopharynx. Unlike other respiratory viruses, clinical symptoms are primarily 
caused by the hosts’ inflammatory immune response to RV infection rather than viral 
cytopathicity, and thus minimal damage to the mucosal epithelial lining occurs. Symptoms 
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include cough, sore throat, sinusitis, rhinorrhea and headaches in otherwise healthy 
individuals, and some of these traits are attributed to nasal secretion of bradykinins [26]. 
Symptom scores tend to reflect virus titres and can arise 10-12h after inoculation in 
experimental infections,  though usually develop 1-2 days p.i., peak between days 2-3 and 
resolve in days 7-10 [21, 27, 28].  
 
Peak symptom scores are associated with peak nasal virus shedding in addition to peak nasal 
neutrophilia, of which the later is a hallmark cellular feature of RV infections. Nasal epithelial 
oedema and mucus hypersecretion also result from viral replication in epithelial cells [29]; 
alongside production of interferons and proinflammatory cytokines and chemokines, 
including IL-1, IL-6, IL-8/CXCL8, IL-10, MIP-1α/CCL3, RANTES/CCL5 and TNF-α, favouring a 
Th1 cytokine profile in otherwise healthy individuals, which limits virus shedding and 
symptoms [30]. Additionally, early studies demonstrated a 4-fold rise in neutralising 
antibody levels after RV infection [31-33].  
 
RV mediated common colds are generally acute infections of the upper respiratory tract 
however, children, the elderly and immunocompromised patients can exhibit severe lower 
respiratory tract infections [34-36]. In asthmatics, RVs have been detected in the lower 
airways, which was associated with exacerbations and more severe and persistent infections 
[37]. RVs are also associated with exacerbations of other chronic airways diseases including 
COPD and cystic fibrosis, accounting for nearly 50% of COPD exacerbations [38, 39]. Other 
more serious diseases mediated by RVs include bronchiolitis and pneumonia. The effect of 
RV infections on the aforementioned diseases highlights the importance of research in the 
immune responses to RV infections and in models of asthma and COPD in particular. 
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1.1.5. Therapies 
Inactivated RVs were used for vaccine development in the 1990s, which conferred some 
immunity to re-infection with the same serotype [40, 41]. However, neutralising antibodies 
produced were found to have limited cross-reactivity, and so vaccine development against 
the 100+ RV serotypes became less hopeful [41]. Efforts shifted towards antiviral 
compounds targeting specific virus functions such as capsid binding agents (pleconaril and 
pirodavir), receptor blockade (soluble ICAM-1), 3C protease inhibitors (Rupintrivir) and 
interferon-α (summarised in Table 1.1) [42]. However, RV-specific antiviral treatment or 
prophylactic drugs are not yet available therefore, treatment of symptoms is the most 
common route, such as use of topical anaesthetics, nasal decongestants, analgesics and 
antitussives. 
 
 
 
Table 1.1 A selection of rhinovirus antiviral therapies. 
(P – prophylactic, T – treatment, i.n. – intranasal). 
 
 
  
Antiviral Agent Mechanism of 
Action 
Route of 
Delivery 
Effect on 
Virus 
Effect on 
Symptoms 
Reference 
Interferon-α 2b Cell 
susceptibility 
 
i.n. (P) 
Reduced 
infection rates 
- [43] 
Pleconaril Capsid binding 
(Prevents viral 
attachment/ 
uncoating) 
 
Oral (T) 
 
Reduced virus 
shedding 
Reduced nasal 
mucus production 
& total symptom 
time 
 
[44] 
Pirodavir Capsid binding 
(Prevents viral 
attachment/ 
uncoating) 
 
i.n. (P) 
 
Reduced virus 
shedding 
No effect on 
resolution of 
symptoms or 
duration of illness 
[45] 
Tremacamra 
(soluble ICAM-1) 
Receptor 
blocking 
i.n. (P & T) - Reduced illness 
severity 
[40] 
Rupintrivir Viral protease 
inhibitor 
i.n. (P & T) Reduced virus 
load 
Reduced illness 
severity 
[44, 46] 
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1.2. Asthma 
1.2.1. Epidemiology 
It is estimated that approximately 300 million people of all ages worldwide suffer from 
asthma, making it one of the most prevalent chronic diseases in the world that significantly 
contributes to morbidity, mortality and health care costs [47]. In the past few decades, the 
prevalence of asthma has dramatically increased in Westernised countries. Western Europe, 
North America and Australasia have the highest rates of asthma [47, 48], with approximately 
10-33% of children and 5-10% of adults afflicted [49]. In less developed countries, asthma 
prevalence is rising and is associated with urbanisation and adoption of Western lifestyles 
[47]. With the projected increase in percentage of the worlds urbanised population, the 
number of asthmatics is expected to rise accordingly, with an estimated additional 100 
million persons afflicted with asthma by 2025. In the UK alone, approximately 5.4 million 
people are currently being treated for asthma (Asthma, UK), one of the highest prevalence 
rates reported worldwide [47]. Of this figure, 1.1 million are children, also depicted as 1 in 
11 children in the UK, thus marking it as the most prevalent chronic disease of children in 
the UK [50].  
 
The economic burden of asthma is staggering, comprised of hospital admission, 
pharmaceutical and indirect medical costs. In the UK, treatment of asthma costs the NHS 
around £1 billion per year, and in 2008-2009 there were over 79,794 emergency hospital 
admissions, of which 30,740 were attributed to children under age 14 years [50]. Further 
indirect costs result from missed work days, which were estimated at 1.1 million working 
days in 2008-2009 [50]. 
 
1.2.2. Definition & Diagnosis 
The word ‘asthma’ itself originally arose from the Greek meaning ‘short of breath’. Asthma is 
a complex and heterogeneous disease that is characterised by chronic inflammation of the 
respiratory system, during which airway obstruction is variable and reversible and occurs 
spontaneously or in response to environmental stimuli [51]. The pathophysiology of asthma 
results from airway oedema, mucus hypersecretion, cellular infiltration, airway 
hyperreactivity (AHR) and airway remodelling [48].   
 
Airway obstruction is caused by constriction of airway smooth-muscle and inflammation in 
the bronchi, resulting in recurrent wheezing, shortness of breath (dyspnea) and chest 
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tightness, all of which are diagnostic features of asthma [48]. Diagnosis is further defined by 
lung function tests to assess airflow obstruction by measuring parameters such as forced 
expiratory volume in one second (FEV1), peak expiratory flow (PEF) and forced vital capacity 
(FVC) [52]. Additionally, reversibility of airways obstruction following use of an inhaled short 
acting bronchodilators or oral corticosteroids also supports diagnosis [52]. Furthermore, 
AHR is a hallmark feature of asthma and is measured based on reduction of the 
concentration of bronchoconstrictors methacholine or histamine required to reduce airflow 
by 20% (PC20) [52]. Asthma is often associated with atopy – individuals genetically 
predisposed, thereby contributing to disease expression and severity – thus, a familial 
history of atopy can be an additional diagnostic factor. 
 
1.2.3. Classification  
The Global Initiative for Asthma (GINA) classifies asthmatic patients into four groups – 
intermittent, mild persistent, moderate persistent and severe persistent –   
depending on the frequency and severity of symptoms in addition to respiratory function 
parameters discussed above [53]. Asthma can be further classified by many different 
phenotypes such as childhood or adult onset asthma, allergic asthma, atopic (extrinsic 
asthma – associated with more than 100 susceptibility genes) or non-atopic (intrinsic asthma 
– an uncommon form that is often more severe), steroid resistant asthma and asthma 
induced by exposure to aspirin, exercise, air pollution or cigarette smoke to name a few [54, 
55]. Different phenotypes can coexist and also act in synergy in patients, affecting responses 
to treatment and prognoses. 
 
1.2.4. Immunology  
The chronic airway inflammation resulting in airway obstruction that defines asthma is 
mediated by numerous immunological pathways involving different inflammatory cells and 
mediators. The majority of research into the mechanisms of asthma has focused on allergic 
asthma, which represents the most common form of asthma. Many observations have been 
acquired from studies assessing the early and late responses to allergen challenge in atopic 
asthmatics, in addition to mouse studies of allergic airways inflammation.  
 
Histological analysis of bronchial biopsies from asthmatic subjects demonstrates infiltration 
of eosinophils, activated mast cells on the mucosal surface of the airway and activated T 
cells. Structural changes that represent airway remodelling include collagen deposition and 
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thus thickening of the basement membrane under the epithelium, hyperplasia and 
hypertrophy of the smooth muscle layer and hyperplasia of mucus-secreting goblet cells [56]. 
Furthermore, epithelial cells in the airway of asthmatics are more easily shed from the 
basement membrane compared to non-asthmatics, and an increased number of blood 
vessels is observed in asthmatic bronchial biopsies [57].  
 
Activated mast cells play a key role in bronchoconstriction through the release of 
inflammatory mediators including histamine, the lipid leukotrienes C4, D4, E4 and 
prostaglandin D2. Environmental triggers such as allergens can activate mast cells, via 
crosslinking of FcεR1 on their surface after binding to IgE-allergen complexes, resulting in 
synthesis and release of mediators such as the above, that account for the variable 
bronchoconstriction observed in asthmatics [51]. Mast cells also secrete cytokines IL-4, IL-5 
and IL-13 which further potentiates allergic airways inflammation [58]. AHR has been 
associated with the presence of mast cells in the airway smooth muscle of asthmatics [59].  
 
Eosinophil infiltration of asthmatic airways is promoted by secretion of chemokines such as 
Eotaxin-1 by airway epithelial cells. In addition to airway infiltration, they contribute to 
inflammation by release of granule proteins including eosinophil cationic protein, eosinophil 
peroxidase and major basic protein, which are toxic to a number of cells in the airway [60]. 
However, their role in AHR is unclear as administration of IL-5 blocking antibody significantly 
reduced blood and sputum eosinophils, but no effect on AHR or asthma symptoms were 
detected [61]. Airway neutrophilia is not normally seen in patients with mild asthma 
however, neutrophils can be detected in individuals with severe asthma, which may be 
mediated by IL-17 secretion [62].  
 
T cells play a central role in allergic airways inflammation in asthma. Increased numbers of 
CD4+ T cells, specifically T helper 2 (Th2) cells, are found in the airways of asthmatics [63]. 
DCs are key regulators of Th2 cells, particularly in allergic asthma, as they act not just at the 
sensitization phase, but also drive inflammatory responses during allergen exposure via 
presenting processed allergen peptides and stimulating Th2 cells [64]. In asthmatic airways, 
Th2 cells secrete cytokines IL-4 and IL-13, which mediate isotype class switching in B cells to 
produce allergen specific IgE. The binding of allergen-IgE complexes to Fc receptors, FcεRI 
and FcεRII, on mast cells, basophils and other inflammatory cells results in their activation, 
further driving allergic inflammation [65]. IL-5 secreted by Th2 cells supports eosinophil 
differentiation and thus promotes increased eosinophil numbers in asthma [66], and IL-9 
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promotes differentiation and recruitment of mast cells to the airway [67]. All of the above 
discussed mechanisms can contribute to the immunopathology of asthma however, the 
contribution of specific pathways depends on the particular asthma phenotype(s). The role 
and magnitude of each immunological response varies between patients and is associated 
with the severity of disease.  
 
Epithelial cells lining the airways are the site of RV infection and allergen exposure, and play 
a central role in the pathogenesis of asthma via secretion of chemokines and cytokines that 
potentiate inflammatory responses. IL-33 is secreted by asthmatic epithelial cells and 
promotes differentiation and chemotaxis of Th2 cells, via binding the ST2 receptor 
specifically expressed on these cells [68]. Thymic stromal lymphopoietin (TSLP) is secreted 
by both asthmatic epithelial cells and mast cells, and induces secretion of the chemokines 
TARC/CCL17 and MDC/CCL22 that also promote recruitment of Th2 cells, via binding CCR4 
also specifically expressed on Th2 cells [69].  
 
Epithelial-derived IL-25 has been shown to significantly drive the pathogenesis of asthma via 
activation of IL-25R+ lymphoid cells, which in turn significantly enhance Th2-mediated 
inflammatory responses. Nuocytes, also termed innate helper cells or innate helper type 2 
cells, are CD25R+ lineage-negative lymphoid cells [70]. In response to IL-25 and IL-33, 
nuocytes are thought to be principal producers of IL-4, IL-5 and IL-13 which promote the 
deleterious Th2 responses in asthmatic lungs. Thus, it is now emerging that nuocytes are a 
central effector cell type in asthma [71]. Figure 1.1 summarises the cellular and humoural 
immune pathways in asthma. 
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Figure 1.1 Functions of inflammatory mediators and immune cells in asthma. 
(Diagram taken from Barnes, 2008, Nat Rev Immunol [51]). 
 
1.2.5. Therapy 
Currently, no cure for asthma exists and treatment acts to achieve better long-term control 
of asthma. Therapy administered depends on the severity of asthma and is classified based 
on short-term quick relief or long-term control. For treatment of mild asthma, occasional 
use of quick acting bronchodilators e.g. short-acting β-adrenergic agonists (SABA) are 
sufficient to rapidly reverse airflow obstruction [48]. For persistent asthma, better long-term 
control is achieved by inhaled corticosteroids (ICS) that act to suppress airway inflammation 
and is the mainstay for asthma therapy; benefits include fewer symptoms, fewer 
exacerbations and increased lung function and overall quality of life [48]. Airway biopsy 
specimens from patients treated by ICS for a long term demonstrate fewer mast cells, 
eosinophils, T cells and DCs in the mucosa and submucosa of the airway and reduced 
vascularity, goblet cell hyperplasia and destruction of the epithelium [72, 73]. Long-acting β-
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agonists can be used in combination with ICS to target bronchoconstriction and airway 
inflammation in patients with severe persistent asthma [48]. Other drugs to control mild-
persistent asthma include leukotriene-receptor antagonists that block the effects of 
leukotrienes at the type I cysteinyl leukotriene receptor [74]; in addition to bronchodilation, 
blood eosinophil levels decreases in response to this treatment [75]. Furthermore, a novel 
therapy using an anti-IgE blocking monoclonal antibody (omalizumab) significantly reduces 
circulating IgE and consequentially results in the downregulation of FcεR1 on 
immunomodulatory cells thus, reducing activation of mast cells and basophils that mediate 
allergic inflammation in the airway [76].  
 
 
1.3. Asthma Exacerbations 
1.3.1. Introduction 
In asthma, acute exacerbations can be triggered by a number of stimuli including respiratory 
virus infections, allergens, cold/humid air and/or exercise to name a few. During 
exacerbations the intensity of airway inflammation increases and can lead to life-threatening 
narrowing and even closure of the airways. Respiratory virus infections including RVs, RSV 
and influenza are the main precipitants of severe exacerbations, accounting for 80-85% of 
exacerbations in school age children [77], with RV infections being the major culprit 
accounting for ~50% and 80% of exacerbations in children and adults respectively [78-80]. 
Exacerbations contribute significantly to morbidity and medical expenditure in asthma. 
Additionally, death rates from asthma are higher in winter coinciding with the rise of 
respiratory virus infections [81]. Despite use of prophylactic and symptom relieving 
medications, asthma mortality rates remain high, indicating the need for development of 
new therapies to target specific pathogenic cellular and molecular mechanisms involved in 
virus-induced exacerbations. 
 
The immunopathogenesis of acute exacerbations is different to steady state asthma, 
demonstrated by increased airway inflammation, particularly of the lower airway, including 
increased cellular infiltration with changes in its composition e.g. more eosinophils, 
neutrophils and activated T cells, higher concentration of inflammatory mediators, increased 
mucus production resulting in mucus plugging of the airway and enhanced AHR [81]. The 
inflammatory profile differs depending on the specific stimulus of exacerbation e.g. allergen 
vs virus.  
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There are currently few treatment options for acute asthma exacerbations and their efficacy 
is limited, thus prevention is the main principle employed for asthma exacerbation therapy. 
Treatment options include inhaled bronchodilators and systemic/oral steroids, though these 
are only partially effective and have significant side effects [77]. The dose of inhaled 
glucocorticoids that induces maximum benefit in persistent asthma only reduces the 
frequency of severe exacerbations by 40% [82] and the same dose does not reduce 
exacerbation frequency in school aged children [83]. These striking statistics illustrate the 
urgent need for further research into the pathways of virus-induced asthma exacerbations, 
as drugs used for treatment of stable asthma are largely ineffective for treatment of 
exacerbations, suggesting that different pathogenic mechanisms are at play.  
 
1.3.2. Interaction Between Infection & Allergic Asthma 
Numerous studies have identified an interaction between virus and allergen exposure and 
increased risk of enhanced airway inflammation and pathogenesis of virus-induced asthma 
exacerbations in individuals with pre-existing allergic sensitisation [84-88]. Children with 
increased nasal eosinophilia and serum IgE demonstrated increased risk of wheezing during 
colds [89] and, experimental RV infection studies in humans showed enhanced inflammation 
and physiological effects in those with allergic sensitisation characterised by higher IgE levels 
[27, 87, 88, 90]. The largest increases in asthma-related hospital admissions were seen with 
virus infected allergen-sensitized asthmatic subjects that were concomitantly exposed to 
allergen [84]. Allergens predominantly stimulate Th2 cells that secrete IL-5, resulting in 
eosinophil mediated allergic airways inflammation however, virus infection induces IL-
8/CXCL8 secretion by epithelial cells and macrophages promoting neutrophil recruitment. It 
is possible that the interaction between allergen and virus challenge could significantly 
enhance airway inflammation contributing to development of exacerbations.  
 
1.3.3. Mechanisms of RV-Induced Asthma Exacerbations 
The association between RV infection and asthma exacerbations poses the question of how 
these viruses induce or potentiate acute exacerbations, and why asthmatics are more 
predisposed to the effects of respiratory infection. The mechanisms resulting in an 
exaggerated response during exacerbations are not fully understood, but a number of 
pathways have been identified through in vitro work using bronchial epithelial cells (BECs) 
and both mouse and human experimental RV infection studies. Human studies provide 
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extremely valuable opportunities to investigate the roles of RV in induction of asthma 
exacerbations.  
1.3.3.1. RV-Modulated Epithelial ICAM-1 Expression 
Major group RVs utilise ICAM-1 on epithelial cells for attachment and entry. RV infection has 
been shown to upregulate ICAM-1 expression in BECs in vivo and in vitro, with enhanced 
expression observed in asthmatic compared to non-asthmatic  BECs [91, 92]. This effect 
could potentially contribute to exacerbations via promoting increased adherence and 
recruitment of polymorphonuclear cells and lymphocytes, thereby intensifying cellular 
inflammation and promoting virus spread [81].  
 
1.3.3.2. RV-Induced Epithelial Expression of Proinflammatory Mediators 
Epithelial cells are the primary site of RV infection and replication in the airway, and play an 
important role in the innate and adaptive immune responses to infection. RV infection of 
BECs in vitro results in secretion of a range of proinflammatory cytokines and chemokines 
including IL-1, IL-6, IL-8/CXCL8, GM-CSF, RANTES/CCL5 and IP-10/CXCL10 [25, 37, 93]. 
Expression of these mediators have been confirmed by analyses of human clinical samples 
(BAL, nasalpharyngeal aspirate and sputum) from experimental infection studies, and was 
associated with increased numbers of neutrophils (via IL-8/CXCL8), eosinophils (via 
RANTES/CCL5) and T cells (via IP-10/CXCL10) in asthmatic airways, which in turn correlated 
with increased AHR and prolonged and enhanced airway narrowing characterised by a 
reduction in FEV1 [31, 94, 95]. Induced sputum from experimentally infected volunteers 
demonstrated increased numbers of eosinophils and neutrophils in asthmatics compared to 
non-asthmatics [96, 97], and enhanced cellular inflammation of the bronchi of asthmatics 
was due to eosinophil, CD4+ T cell and CD8+ T cell infiltration [94]. Mast cell activation was 
indicated by increased levels of leukotrienes and prostaglandins in asthmatic airways [98]. In 
contrast to the pathological consequences of enhanced cellular responses in asthmatics, RV-
induced nitric oxide production was shown to mediate protection, indicating a potential 
target for therapy [86]. Despite the potential harmful consequences of the proinflammatory 
mediators expressed by BECS, they also play a role in antiviral immunity, thus a fine balance 
between protection and pathology exists and further investigation is required to define this 
balance. 
 
Expression of the above proinflammatory mediators requires NF-κB, and increased levels of 
activated NF-κB p65 and p50 subunits are observed in bronchial biopsies, sputum cells and 
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cultured BECs from asthmatics compared to non-asthmatics [99, 100]. Higher levels of NF-κB 
p65 protein is also detected in PBMCs from individuals with moderate and severe asthma 
compared to non-asthmatics at baseline [101, 102]. These data suggest that NF-κB could be 
a good therapeutic target to inhibit excessive proinflammatory responses during virus 
infection in asthmatics, although the beneficial role of this transcription factor for defence 
against pathogens, particularly for IFN expression, needs to be fully assessed in asthmatics.  
 
1.3.3.3. RV Infection of the Lower Airways in Asthmatics 
RVs replicate optimally at 33°C and thus normally infect the upper airways however, 
bronchoscopy has demonstrated the presence of RVs in BECs of the lower airways of 
asthmatics, which may be involved in potentiating lower airways disease [37, 103]. Studies 
have confirmed no difference in infectivity or virus yields upon infection of upper and lower 
airway epithelial cells in vitro [104]. Therefore, it is possible that the damaged epithelium in 
asthmatics increases susceptibility to infection in the lower airways, not normally seen in 
healthy individuals [105]. Assessment of lactate dehydrogenase (LDH) levels in sputum, a 
marker for virus-induced lower airway cellular damage, from virus infected patients 
admitted to hospital due to exacerbations demonstrated a strong correlation between 
increased LDH, severity of exacerbation and length of hospital stay; this suggests that virus-
induced lower airways damage is a major precipitant of more severe exacerbations [106]. 
Although asthmatics are not more susceptible to RV infections per se, they often display 
more severe and prolonged symptoms [87, 107], strongly suggesting inherent differences in 
responses to respiratory viral infections between asthmatics and non-asthmatics.  
 
1.3.3.4. Deficient type I and III Interferon Responses in Asthmatic Airway Epithelial Cells 
Such differences include deficient innate antiviral immune responses detected in atopic 
asthmatic BECs cultured ex vivo and infected with RV-16. In these cells, IFN-β production 
was impaired after RV infection compared to cells from non-asthmatic volunteers, which 
correlated with increased virus replication, impaired induction of apoptosis and increased 
cell lysis; BECs from non-asthmatics underwent early apoptosis, thus limiting virus 
replication [108]. These pathogenic responses detected in asthmatic BECs were reversed 
upon exogenous administration of IFN-β in vitro, thereby identifying IFN-β as a novel 
potential therapeutic option to treat or prevent RV-induced asthma exacerbations via 
augmenting antiviral immunity. Expression of type III IFNs by asthmatic BECs and 
macrophages upon RV infection in vitro was also found to be deficient, which correlated 
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significantly with severity of RV-induced asthma exacerbations and virus load in 
experimentally infected individuals [109]. It is possible that excessive TGF-β expression in 
asthmatic airways acts to suppress type I IFN responses, thereby mediating enhanced RV 
replication [2]. Further work is needed to confirm type I and III IFN deficiencies in vivo during 
RV infection of asthmatics. 
 
1.3.3.5. Imbalanced Th1 and Th2 Responses to RV Infection in Asthmatics  
Adaptive immune responses are also key for antiviral immunity, although the interaction 
between virus and allergen induced responses are unclear. Virus infections induce a Th1 
response characterised by IFN-γ expression and recruitment of CD8+ T cells, which is 
opposite to that seen in asthmatics where a Th2 response dominates with expression of IL-4, 
IL-5 and IL-13. The balance between Th1 and Th2 responses is pertinent for viral control. In 
asthmatics, a lower IFN-γ:IL-5 ratio detected in sputum after RV infection correlated with 
more severe cold symptoms and deficient clearance of virus in vivo, compared to non-
asthmatics [30]. This study implies that deficient virus-mediated Th1 responses in asthmatics 
are associated with increased disease due to poor virus control. In vitro RV infection of 
PBMCs obtained from asthmatics and non-asthmatics resulted in secretion of IFN-γ, IL-12, IL-
10 and IL-13 in both groups however, significantly lower levels of IFN-γ and IL-12, and 
expression of IL-4 was detected with asthmatic PBMCs [110]. Deficient induction of Th1 
cytokines and IL-10 and augmented Th2 cytokine expression in asthmatics was observed 
during experimental RV-16 infection; Th1 and IL-10 responses were associated with 
protection from exacerbation, and increased disease severity was associated with 
augmented Th2 responses [27]. These observations suggest that the imbalance between 
Th1/IL-10 and Th2 responses in asthmatics compared to healthy individuals contributes to 
the pathogenic mechanisms of RV-induced asthma exacerbations.  
 
1.4. Interleukin-15 
1.4.1. Structure, Expression & Regulation 
IL-15 is a pleiotropic cytokine that is a member of the four -helix bundle family of cytokines. 
IL-15 was discovered in 1994 by two independent groups whom isolated a 14-15kDa 
lymphokine that was able to mimic IL-2-dependant proliferation of CTLL-2 cells and 
stimulate activation of large granulocytes [111, 112]. IL-15 is structurally similar to IL-2 and 
shares the IL-2 receptor β and common γ chains (IL-2R and IL-2R/c), thus shares some 
immunomodulatory properties with IL-2 [113] and other cytokines that use the c chain 
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including IL4, IL-7, IL-9 and IL-21. Binding to its more specific, high affinity receptor α subunit 
(IL-15Rα) confers its unique functions.  
 
IL-15 mRNA has been detected in both immune and non-immune tissues including 
macrophages, DCs, keratinocytes, epidermal skin cells, fibroblasts and nerve cells to name a 
few [112], reflecting its wider spectrum of physiological functions unlike IL-2, that is almost 
exclusively produced by and modulates T cells. The main producers of IL-15 are monocytes, 
macrophages and DCs and expression is induced by a number of stimuli including various 
proinflammatory cytokines, type I IFNs, dsRNA, LPS and bacteria such as  S. pneumoniae and 
viruses including herpesvirus 6 and 7, influenza and vaccinia virus [114-118]. In addition to 
these stimuli, cellular production of functional IL-15 protein requires passing stringent 
control mechanisms during transcription, translation, translocation and intracellular 
trafficking [119].  
 
The IL-15 gene is composed of nine exons and eight introns however, the mature 114-amino 
acid protein is encoded by only four exons (5-8) and 3 introns [120]. Transcription occurs 
after binding of various transcription factors to the promoter region, which contains 
consensus sequences for NF-κB, IRF-E, γIRE, NF-IL-6, myb, αIFN-2, AP-1 and GCF [121], many 
of which are important for activating various arms of the immune system [122]. As specific 
factors able to initiate transcription in one cell type may not do so in another, it is suggested 
that there is a cell-specific control over gene expression, adding further complexity into the 
control of IL-15 mRNA expression.  
 
There are two alternatively spliced variants of IL-15 that differ only in the length of the signal 
peptide: a 48-amino acid long signal peptide isoform (IL-15 LSP) and a 21-amino acid short 
signal peptide isoform (IL-15 SSP), of which the latter is expressed at lower levels [123]. IL-15 
LSP is stored in the cytoplasm and has been shown to co-localise with IL-15Rα in the nucleus, 
perhaps to act as an autocrine regulatory mechanism to downregulate IL-15 transcription 
[123]. IL-15 LSP is trafficked to the plasma membrane for cell signalling [124].  
 
Although IL-15 mRNA is detected in many tissues types, protein detection has been limited 
to a few cell types including monocytes, macrophages, DCs and epithelial cells [118, 125, 
126]. Transfection studies demonstrated that equal expression of IL-2 and IL-15 mRNA 
yielded far more IL-2 protein compared to IL-15 [127], and many studies report it difficult to 
detect released soluble IL-15 in cell culture supernatants and biological fluids despite mRNA 
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expression. These discrepancies result from multiple regulatory barriers during translation 
and intracellular trafficking of IL-15, which is an indication of the potency of IL-15 signalling, 
as demonstrated by the damage caused by excessive IL-15 activity in proinflammatory 
disorders [128] such as rheumatoid arthritis [129], inflammatory bowel disease [130] and 
systemic lupus erythematosus [131]. 
 
Translational barriers include the presence of multiple translation initiation start sites 
(AUGs) in the 5’-UTR of IL-15 mRNA (12 in humans and 5 in mice), removal of which 
enhanced protein production 10-15-fold [127, 132]. In addition, the signal peptide is not 
optimal for translation as replacement with that of CD33 resulted in significantly greater IL-
15 protein production. Deletion of the molecular hurdles present in IL-15mRNA increased 
protein production more than 250-fold [127]. 
 
IL-15Rα is a type I transmembrane protein and binds IL-15 with an extremely high affinity (Ka 
≥1011 M-1) [133]. IL-15Rα mRNA is expressed by most haematopoietic and parenchymal cells 
including B and T cells, macrophages, thymic and bone marrow stromal cells, endothelial 
cells and in lung, spleen, liver, heart and skeletal muscle tissues [134]. Intracellular 
trafficking, secretion and signalling of IL-15 is dependant on IL-15Rα expression; within the 
endoplasmic reticulum, IL-15 protein is stabilised upon association with IL-15Rα, preventing 
its degradation by the proteasome [135] and the complex is then transported to the cell 
surface via the secretory pathway [136].  
 
1.4.2. Signalling 
IL-15 signals by a unique mechanism called trans-presentation, which depends on cell to cell 
contact and has only been characterised recently, consistent with the difficulty in protein 
detection reported by previous studies. As Figure 1.2 illustrates, IL-15 remains attached to 
the cell surface in complex with IL-15Rα of the producing cell and signals to adjacent IL-15 
responsive cells via the IL-2R/c dimeric or IL-15Rα/IL-2R/c trimeric receptor, with an 
intermediate affinity to the former [135, 137, 138]. However, signalling may occur by more 
than one mechanism; cleavage of membrane bound IL-15Rα by metalloproteinases such as 
TACE and ADAM17 has been shown to produce a soluble form of the receptor (sIL-15Rα) 
[139, 140], and soluble IL-15/IL-15Rα complexes have also been detected and shown to 
induce expansion of NK and T cell populations in vivo [135, 138]. Although trans-
presentation is widely accepted as the predominant mechanism at play, further work is 
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needed to fully characterise the ways in which IL-15 signals to mediate specific responses in 
vivo. 
 
IL-15 shares the Janus Kinase (JAK) – Signal Transducer and Activator of Transcription (STAT) 
signalling pathway with many cytokines for the generation of inflammatory and adaptive 
immune responses [141]. Upon binding to the receptor complex, IL-15 signals through the 
IL-2R β and cγ chains; JAK1 is recruited by the β chain bringing it into close proximity with 
JAK3, that is constitutively associated with the cγ chain, resulting in their cross-
phosphorylation; activation of these kinases results in phosphorylation of STAT3 and STAT5, 
which translocate to the nucleus as homo- and heterodimers to initiate expression of target 
genes [113]. IL-15 can also activate other signalling cascades through recruitment of other 
non-receptor tyrosine kinases including Src, Lck, Lyn, Fyn, and Syk and can cross-talk with 
proteins in the PI3K and MAPK pathways [134].  
 
Structural analysis demonstrated no obvious docking sites or signalling motifs in the short 
cytoplasmic tail of the IL-15Rα subunit. However, studies have observed some signalling 
mediated through this chain via recruitment of TRAF2, culminating in NF-κB activation in 
TNF-α activated fibroblasts [142]. IL-15 mediated anti-apoptotic effects in a B cell line, in 
addition to enhanced phagocytosis in neutrophils, was found to be mediated through 
recruitment of Syk to the IL-15Rα chain [143, 144]. These observations suggest that IL-15Rα 
is able to signal independently of the IL-2R/c complex. 
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Figure 1.2 IL-15 trans-presentation. 
(a) IL-15Rα binds and stabilises IL-15 protein in the endoplasmic reticulum, and the complex is 
transported via the secretory pathway to the cell surface. (b) The IL-15/IL-15Rα complex is presented 
in ‘trans’ to adjacent cells expressing the dimeric IL-2Rβ/γc receptor complex. (Diagram from 
Jakobisiak et al. [145]). 
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1.4.3. Role of IL-15 in the Immune System  
IL-15 is a proinflammatory cytokine produced early after infection and exhibits a number of 
antiviral functions via stimulating immune cells (summarised in Table 1.2). Macrophages 
produce and respond to IL-15, which is important for their functional maturation as antigen 
presenting cells, and for expression of iNOS [146] and IL-12, of which the latter in turn 
stimulates IFN-γ production in multiple cell types as a positive feedback mechanism [147]; 
nitric oxide, IL-12 and IFN-γ production are severely impaired in IL-15 knockout mice. IL-15 
signalling in human monocytes induces IL-8/CXCL8 and monocyte chemotactic protein-1 
(MCP-1/CCL2) production, attracting neutrophils and monocytes to the site of infection 
[148]. A high level of IL-15 signalling in macrophages results in increased production of 
proinflammatory cytokines IL-1, IL-6 and TNF-α compared to low-level signalling, which 
favours IL-10 expression [149].  
 
IL-15 expression by DCs is induced by LPS, dsRNA, type I IFNs and CD40 ligation stimulation 
[118], and DC mediated IL-15 signalling is crucial for NK cell development, activation and 
cytotoxicity (further discussed in Section 1.6.5). Stimulation of DCs by IL-15 results in their 
functional maturation and activation, including upregulation of IFN-γ expression and co-
stimulatory molecules CD40, CD86 and MHC class II [147]. Epithelial-derived IL-15 in the 
airway has been shown to stimulate monocyte differentiation into DCs [150]. In human 
follicular DCs, IL-15 signalling enhances proliferation and chemokine secretion [151]. 
Moreover, IL-15 is a survival factor for DCs, as numbers in blood and spleen are significantly 
reduced due to increased DC apoptosis in IL-15 and IL-15Rα knockout mice, and exogenous 
administration of IL-15 partially restored numbers [152].  
 
Neutrophils are amongst the first innate cells to arrive at sites of inflammation and act to 
remove and kill pathogens via phagocytosis and release of granules containing anti-microbial 
proteins. They express all 3 components of the IL-15 receptor complex and responses to IL-
15 signalling include cytoskeletal rearrangement, increased phagocytosis [153], delayed 
apoptosis, IL-8 production – thereby amplifying the neutrophilic response [154, 155] – and 
induction of MHC class II expression allowing antigen presentation by neutrophils [156].  
 
IL-15 also influences the adaptive immune response, though T cells do not express IL-15. 
Most significantly, IL-15 is critical for the basal homeostatic proliferation required for 
maintenance of CD44high CD8+ memory T cells, as IL-15Rα knockout mice have a reduced 
pool of these cells [157, 158], and transfer of IL-15 expressing DCs from wild type to IL-15 
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knockout mice resulted in the appearance of this population [152]. IL-15 promotes survival 
of CD44high CD8+ memory T cells via inducing expression of anti-apoptotic molecules Bcl-2 
and Bcl-XL [159]. IL-15 also induces Bcl-2 expression in CD44
lo CD8+ T cells, supporting 
survival of thymic and peripheral CD8+ T cells [160]; however, their lower expression levels 
of IL-2Rβ reflect their lower dependency on IL-15 for survival compared to memory CD8+ T 
cells. IL-2 mediated activation induced T cell death is inhibited by excessive IL-15 signalling, 
further exemplifying the role of IL-15 in T cell survival [161].  
 
CD4+ T cell survival is not dependant on IL-15 as normal levels of CD4+ T cells are detected in 
IL-15 and IL-15Rα knockout mice. Although, in the presence of TCR engagement, IL-15 can 
induce significant proliferation of CD4+ T cells, in addition to expression of CD40 ligand and 
the co-stimulatory molecule CD28, promoting more effective interactions with antigen 
presenting cells [162].  
 
 
Cell Type Functional Effects of IL-15 Signalling References 
Macrophages Induces functional maturation and activation required for antigen 
presenting functions; and induces iNOS and IL-12 production. 
[146, 147] 
Dendritic Cells Induces functional maturation and activation required for antigen 
presenting functions; and promotes DC survival. 
[147, 152] 
Neutrophils Stimulates iNOS production; enhances phagocytosis; and inhibits 
apoptosis. 
[144] 
NK Cells Supports development, differentiation, homeostasis, proliferation and 
activation. 
[157, 163-165] 
CD8+ T Cells Supports homeostasis and proliferation of memory CD8+ T cells; and 
supports survival of CD8+ T cells at all developmental stages.  
[158, 160] 
CD4+ T Cells Promotes proliferation.  [166, 167] 
B Cells Inhibits apoptosis; supports proliferation and differentiation; and 
promotes production of IgA, IgG1 and IgM. 
[168-170] 
 
Table 1.2 Functional effects of IL-15 signalling on immune cells. 
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1.5. Interferons 
1.5.1. Type I Interferons 
Interferons (IFNs) were discovered 50 years ago as molecules produced by cells upon 
stimulation with inactivated virus, which then protected the cells against subsequent 
infection with live virus. Thus, IFNs were first described as molecules that could ‘interfere’ 
with virus replication [171]. Type I IFNs are a family of cytokines produced early after viral 
infection by host cells and are crucial for antiviral defence. The type I IFN family is composed 
of several members: IFN-α, -β, -κ, -ε and –ω, of which IFN-α and IFN–β are the best 
characterised. There are thirteen and seven IFN-α subtypes in mice and humans respectively 
and only one IFN-β in both species [172]. Mice deficient in IFN-β or subunits of the type I IFN 
receptor are more susceptible to viral infections [173, 174].  
 
1.5.2. Expression of Type I Interferons 
Cells possess a number of molecular sensors that can detect viral infection and stimulate 
redundant pathways to induce expression of type I IFNs. The Toll-like receptor (TLR) family 
of transmembrane proteins recognises conserved pathogen-associated molecular patterns 
(PAMPs) and were the first receptors demonstrated to sense viral nucleic acids [175]. TLR3 
recognises double-stranded RNA (dsRNA), a common viral PAMP not normally produced by 
host cells but produced by both DNA and RNA viruses as a by-product of viral replication and 
transcription [176]. TLR7 and TLR8 recognise specific viral PAMPs on single-stranded RNA 
(ssRNA) such as the genomic RNA of influenza virus and HIV [177], and TLR9 recognises DNA 
viral PAMPs (e.g. unmethylated CpG motifs) such as the genomic DNA of herpesviruses [178].  
 
These TLRs are located in endosomes, thus enhancing viral nuclei acid detection as 
endosomes are part of the replication cycle of many RNA viruses; for example, during 
endosome-mediated internalisation of virions or during the budding stage of viral particles 
allowing detection by TLRs 7/8/9, or from endocytosis of viral replication products from 
lysed or apoptotic virus-infected cells allowing detection by TLR3 [178]. In addition, 
endosomal compartmentalisation of the sensors facilitates differentiation between self and 
foreign nucleic acids. TLR3 has been shown to be expressed on the surface of macrophages 
and fibroblasts for detection of extracellular dsRNA, likely released upon virus-mediated lysis 
of cells [175]. 
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The complex signalling networks triggered by these TLRs results in activation of the neural 
factor κB (NF-κB), activating protein 1 (AP-1) and interferon regulatory factor 3 (IRF3) (via 
TLR3) or IRF7 (via TLR7/8/9) to stimulate expression of IFN-α and IFN-β [178]. Plasmacytoid 
DCs in particular are specialised to produce copious amounts of type I IFNs in the early 
antiviral response, facilitated by their constitutive expression of TLR7/8/9 and IRF7.  
 
Secondly, type I IFN expression also results from recognition of viruses via stimulation of 
cytoplasmic pattern recognition receptors that detect viral RNA, resulting in elimination of 
replicating viruses. Two of these sensors include the RNA helicases retinoic acid-inducible 
gene I (RIG-I) and the melanoma differentiation-associated gene 5 (MDA-5) that is also 
known as a RIG-I-like receptor [179]. RIG-I is currently the best characterised of the two 
molecules, and interaction of the helicase domain with dsRNA ultimately activates NF-κB, 
AP-1 and IRF-3 for type I IFN production [180]. In BECs, TLR3, RIG-1 and MDA-5 all co-
ordinately recognise RV infection, resulting in the initiation of innate anti-viral defences 
[181].  
 
1.5.3. Type I Interferon Signalling & Expression of Interferon Stimulated Genes 
The type I IFNs share a common ubiquitous heterodimeric receptor composed of the IFN-α 
receptor 1 and 2 subunits (IFNAR1 and IFNAR2). Ligand binding results in activation of JAK1 
and tyrosine kinase 2 (TYK2), which are constitutively associated with the cytoplasmic tails of 
the receptor subunits. These in turn phosphorylate STAT1 and STAT2, resulting in formation 
of a trimeric complex with IRF9, known as the IFN-stimulated gene factor 3 (ISGF3). ISGF3 
translocates into the nucleus and binds to promoter sequences containing IFN-stimulated 
response elements (ISREs), resulting in expression interferon stimulated genes (ISGs) [178]. 
Type I IFNs also stimulate other intracellular signalling pathways that result in expression of 
ISGs [182]. 
 
Since their discovery over 25 years ago, more than 300 ISGs have been identified, and the 
resultant effector molecules act to generate an ‘anti-viral’ state within cells and mediate the 
immunomodulatory functions associated with IFNs. However, the function of many ISGs 
remains uncharacterised [183]. Type I IFN signalling also acts in an autocrine and paracrine 
fashion to further enhance type I IFN production, for example early IFN-β expression results 
in induction of IRF-7 to stimulate expression of IFN-α [184].  
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Of the many ISGs, serine/threonine protein kinase (PKR) and 2’-5’ oligoadenylate synthetase 
(OAS) are the best characterised. PKR is activated upon binding dsRNA (e.g. viral replicative 
intermediates) and acts to block protein synthesis via phosphorylation of a number of 
substrates, including the protein synthesis initiation factor eiF2α, thereby limiting viral 
replication [185]. PKR is also involved in dsRNA-induced signal transduction pathways that 
upregulate other antiviral mechanisms, including activation of transcription factors NF-κB, 
STAT1, IRF-1 and p53, and induced expression of FAS for initiation of apoptosis [186]. OAS is 
also activated by dsRNA and subsequently generates 2’-5’ oligoadenylates that bind to 
RNaseL, leading to its dimerisation and activation; this activated endoribonuclease cleaves 
viral and cellular ssRNA including 28S ribosomal RNA, and thereby inhibits protein synthesis 
and has been shown to prevent replication of encephalomyocarditis virus, Coxsackie virus B4, 
West Nile virus, HCV and some retroviruses [187]. In addition, the cleaved RNAs can activate 
RIG-I and MDA-5, resulting in a positive feedback loop amplifying IFN-β production [188]. 
Similar to PKR, the OAS/RNaseL system is implicated in signalling pathways that promote 
apoptosis of infected cells, further indicated by the damage to host cell machinery as a 
result of the mechanism of action. IFN-induced apoptosis of infected cells can also result via 
induction of TNF-related apoptosis-inducing ligand (TRAIL). 
 
Viperin (virus inhibitory protein, endoplasmic reticulum-associated, IFN-inducible) is an ISG 
that interferes with the assembly and maturation stage of new virus particles including 
influenza [189], thereby limiting virus replication. Viperin acts through a number of different 
mechanisms which are still largely under investigation [190]. Type I IFN signalling also 
induces expression of immunomodulating cytokines, including IL-12, IL-15 and IFN-γ, which 
act on immune cells to direct activation and development of the appropriate downstream 
innate and adaptive immune responses.  
 
1.5.4. Type II Interferon 
Type II IFN only comprises IFN-γ [191] and is expressed during viral infections. In vitro 
stimulation of T and NK cells with phytohemagglutinin and phorbol esters or ionophores 
induces IFN-γ expression. In contrast to type I IFNs, IFN-γ is produced by activated 
macrophages, DCs, NK cells and T cells and not by virus infected cells. Stimulation of NK cells 
by type I IFN and IL-12 can induce IFN-γ expression during viral infections [192, 193]. IFN-γ 
expressing cells can respond in an autocrine/paracrine fashion to IFN-γ, resulting in 
enhanced activation of macrophages and NK cell cytotoxic activities. IFN-γ promotes 
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development of Th1 adaptive responses via inducing upregulation of MHC class II molecules 
on DCs for presentation of antigens and activation of T cells, expression of Th1 cytokines by 
CD4+ T cells and development of cytotoxic CD8+ T cells [194, 195]. Expression of chemokines 
MIG/CXCL9 (monokine induced by IFN-γ), IP-10/CXCL10 (IFN-γ 10kD inducible protein) and I-
TAC/CXCL11 (IFN-inducible T-cell α-chemoattractant) are stimulated by IFN-γ to mediate 
leukocyte recruitment to the site of infection [187]. Thus, IFN-γ primarily stimulates cell-
mediated responses that protect the host from intracellular pathogens.  
 
IFN-γ signals via the heterodimeric receptor composed of IFNGR1 and IFNGR2 subunits, 
which are constitutively associated with JAK1 and JAK2 respectively [191]. IFN-γ binding 
results in cross-phosphorylation of the JAK proteins, which in turn phosphorylate STAT1, 
forming transcriptional activator complexes of STAT1 homodimers also called IFN-γ activated 
factor (GAF). GAF translocates to the nucleus and binds DNA regulatory sequences 
containing IFN-γ activated sequences (GAS), promoting expression of specific ISGs [196]. 
Type I IFNs can also activate this signalling pathway, but not as strongly as IFN-γ [182].  
 
1.5.5. Type III Interferons 
The type III IFN family is composed of IFN-λ1, -λ2 and –λ3 in humans, also known as IL-29, IL-
28A and IL-28B respectively, and IFN-λ1 is non-functional in mice [197, 198]. IFN-λ has been 
shown to inhibit hepatitis B virus (HBV) replication in a mouse hepatocyte cell line [199], 
HCV replication in the human Huh7 hepatoma cell line [199] and over-expression of IFN-λ in 
a vaccinia virus construct significantly reduced viral replication in mouse models of several 
virus infections [200]. 
 
Type III IFNs can be induced by the same stimuli as type I IFNs, including a number of viruses 
and TLR agonists [201, 202], and expression of type I and III IFNs are similarly regulated by 
transcription factors NF-κB and AP-1 [203] thus, both type I and III IFNs are usually co-
expressed in virus infected cells. Signalling by type III IFNs via a receptor complex of IFN-
λR1/L-28Ra and IL-10R2 chains stimulates the same JAK-STAT pathway as type I IFNs, 
inducing a similar repertoire of genes (including OAS, PKR and upregulation of MHC class I 
molecules) and resultant antiviral activity in cells [197, 204, 205]. Despite the similar 
expression pattern and resultant biological activities upon signalling, the relative magnitude 
of gene expression induced by type I IFNs is generally greater than that by type III IFNs [203]. 
Differences in signalling strength by the different receptor complexes, receptor density on 
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the surface of cells and receptor distribution between cell and tissue types contributes to 
the specific functions of these cytokines. Epithelial cells express significant levels of IFN-λR1, 
and appear to be the main targets of IFN-λ signalling [206]. Studies using IFN-λR1 knockout 
mice show that IFN-λ signalling is particularly important for the immune response against 
viral infections that preferentially infect lung and/or gastrointestinal tract epithelial cells 
[207].  
 
1.6. Natural Killer Cells 
1.6.1. Introduction  
NK cells are large granular cytotoxic lymphocytes that are derived in the bone marrow and 
participate in early defence as part of the innate immune system. They posses some 
overlapping functions with CD8+ T cells but do not express the antigen-specific T cell 
receptor nor CD3. NK cells were initially identified in 1975 by their ability to spontaneously 
lyse certain susceptible tumour cell lines [208-210]. In humans, NK cells comprise ~10-15% 
of peripheral blood lymphocytes (PBMCs), and are also found in peripheral tissues such as 
the lungs and spleen [210, 211]. Surface expression of NK1.1 is used as an NK cell marker in 
some rodent species however, NKp46 is now the common NK cell marker across all 
mammalian species [212]. Human NK cells are usually defined as CD3- CD56+ [213]. The 
importance of NK cells is best characterised during protection against viruses and tumour 
immunesurveillance [214, 215].  
 
1.6.2. NK Cell Activating & Inhibitory Surface Receptors 
In the last two decades, much work has identified cell surface receptors involved in the 
functional activities of NK cells, and their activation is governed by the balance of activating 
and inhibitory signals received from these germ-line encoded receptors. Activating receptors 
(ARs) include those that bind soluble ligands (e.g. cytokines and chemokines) and those that 
interact with cell surface molecules on target cells; some of these receptors include cytokine 
receptors for IL-12, IL-15, IL-18, IL-21, type I IFNs and IFN-γ; CD16, the FcγRIIIA cell surface 
receptor that mediates antibody-dependant cell cytotoxicity (ADCC); NKG2D, which binds 
stress ligands expressed on the surface of infected or transformed cells including MICA, 
MICB and ULBP molecules; the natural cytotoxicity receptors NKp46 and NKp44, which bind 
specific virus-derived molecules such as hemagglutinins from influenza and parainfluenza 
viruses [216]; and TLRs. Most ARs are coupled to and signal via intracytoplasmic 
immunoreceptor tyrosine-based activation motifs (ITAMs).  
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Alternatively, inhibitory receptors (IRs) such as killer cell immunoglobulin-like receptors 
(KIRs) in humans, CD94/NKG2A heterodimers in both humans and mice and lectin-like Ly49 
dimers in mice, recognise MHC class I molecules [217, 218] that are constitutively expressed 
on most healthy nucleated cells, and are particularly important for the ‘missing self’ 
hypothesis [219]. IRs on NK cells signal via intracytoplasmic immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) [220] and act to spare healthy cells from NK cell cytotoxicity. Certain 
viral infections and cellular transformations downregulate MHC class I molecules on the 
surface of cells to evade CD8+ T cell immunity; however, this removes/reduces the 
overriding inhibitory signals received by NK cells, and the decision to selectively kill the 
distressed cell is tipped by the weight of signals from ARs, otherwise summarised as the 
‘dynamic equilibrium concept’.  
 
1.6.3. NK Cell Cytotoxicity & Expression of Soluble Mediators 
The role of NK cells in anti-viral immunity was initially recognised upon observation of their 
enhanced cytotoxicity in response to virus-induced type I IFNs [221] however, NK cell 
mediated early defence is important against some and not all viruses [222]. NK cell 
cytotoxicity against virus-infected cells occurs via several direct and indirect pathways. 
Formation of an immunological synapse between the NK cell and target cell allows directed 
secretion of lytic granules at the interface, whilst minimising damage to healthy surrounding 
cells [223]. Unlike cytotoxic CD8+ T cells, lytic granules are preformed in resting human NK 
cells, emphasising the rapid nature of the response [224]. Lytic granules are lysosomes with 
specialised secretory machinery, containing membrane-perturbing proteins granulysin and 
perforin, serine proteases granzyme A, B and C, and CD95/FAS ligand, which act together to 
induce caspase-dependant apoptosis and perforin-mediated lysis of target cells [225, 226]. 
Activated NK cells are described to have a serial killing ability, generating new lytic granules 
and ARs after detaching from killed cells, to kill other susceptible cells [227]. Expression of 
FAS ligands, TNF-α and TNF-related apoptosis-inducing ligands (TRAIL) by activated NK cells 
induces apoptosis via engagement of death receptors (TNF receptor family) on target cells 
[228]. IFN-β inducible expression of TRAIL (TNF-related apoptosis-inducing ligand) by mouse 
NK cells is ISGF3 mediated and linked to anti-EMCV activity [229].  
 
Activated NK cells also secrete cytokines that play important anti-viral and 
immunomodulatory roles to help shape the appropriate innate and adaptive immune 
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responses. In murine models of virus infection, particularly with cytomegalovirus (CMV), 
cytokines released by activated macrophages, DCs and infected tissue cells, such as IL-1, IL-
10, IL-12, IL-15 and IL-18 stimulate NK cells [230, 231]; in response and depending on the 
specific receptor-ligand interactions such as engagement of ARs NGK2D, 2B4, LFA-1 and/or 
CD16 during target cell recognition, NK cells can relay and amplify these signals via 
producing proinflammatory cytokines and chemokines including IFN-γ, TNF-α, MIP-1α/CCL3, 
MIP-1β/CCL4, IL-8/CXCL8, IL-12 and RANTES/CCL5 [231].  
 
NK cells are major producers of IFN-γ during viral infections particularly during the early 
immune response, and along with TNF-α stimulates a number of functions key for viral 
clearance (Figure 1.3). Upon pathogen-mediated activation, DCs and macrophages produce 
a number of soluble mediators such as type I IFNs, IL-12 and IL-15 that stimulate NK cell IFN-
γ production, which feeds back to enhance activation of macrophages and DCs to secrete 
more proinflammatory cytokines and chemokines into the microenvironment, including 
MIP-1α/CCL3, IP-10/CXCL10 and MIG/CXCL9 to regulate trafficking of NK cells and other 
immune cells [232]. IFN-γ and TNF-α act to sensitise target cells to NK cell cytotoxicity via 
NF-κB-dependant ICAM-1 upregulation, promoting adhesion and formation of lytic synapses 
[233]. NK cell produced IFN-γ also mediates inhibition of viral replication in infected cells 
[234], and also acts on potential target cells to increase surface expression of MHC class I 
and/or II molecules, promoting development of a Th1 adaptive immune response, which is 
critical for efficient antiviral immunity. 
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Figure 1.3 NK cell mediated immune functions. 
Macrophages and DCs activated upon microbial challenge secrete soluble factors, including type I 
IFNs, IL-15, IL-12 and IL-18, which prime NK cell cytotoxicity and cytokine/chemokine secreting 
functions. Primed NK cells secrete IFN-γ and TNF-α (red arrows), which boosts maturation and 
activation of macrophages and DCs, allowing more effective antigen presentation to T cells; and IFN-γ 
stimulation of T cells promotes development of a Th1 phenotype, thus helping shape the adaptive 
immune response. Moreover, NK cells exhibit regulatory functions (blue arrows) such as the ability to 
kill immature DCs, hyperactivated macrophages and activated CD4+ T cells, though these activities are 
controlled by inhibitory receptors on NK cells. (Diagram taken from Vivier et al., 2008 Nat Immunol 
[235]). 
 
1.6.4. Importance of NK Cell Mediated Antiviral Immunity 
In mice, many virus infections including herpes simplex viruses (HSV), influenza and 
coxsackie virus can be controlled by NK cells. Some of the most convincing evidence for the 
importance of NK cells in early virus control resulted from studies showing increased 
susceptibility to murine CMV (MCMV) after NK cell depletion, and alternatively increased 
resistance upon adoptive transfer of NK cells in NK cell deficient mice [236, 237]. Defects in 
NK cell cytotoxicity or IFN-γ production alone also increases susceptibility to MCMV infection 
in mice [235, 238]. Lessons learnt in mouse studies holds true in humans for specific viruses, 
as demonstrated by severe recurrent or chronic disseminating herpes group virus infections, 
including HSV, Epstein-Barr virus (EBV) and human CMV documented in the few cases of 
natural selective NK cell deficiencies [239, 240]. Thus, there are compelling correlations 
between reduced or no NK cell function and susceptibility to viruses, indicating a clear role 
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of NK cell defence against viruses. The role of NK cells during RV infections in humans 
(asthmatic and non-asthmatics) is yet to be characterised. 
 
1.6.5. IL-15 Mediated Regulation of NK Cells 
IL-15 and IL-15Rα are both critical for the generation and maintenance of NK cells, as 
demonstrated by the severe lack of NK cells in both IL-15 and IL-15Rα knockout mice [157, 
158]. IL-15 expression on bone marrow stromal cells supports development of NK cell 
precursors and aids differentiation of immature NK cells [241]. In the periphery, IL-15 
promotes survival/homeostasis of NK cells via inhibiting expression of the pro-apoptotic 
molecule Bim and upregulating expression of survival promoting Bcl-2 [242].  
 
Many studies have demonstrated that regulation of NK cell activities is the most prominent 
antiviral function of IL-15. For example, resting NK cells exhibit high levels of perforin and 
granzyme B mRNA but low protein levels, and stimulation with IL-15 removes this 
translational block resulting in significant increases in protein levels; thus, IL-15 supports the 
conversion of resting NK cells into cytolytic effectors [243, 244]. Stimulation of human NK 
cells in vitro with IL-15 in combination with IL-12 induces production of IFN-γ, TNF-α and 
MIP-1α/CCL3 [245]. 
 
DCs co-localise with NK cells in lymphoid organs and peripheral tissues to mediate trans-
presentation of IL-15 [138, 246]. Lucas et al. [247] demonstrated that priming of NK cell 
effector functions in vivo in response to viral and bacterial pathogens requires IL-15 
production and trans-presentation by CD11chigh DCs, expression of which was induced upon 
type I IFN stimulation of CD11chigh DCs; this was the first study to demonstrate the type I IFN, 
DC, IL-15 and NK cell link in vivo, necessary for the activation of resting NK cells during 
infections. Activation of NK cell cytolytic functions is critical for clearance of a number of 
viral infections, particularly of the herpes group [164, 165, 248, 249]. Infection of human 
PBMCs with herpes viruses resulted in induction of IL-15, which in turn was responsible for 
increased NK cell cytolytic activity [116, 250]. Human herpes virus-6 infection of PBMCs in 
vitro resulted in rapid upregulation of NK cell cytotoxicity, which was inhibited by the 
presence of monoclonal antibodies against IL-15 [251].  
 
In mice, survival/accumulation of proliferating NK cells during MCMV infection necessary for 
virus clearance was dependant on IFN-α/β-mediated IL-15 induction [193]. A mouse model 
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of genital HSV-2 infection showed that protection was critically dependant on the presence 
of IL-15, NK cell and NK-T cells [252]. Similarly, control of HSV-1 infection was shown to be 
due to IL-15-mediated enhancement of NK cell activity that suppressed viral replication 
[250]. During vaccinia virus infection in mice, viral clearance was accelerated upon infection 
with an IL-15 expressing recombinant vaccinia virus compared to wild type virus, and the 
effect was attributed to IL-15 promoted survival/accumulation and increased cytolytic 
activity of NK cells [117, 253]. However, IL-15 driven NK cell responses can also contribute to 
immunopathology and mediate disease progression, as observed in patients with active 
Hepatitis B or C virus infection [254]. The role of IL-15 on NK cell responses during RV 
infection and RV-induced asthma exacerbations, whether beneficial or not, are unknown; 
therefore, it is the aim of this study to investigate these responses, in addition to their 
regulation by type I IFNs. 
 
1.7. Mouse Models of RV Infection and RV-Induced Asthma Exacerbation 
A mouse model of RV infection was published by Bartlett et al. [255] whom demonstrated 
minor group RV infection of BALB/c mice and major group RV infection of transgenic BALB/c 
mice expressing a mouse-human ICAM-1 chimera. Airway neutrophilia, expression of 
proinflammatory cytokines and chemokines and virus replication was demonstrated in these 
mice, similar to that observed in humans. A mouse model of RV-induced exacerbation of 
allergic airway inflammation (asthma) was also demonstrated, which allows investigation of 
RV infection in an asthma mouse model with OVA as the inhaled allergen. In this study, we 
used the above models to investigate the role of IL-15 in the immune response to RV 
infection and RV-induced exacerbation of allergic airways. RV-mediated lower airways 
disease is prominent in asthmatics and our mouse models demonstrate lower airway 
infection, thus appropriately modelling the situation in humans.  
 
1.8. Study Rationale, Hypotheses, Aims & Thesis Outline 
1.8.1. Rationale 
Deficient expression of IFN-β by bronchial epithelial cells from asthmatics infected with RV 
ex vivo has been demonstrated, which was associated with increased viral replication and 
impaired induction of apoptosis [108]. Deficient expression of IL-15 by BAL macrophages 
from asthmatics infected with RV ex vivo and lower levels of BAL IL-15 protein in asthmatics 
compared to non-asthmatics was also demonstrated, which was inversely correlated with 
lower airway symptom severity, AHR and viral load during subsequent in vivo experimental 
RV infection [256]. Type I IFN stimulation of DCs in vivo results in upregulation and trans-
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presentation of IL-15 to NK cells, which is necessary for activation of NK cell 
effector/antiviral functions during infections [247]. These studies imply that IL-15 expression 
is deficient in asthma, which is associated with deficient IFN-β expression, and may play a 
role in the pathogenesis of RV-induced asthma exacerbations. The role of IL-15 and NK cells 
during RV infections has not been previously investigated. In this study, we aimed to further 
examine the link between type I IFNs, IL-15 expression and the NK cell responses in the 
aforementioned mouse models, to more specifically define the importance of this pathway 
during RV infections in allergic (asthma) and non-allergic airways.  
 
1.8.2. Hypotheses  
 
i. IL-15 expression is induced in the airways and lungs during RV infection. 
ii. RV-induced IL-15 is necessary for the NK cell responses to RV infection. 
iii. RV-induced IL-15 and the NK cell responses affect the lung viral load. 
iv. RV-induced IL-15 is dependant on type I IFN signalling. 
v. NK cells are a major source of IFN-γ production early after RV infection, and the 
absence of NK cell IFN-γ production is associated with development of a Th2 
response. 
vi. RV-induced IL-15 and the associated NK cell responses are deficient during RV 
infection in allergic airways (asthma). 
 
1.8.3. Aims 
 
i. To investigate the magnitude, kinetics and cellular source(s) of IL-15 and IL-15Rα 
expression in the airways and lung tissue in response to RV infection.  
ii. To investigate whether the NK cell responses to RV infection is dependant on IL-15 
signalling using two models of deficient IL-15 signalling: (i) administration of an IL-15 
neutralising antibody intranasally at the time of infection to transiently and locally 
block IL-15 in the airways/lungs and (ii) IL-15Rα knockout mice which have a 
constitutive and systemic block to IL-15 signalling.  
iii. To investigate the role of type I IFN signalling on RV-induced IL-15 and the NK cell 
responses using IFNAR1 knockout mice.  
iv. To investigate expression of Th2 mediators in response to RV infection in the 
aforementioned models of deficient IL-15 signalling and type I IFN signalling.  
v. To investigate RV-induced IL-15 and the NK cell responses in a mouse model of RV-
induced asthma exacerbation. 
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1.8.4. Thesis Outline 
Chapter 1 is the introduction which explains the background of the topics covered within 
this thesis, including RVs, asthma, asthma exacerbations, type I IFNs, IL-15 and NK cells. 
Chapter 2 details the materials and methods used within this study. This is followed by the 
results chapters: Chapter 3 investigates RV-induced IL-15 expression and the NK cell 
responses in a mouse model of RV infection; Chapter 4 investigates IL-15 dependancy of the 
NK cell responses to RV infection using 2 different models of deficient IL-15 signalling; 
Chapter 5 investigates the importance of type I IFN signalling for RV-induced IL-15 
expression and NK cell responses using IFNAR1 knockout mice; and Chapter 6 investigates IL-
15 expression and the NK cell responses in a mouse model of RV-induced asthma 
exacerbation. Lastly, Chapter 7 entails a discussion of the results presented in this thesis, the 
conclusions and plans for future work. 
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2. Chapter 2: Materials and Methods 
2.1. Virological Techniques 
2.1.1. Virus Propagation 
RV-1B was obtained from the American Type Tissue Culture Collection (ATCC VR-1366) and 
was passaged 7 times in Ohio HeLa cells to produce working stocks. Ohio HeLa cells are 
grown in HeLa cell growth medium at 37°C with 5% CO2, in 25x175cm
2 flasks. When flasks 
were 90% confluent, the cells were washed twice with phosphate buffered saline (PBS), 
prior to inoculation with 10ml working stock RV-1B in HeLa infection medium for 1 hour (1h) 
at room temperature (RT) with gentle agitation. An additional 10ml of HeLa infection 
medium was added followed by incubation at 37°C for 24h or until 100% cytopathic effect 
(CPE) is observed. The cells and medium were harvested, freeze-thawed twice at -80°C to 
release the virus into the supernatant, which was then centrifuged and filtered via 0.2μm 
syringe filter. This RV-1B inoculum stock was then used to infect H1 HeLa cells (ATCC CRL-
1958) to produced experimental RV-1B working stocks for in vivo work. 
 
H1 HeLa cells were grown in the same conditions as Ohio HeLa cells, however the infection 
protocol is modified. At 90% confluence, the growth medium was replaced with 20ml of 
infection medium containing working stock RV-1B. Flasks were gently agitated at RT for 1h 
prior to incubation at 37°C for approximately 24h or until CPE is observed throughout. The 
cells are collected and washed with PBS during 4 rounds of centrifugation, prior to freezing 
the cell pellet in 36ml of PBS at -80°C. 
 
2.1.2. Virus Purification and Concentration 
The cell pellet/PBS mix was freeze-thawed twice to lyse the cells, followed by centrifugation 
to remove cellular debris. Virus was precipitated out by dissolving 2.8g of Polyethylene 
Glycol-6000 (Fluka Germany or Sigma) in the supernatant containing 4ml of 5M (final 
concentration) sodium chloride, followed by incubation at 4°C for 1h. The precipitate was 
recovered by centrifugation, re-dissolved in 15ml of PBS, and further centrifugation removed 
any insoluble matter. The supernatant was then filter-sterilized via a 0.2μm syringe filter 
into 15ml Amicon Ultra centrifugal filtration devices (Millipore, USA), and the virus washed 
twice with 15ml PBS before concentration to ~2.5ml. RV-1B stocks were stored at -80°C and 
were routinely neutralised with serotype-specific antibodies (ATCC) to confirm identity. 
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2.1.3. Virus Titration 
Ohio HeLa cells were seeded at 7.4x105 cells/ml in 96-well plates in 150μl HeLa virus titration 
medium. RV-1B stocks were serially diluted to give concentrations from 10-1 to 10-8 and 50μl 
of each dilution was added to 8 replicate wells of HeLa cells. Control wells contained no virus. 
Plates were incubated at 37°C (5% CO2) for 5 days, after which CPE was assessed by light 
microscopy and scored to calculate the 50% tissue culture infective dose (TCID50) via the 
Spearman-Karber formula. 
 
2.1.4. Virus Inactivation 
UV-inactivated virus (UV-RV-1B) was used as a control for the inoculum. Concentrated virus 
was exposed to 1200μJ/cm2 ultraviolet (UV) light for 30min. 
 
2.2. Mice 
6-8 week old female BALB/c mice were purchased from Charles River UK and were housed in 
specific pathogen-free conditions. Type I IFN receptor1 knockout mice (IFNAR1-/-) were a gift 
from Dr Cecilia Johansson, and 6-8 week female control C57BL/6 mice were purchased from 
Harlan UK. IL-15Rα knockout mice and control B6.129 mice were purchased from The 
Jackson Laboratory USA, and bred under specific pathogen-free conditions. All animals were 
housed at the CBS facility at St. Mary’s Campus, Imperial College London. 
 
2.3. Mouse Models 
2.3.1. RV Infection Model 
Prior to intranasal (i.n.) challenge, mice were lightly anaesthetised with vaporized isoflurane 
(‘Isoflurane-Vet’, Merial, UK). On day 0 (d0), BALB/c, C57BL/6, B6.129, IFNAR1 ko and/or IL-
15Rα ko mice were treated i.n. with 50μl RV-1B (5.0x106 TCID50), UV-inactivated RV-1B (UV-
RV-1B) or PBS (mock-infected). Terminal anaesthesia was performed at the indicated times 
post-infection (p.i.) for end-point analyses via intraperitoneal (i.p.) injection of 200μl of 
pentobarbitone sodium solution (‘Pentoject’, AnimalCare Ltd, UK).  
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2.3.2. RV Infection Model with Neutralisation of Airway/Lung IL-15 
BALB/c mice were treated i.n. with 50μl RV-1B (5.0x106 TCID50) or PBS (mock-infected). 
Immediately after infection (0h) and 24h later, mice were treated i.n. with 20μg of an IL-15 
neutralising antibody (M96), which was a gift from Amgen Inc., or mouse IgG2a isotype 
control (R&D Systems). Terminal anaesthesia was administered at 24h and 48h p.i. for end-
point analyses. 
 
 
 
Figure 2.1 RV infection model with antibody-mediated neutralisation of airway/lung IL-15 
 
 
Experimental 
Groups 
RV-1B Infection 
(0h) 
Antibody Treatment  
(0h & 24h) 
RV-M96 YES M96 
RV-ISO YES mIgG2a Isotype Control 
RV-PBS YES PBS 
Mock NO PBS 
 
Table 2.1 RV infection model with neutralisation of airway/lung IL-15, treatment group 
nomenclature. 
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2.3.3. RV-Induced Asthma Exacerbation Model 
All BALB/c mice were sensitized i.p. with 200μl of PBS containing 50μg chicken egg 
ovalbumin (OVA) (Calbiochem, UK) and 2mg aluminium hydroxide (Alum) (Sigma, USA) on d-
13. Mice were then challenged i.n. with 30μl PBS containing 40μg OVA or PBS alone on d-2, -
1 and 0. Immediately following the third OVA challenge on d0, mice were also infected i.n. 
with 50μl RV-1B (2.5x106 TCID50) or UV-RV-1B. Lung function was assessed at 24h p.i. 
(section 2.3.3.1). Terminal anaesthesia was administered at the indicated times p.i. for end-
point analyses. 
 
 
 
Figure 2.2 RV-induced asthma exacerbation model. 
 
 
Experimental Groups I.P. Sensitization 
(d-13) 
I.N. Challenges 
(d-2, -1 & 0) 
I.N. Infection 
(d0) 
RV-OVA OVA-ALUM OVA RV-1B 
UV-OVA OVA-ALUM OVA UV-RV-1B 
RV-PBS OVA-ALUM PBS RV-1B 
UV-PBS OVA-ALUM PBS UV-RV-1B 
 
Table 2.2 RV-induced asthma exacerbation model, treatment group nomenclature. 
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2.3.3.1. Lung Function: Assessment of Airway Hyperreactivity (AHR) 
Airway hyperreactivity was assessed using a wh ole body plethysmography system 
(Electromedsystems, UK) to determine enhanced pause (Penh) area under the curve (AUC). 
Mice were challenged for 1min to increasing doses (0, 3, 10, 30 and 100mg/ml) of 
aerosolized acetyl-β-methyl-choline chloride (methacholine) (Sigma, USA) in H2O, and Penh 
was assessed over 5min periods. A skilled technician (Peter Sowinkski) performed this work 
and the analysis was carried out by myself. Data was acquired and analysed using eDacq 
v1.8 software (Electromedsystems, UK), and is presented as Penh AUC for the 5min log 
period after methacholine challenge. The equation for calculation of Penh is as follows: 
 
 
 
PEF = Peak Expiratory Flow (ml/s) 
PIF = Peak Inspiratory Flow (ml/s) 
Te = Time of Expiration (total) 
Rt = Relaxation Time (time taken for expiration of 65% total expiratory volume 
 
 
2.4. Sample Harvesting & Processing 
2.4.1. Bronchoalveolar Lavage (BAL) 
Lungs of mice were lavaged from the trachea with 1.5ml of BAL fluid. Cells were separated 
from the supernatant/BAL fluid via centrifugation and the latter stored at -80°C for protein 
analysis. BAL cells were treated with 1ml ACK buffer for 1min to lyse the red blood cells, 
prior to resuspension in 1ml of BAL/lung culture medium. The total live BAL cell counts were 
performed by trypan blue exclusion. 
 
2.4.2. Cytospins 
Cytospin3 system (Shandon, USA) was used to spin 100μl of the BAL cell suspension onto 
Shandon Cytoslides. Slides were air dried, followed by fixation with 90% methanol and 
staining with xanthene and thiazine (REASTAIN Quick-Diff kit, Thermo Shandon, PA, USA). 
Slides were air dried again, blinded to experimental conditions and counted using light 
microscopy (400x magnification); at least 300 cells were counted per slide to determine 
differential cell counts. 
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2.4.3. Lung Tissue Processing for Protein Analysis 
The right azygous, cardiac and diaphramic lung lobes were excised post BAL, rinsed in PBS 
and stored at -80°C until further processing. Lungs were homogenised using a  rotor-stator 
for 30 seconds in 600μl homogenising buffer. The homogenate was centrifuged and the 
clarified supernatant removed and stored at -80°C for protein analysis by ELISA (Section 2.9). 
 
2.4.4. BAL Cell and Lung Tissue Processing for RNA Extraction 
BAL cell suspensions were centrifuged and resuspended in 350μl of RLT cell lysis buffer 
(Qiagen, USA) and stored at -80°C until further use. The right apical lung lobe was excised 
following BAL, rinsed in PBS and stored at -80°C in 600μl of RNAlater (Qiagen, USA). 
 
2.4.5. Isolating Lung Cells for Flow Cytometry 
The left lung lobe was excised post BAL for preparation of a single-cell suspension. Lung 
tissue was crudely dissociated in gentle MACS C-tubes containing 5ml of digestion buffer 
using the gentle MACS Dissociator system (Militenyi Biotech, Germany) before incubation 
for 45mins at 37°C (5% CO2). A second round of mechanical dissociation completed the 
digestion protocol before clarification by centrifugation. Red blood cells were lysed in 5ml of 
ACK buffer for 5min, which was neutralised by lung culture medium. Cells are filtered 
through a 100μm cell strainer and washed with PBS, before re-suspending in 2ml lung 
culture medium. The total live lung cell counts were performed by light microscopy with 
trypan blue exclusion and expressed as total number of cells of the left lung lobe. 
 
2.5. Flow Cytometry 
2.5.1. Surface Staining of BAL and Lung Leukocytes 
1x105 BAL cells or 1x106 lung cells were incubated with 5μg/50μl of Fc Block (anti-mouse 
CD16/CD32, BD Biosciences) for 15mins at 4°C. Subsequently, 50μl of fluorochrome-
conjugated monoclonal antibodies specific for surface markers (Table 2.3) diluted in FACS 
buffer was added to the cells/FcBlock and incubated for 30min at 4°C in the dark. Cells were 
then washed with PBS and incubated with 100 μl of a live/dead cell marker (Aqua, 
LIVE/DEAD Fixable Dead Cell Stain Kit, Invitrogen) for 30min at 4°C in the dark. After further 
washes in PBS, cells were fixed and permeabilised during incubation with BD 
Cytofix/Cytoperm buffer (BD Biosciences) for 20min at 4°C in the dark. Cells were then 
washed, resuspended in FACS buffer and analysed immediately. 
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2.5.2. Intracellular Cytokine Staining (ICS) of BAL and Lung Leukocytes 
Unsorted lung and BAL cells were stimulated ex vivo prior to staining protocols to detect 
IFN-γ and IL-4 production. 1x106 cells were incubated in 1 ml of lung cell culture medium 
containing 50ng/ml phorbolmyristate acetate (PMA) (Sigma USA), 500ng/ml ionomycin 
(Sigma, USA) and 1μl/ml BD GolgiPlug or BD GolgiStop (BD Biosciences) for 3h at 37°C (5% 
CO2). Following stimulation, cells were stained and fixed/permeabilised as detailed in 
Section 2.5.1. Subsequently, cells were washed in BD Perm/Wash (BD Biosciences), and 
incubated with 100μl of fluorochrome-conjugated monoclonal antibodies specific for 
intracellular cytokines or isotype control antibodies (Table 2.3) diluted in BD Perm/Wash, for 
30min at 4°C in the dark. Cells were then washed with BD Perm/Wash, resuspended in FACS 
buffer and analysed immediately. 
 
2.5.3. Flow Cytometry Data Acquisition and Analysis 
Stained cells were acquired using a BD LSR II digital flow cytometer (BD Biosciences, San Jose, 
CA) and BD FACS Diva software. Data was analysed using FlowJo 9.3.1.2 software. 
Representative gating strategies and control stains for both surface and intracellular staining 
of BAL and lung cells are illustrated in Figures 2.3-2.7. All flow cytometry data are presented 
as percentage of cell type of the lymphocyte gate or total number of cell type (calculated 
using flow cytometry percentage of cells and total lung or BAL leukocyte counts). 
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Specificity Clone Conjugate Working Dilution 
Rat anti-mouse CD3e 500A2 Alexa Fluor® 700 1:200 – 2.5μg/ml 
Hamster anti-mouse CD4 RM4-5 V450 1:800 – 0.63μg/ml 
Rat anti-mouse CD8a 53-6.7 PE-Cy7 1:400 – 1.25μg/ml 
Hamster anti-mouse CD69 H1.2F3 FITC 1:100 – 5μg/ml 
Rat anti-mouse NKp46 29A1.4 PerCP-Cy5.5 1:100 – 5μg/ml 
Rat anti-mouse NK1.1 PK136 PE 1:100 – 5μg/ml 
Mouse anti-human GranzymeB GB12 APC 1:200 – 2.5μg/ml 
Rat anti-mouse IFN-γ  XMG1.2 PE 1:100 – 5μg/ml 
Rat anti-mouse IFN-γ  XMG1.2 FITC 1:100 – 5μg/ml 
Rat anti-mouse IL-4 11B11 PE 1:100 – 5μg/ml 
Rat anti-mouse CD16/CD32 2.4G2 None (purified) 1:100 – 5μg/ml 
Isotype control GranzymeB - APC 1:200 – 2.5μg/ml 
Isotype control IFN-γ  - PE 1:100 – 5μg/ml 
Isotype control IFN-γ  - FITC 1:100 – 5μg/ml 
Isotype control IL-4 - PE 1:100 – 5μg/ml 
 
Table 2.3 Monoclonal antibodies used for flow cytometry (BD Biosciences). 
Abbreviations: PE – Phycoerythrin, FITC – Fluorescein isothiocyanate, PerCP – Peridinin chlorophyll 
proteins, Cy – Cyanine and APC –Allophycocyanin.  
 
 
2.6. Taqman Quantitative PCR 
2.6.1. RNA Extraction and Reverse Transcription 
The right apical lung lobe was homogenised in 600μl RLT cell lysis buffer (Qiagen, USA) using 
rotor-stator for 30 seconds, and RNA was extracted using the Qiagen RNeasy Mini kit 
(Qiagen, USA) according to manufacturers’ instructions. This kit was also used to extract RNA 
from lysed BAL cells. During the extraction protocol, contaminating DNA was removed by 
incubation with DNase I (Qiagen, USA). The eluted RNA (5μg/sample extraction) was 
converted into cDNA in reactions containing 10μM random hexamers as primers (Promega, 
USA), 0.5μM dNTPs, RT (reverse transcriptase) buffer and 0.2units/μl Reverse Transcriptase 
(all Omniscript RT kit, Qiagen, USA); the reaction was performed for 1.5h at 37°C. 
 
2.6.2. qRT-PCR  
Taqman quantitative real-time PCR (qPCR) was carried out using 1μl of cDNA with 
Quantitect Probe PCR Mastermix (Qiagen, USA) and primers (Invitrogen, UK) and 
FAM/TAMRA-labelled probes (Qiagen, UK) specific for the 5’–unstranslated region of the 
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gene of interest, positive sense RV RNA (Cantoli et al., 2006) or 18s ribosomal RNA (Table 
2.4). cDNA was diluted 1:100 in dH20 for analysis of 18s ribosomal RNA (rRNA) expression 
levels. Reactions were performed in duplicate on an ABI 7500 Fast Real-Time PCR System 
(Applied Biosystems, USA). PCR cycling conditions were as follows: 2min at 50°C, 10min at 
95°C and 45 cycles of 15 seconds at 95°C and 1min at 60°C. Data was analysed on SoftMax 
Pro software, and results are expressed as gene mRNA or viral RNA copies per μl of cDNA 
sample generated from the RT process (copies/μl). Table 2.4 is an example of the analysis 
producing the normalised gene copy numbers per sample of a data set/experiment. Gene 
copy numbers were obtained using a plasmid DNA standard curve run on the same Taqman 
qPCR plate, which was then normalised by taking into account the differences in 18s rRNA Ct 
values between each sample in a data set/experiment.  
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1 6670 5438 6054 19.000 19.056 19.028 0.482 1.397 8457 
2 3037 2627 2832 18.776 18.672 18.724 0.179 1.132 3206 
3 2245 2433 2339 19.032 18.861 18.947 0.401 1.321 3089 
4 3053 3750 3402 18.820 18.925 18.873 0.327 1.254 4268 
5 2147 2339 2243 19.073 18.971 19.022 0.476 1.391 3121 
6 2316 2274 2295 19.202 19.234 19.218 0.672 1.594 3657 
7 2075 2087 2081 18.969 19.117 19.043 0.497 1.412 2938 
8 2579 2789 2684 18.623 18.468 18.546 0.000 1.000 2684 
9 2601 3105 2853 18.641 18.541 18.591 0.046 1.032 2945 
10 4483 5299 4891 19.036 18.964 19.000 0.454 1.370 6702 
 
Table 2.4 Example of Taqman qPCR Analysis. Calculations to generate gene mRNA or viral rRNA 
copies per µl of cDNA sample generated from the RT process after RNA extraction from lung tissue or 
BAL cells, in which 5µg of extracted RNA was used to generate cDNA in each sample. Plasmid DNA 
standards were run on each Taqman qPCR plate to generate a standard curve, from which gene copy 
numbers were obtained based on corresponding Ct values. Gene copy numbers were then normalised 
between samples in an experimental data set based on differences in the quantity of the house 
keeping gene 18s rRNA.  
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2.6.3. qPCR Standards 
PCR products for specific genes were generated (Section 2.6.2) and separated on a 1% (w/v) 
agarose, tris-acetate-EDTA (TAE) gel alongside a 100bp-12kB DNA ladder (Invitrogen, USA). 
The correct sized PCR product was excised from the gel and purified using a QIAquick gel 
extraction kit (Qiagen, USA), and subsequently ligated into pCR2.1 TOPO TA vector 
(Invitrogen, USA). Chemically competent TOP10 E.coli cells (Invitrogen, USA) were 
transformed with the vector by heat shock, and cultured overnight at 37°C on Lysogeny 
broth (LB) agar plates containing 50μg/ml ampicillin (Sigma, USA). Colonies transformed 
with vectors containing the insert were screened by restriction digest using EcoR1 restriction 
endonuclease (Promega, USA) and by qPCR as described. Positive clones were amplified by 
culturing in batch overnight in LB broth containing 50μg/ml ampicillin at 37°C with shaking. 
Plasmid DNA was purified using a plasmid ‘Maxi’ or ‘Midi’ kit (Qiagen, USA), quantified by 
qPCR and diluted in nuclease-free H2O for use as a standard in further qPCR assays. 
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Gene Primer/ 
Probe 
Sequence 5’-3’ 
 
IL-15 
Forward cctgcaagtctctcccaattct 
Reverse tccctgcagcgcgctaag 
Probe FAM – cgcccaaaagacttgcagtgcatct– TAMRA 
 
IL-15Rα 
Forward tctccccacagttccaaaatg 
Reverse aacccctgcaccaaccaa 
Probe FAM – cgaaagtggccatctctacatcggtcc– TAMRA 
 
IFN-β 
Forward ccatcatgaacaggtggat 
Reverse gagagggctgtggtggagaa 
Probe FAM – ctccacgctgcgttcctgctgtg– TAMRA 
 
IFN-λ2/3 
Forward aaaggattgccacattgctc 
Reverse tcaagcagcctcttctcgat 
Probe FAM – tccccaaaagagctgcaggc– TAMRA 
 
IFN-γ 
Forward tcaagtggcatagatgtggaagaa 
Reverse tggctctcgaggattttcatg 
Probe FAM – tcaccatccttttgccagtt – TAMRA 
 
OAS-1a 
Forward tcctgggtcatgttaatacttcca 
Reverse ccccagggaggtacattcct 
Probe FAM – caagcctgatcccagaatctatgc cat c – TAMRA 
 
PKR 
Forward cggaacatcctctagcgttgtc 
Reverse gggaaacaccattacttgtcatagac 
Probe FAM – agctgctggaaaagccactga – TAMRA 
 
Viperin 
Forward cgaagacatgaatgaacacatcaa 
Reverse aattaggaggcactggaaaacct 
Probe FAM – ccagcgcacagggctcaggg – TAMRA 
 
IL-4 
Forward acaggagaagggacgccat 
Reverse gaagccctacagacgagctca 
Probe FAM – tcctcacagcaacgaaga – TAMRA 
 
IL-5 
Forward cccatgagcacagtggtgaa 
Reverse gggacaggaagcctcatcg 
Probe FAM – ccgctcaccgagctctgttgacaag – TAMRA 
 
IL-13 
Forward gatattgcatggcctctgtaacc 
Reverse gggctacttcgattttggtatcg 
Probe FAM – caaggcccccactacggtctcca – TAMRA 
 
HRV 
Forward gtgaagagccacttgtgct 
Reverse gctacagggttaaggttagcc 
Probe FAM – tgagtcctccggcccctgaatg – TAMRA 
 
18s 
Forward cgccgctagaggtgaaattct 
Reverse cattcttggcaaatgctttcg 
Probe FAM – accggcgcaagacggaccaga – TAMRA 
 
Table 2.5 Taqman quantitative PCR primers and probes.  
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2.7. ELISA 
ELISAs for mouse IL-1β, IL-4, IL-5, IL-6, IL-12, IL-13, IL-15, IFN-λ/IL-28, KC/CXCL1, tumour 
necrosis factor alpha (TNF-α), Regulated upon Activation, Normal T-cell Expressed, and 
Secreted (RANTES/CCL5), macrophage derived chemokine (MDC/CCL22), thymus and 
activation regulated chemokine (TARC/CCL17), IFN-γ inducible protein 10 (IP-10/CXCL10), 
IFN-inducible T cell alpha chemoattractant (I-TAC/CXCL11), and Eotaxin/CCL11 were all 
performed with Duoset ELISA kits (R&D Systems, USA) according to manufacturers’ 
instructions. All steps were performed at RT. Briefly, 96-well Nunc Maxisorp Immunoplates 
(Thermo-Fischer, USA) were coated with 100μl of capture antibody in PBS overnight, and 
subsequently washed thrice with ELISA wash buffer and blocked with 250μl reagent diluent 
for 1h. Plates were washed and 100μl of appropriately diluted sample (BAL fluid or clarified 
lung homogenate) was added in duplicate and incubated for 2h. Plates were washed and 
incubated with a biotinylated detection antibody in reagent diluent for 2h, followed by 
further washes and incubation with 250ng/ml Streptavidin-horseradish peroxidase (HRP) 
conjugate in reagent diluent for 20min. After the final washes, 100μl of 3,3’3,5’ 
tetramethylbenzidine (TMB) single solution chromagen substrate (Invitrogen, USA) was 
added and the reaction subsequently stopped upon addition of 50μl 1M H2SO4.  
 
The soluble IL-15/IL-15Rα complex ELISA kit (eBiosciences) differed in that the capture 
antibody was incubated at 4°C overnight and both detection antibody and HRP were 
incubated for 1h. IFN-α and IFN-β ELISA kits (R&D Systems/PBL Interferon Source, USA) also 
differed to the above protocols as follows. Primarily, plates provided were pre-coated with 
capture antibody. For the IFN-β ELISA, incubation with sample, secondary antibody and HRP 
were performed for 1h. For the IFN-α ELISA, sample was incubated simultaneously with 
detection antibody for 1h at RT with shaking (450rpm), followed by overnight incubation at 
4°C. Subsequently, plates were washed and incubated with HRP solution for 2h at RT with 
shaking, prior to washing and reaction development.  
 
Proteins were quantified by comparison to an 8-point standard curve using recombinant 
protein. Plates were analysed by a Spectramax Plus plate reader, and the optical density of 
each well determined by the absorbance at 450nm. Data was analysed with Softmax Pro 
3.1.2 software (Molecular Devices, USA). 
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2.8. Immunohistochemistry 
Formalin-fixed paraffin/embedded mouse lungs were single stained for 
immunohistochemistry as previously described [255]. Briefly, lungs sections were 
deparaffinised and rehydrated to expose immunoreactive epitopes and incubated in a 
microwave oven (model NN SN00W; Panasonic, Milano, Italy) with the sections immersed in 
citrate buffer (5mM at pH6.0) for 40min. Slides were then incubated in 3% hydrogen 
peroxide/PBS to inhibit endogenous peroxidase activity and subsequently washed in PBS. 
Incubation in 0.1% saponin/PBS permeabalised cell membranes. Non-specific staining was 
blocked by incubation with coating serum (5% rabbit serum) for 20 min at RT, followed by 
PBS washes. Sections were then incubated for 1h at RT with goat anti-mouse IL-15 (R&D 
Systems) at dilution of 1:50. Negative control slides were stained with normal goat non-
specific immunoglobulins (Santa Cruz Biotechnology) at the same concentration. After PBS 
washes, sections were incubated with rabbit anti-goat biotinylated antibody (Vectastain Elite 
ABC Kit, Vector Laboratories; www.vectorlabs.com) for 30 min at RT, followed by PBS 
washes. Subsequently, slides were incubated with ABC reagent (Vectastain Elite ABC Kit, 
Vector Laboratories) for 30min at RT, followed by incubation with chromogen-fast 
diaminobenzidine (DAB) as a chromogenic substrate. Slides were then counterstained in 
haematoxylin and mounted on permanent mounting medium. Staining and scoring my light 
microscopy was performed by Gaetano Caramori (Rome, Italy). 
 
2.9. Statistical Analysis 
All graphical data are expressed a means ± SEM of at least 4 mice per experimental 
condition, and is representative of or including at least 2 independent experiments. Data 
was analysed by two-way ANOVA, and individual significant differences between specific 
groups were indicated by Bonferroni’s post-tests. Significant differences are indicated within 
95% confidence intervals i.e. p <0.05, and specific p values are indicated in figure legends. 
Where differences between data are not significant, no statistics are stated. All data was 
statistically analysed by Prism4 software (Graphpad, USA). 
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Medium/Buffer Composition 
 
HeLa Cell Growth Medium 
Dulbecco’s Modified Eagles Medium (DMEM) (PAA Laboratories) containing 
2mM L-glutamine, 20μM HEPES buffer, 1% (v/v) sodium bicarbonate and 
10% (v/v) foetal bovine serum (FBS) (all Gibco). 
HeLa Cell Infection Medium Same as ‘Growth Medium’ except 2% (v/v) FBS. 
HeLa Cell Virus Titration 
Medium 
Same as ‘Growth Medium’ except 4% (v/v) FBS. 
 
Lung/BAL Cell Culture 
Medium 
RPMI 1640 Medium (PAA Laboratories) containing 2mM L-glutamine, 20μM 
HEPES buffer, 1% (v/v) sodium bicarbonate, 10% (v/v), 100μg/ml 
streptomycin (Sigma, USA), 100units/ml penicillin (Sigma, USA) and 10% 
(v/v) foetal bovine serum (FBS). 
BAL Fluid Phosphate buffered saline (PBS) (Company) containing0.5M disodium EDTA 
solution (Gibco) and 12mM lidocaine hydrochloride monohydrate (Sigma). 
 
ACK Lysis Buffer 
1 litre dH2O containing 0.15M Ammonium chloride (Sigma), 1mM potassium 
bicarbonate (Sigma) and 0.1mM disodium EDTA (Gibco). Filter-sterilized 
through a 0.22μm filter. 
Lung Digestion Buffer ‘Lung Cell Culture Medium’ containing 1mg/ml Collagenase Type XI (Sigma) 
and 30μg/ml Bovine Pancreatic DNase I Type IV (Sigma). 
Lung Homogenisation Buffer PBS containing  ‘Complete, Mini, EDTA-free Protease Inhibitor Cocktail 
Tablets’ (Roche). 
FACS Buffer PBS containing 1% (w/v) BSA (Sigma) and 0.01% (v/v) sodium azide. 
ELISA Wash Buffer PBS containing 0.05% (v/v) polyethylene glycol sorbitan monolaurate 
(‘Tween20’, Sigma)  
ELISA Reagent Diluent PBS containing 1% (w/v) BSA (Sigma) 
RLT Cell Lysis Buffer RLT lysis buffer (Qiagen) containing 2-mercaptoethanol (Sigma). 
LB Medium 1 litre of dH2O with 10g Tryptone powder (Fluka, Germany), 5g yeast extract 
(Sigma) and 5g sodium chloride (VWR, UK). Autoclave sterilised.  
LB Agar  ‘LB Medium’ containing 14g Bacto-Agar (Difco, USA).  
 
Table 2.6 Media and Buffers. 
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Figure 2.3 Representative flow cytometry gating for live, single lymphocytes. 
All flow cytometry data is presented as live lymphocytes as the common denominator.  
Abbreviations: FSC-A Forward Scatter-Area, FSC-W Forward Scatter-Width, SSC-A Side Scatter-Area, 
SSC-W Side Scatter-Width. 
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Numbers indicated on plots represent the percentage of events falling within the indicated gate. 
 
  
Figure 2.4 Representative flow cytometry gating for BAL lymphocytes in BALB/c mice and NK 
cells in C57BL/6 mice. 
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Numbers indicated on plots represent the percentage of events falling within the indicated gate. 
  
Figure 2.5 Representative flow cytometry gating for lung lymphocytes in BALB/c mice and NK 
cells in C57BL/6 mice. 
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Figure 2.6 Representative flow cytometry gating for intracellular cytokine staining in lung NK cells. 
Numbers indicated on plots represent the percentage of events falling within the indicated gate. 
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Figure 2.7 Representative flow cytometry gating for intracellular cytokine staining in lung T cells. 
Numbers indicated on plots represent the percentage of events falling within the indicated gate. 
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3. Chapter 3: Results - IL-15 expression and the NK cell response during RV-1B 
infection 
3.1. Introduction 
RV infections are amongst the most frequent infections encountered and are the most 
common etiological agents of the common cold [3]. RV infections are self limiting, and a 
healthy host does not usually suffer profoundly. However, RV infections are associated with 
more severe airways disease in asthmatics as they trigger approximately two thirds of acute 
exacerbations [77], and this is the major reason for investigating the immune response to RV 
infections.  
 
IL-15 is a proinflammatory cytokine that exhibits a number of antiviral properties, and plays 
a significant role in defence against viruses. Stimulation of macrophages and DCs with LPS, 
dsRNA and IFN-α/β has been demonstrated to induce IL-15 expression [118]. To date, only 
one study has specifically analysed expression of IL-15 in response to RV infection using 
cultured macrophages [256]; data of IL-15 expression and its role in the immune response to 
RV infections in vivo is lacking.  
 
NK cells are key innate antiviral effector cells, which unlike T cells do not require priming for 
activation. NK cells express a variety of activating and inhibitory receptors that allow quick 
and early detection of virus infection, resulting in their activation and early control of virus 
replication and spread. IL-15 is critical for the development and maintenance/homeostasis 
of NK cells, as demonstrated by their absence in IL-15 and IL-15Rα knockout mice. As 
discussed in chapter 1, regulation of NK cell responses appears to be the main reported 
antiviral function of IL-15.  
 
No previous study has provided a thorough analysis of IL-15 and NK cell responses to RV 
infection in vivo. Analysis of this pathway may provide insight into the early innate control of 
RV spread, which could be important when assessing potential therapeutic targets for 
individuals that experience more severe RV infections. A mouse study of RV infection can 
provide a more thorough analysis of IL-15 and type I IFN expression in addition to the NK cell 
response than afforded in human studies. A comprehensive timecourse allows us to 
examine gene expression and protein levels in the airway lumen and lung tissue. Flow 
cytometry allows real time analysis of the NK cell response in both the airway/mucosal 
surfaces (in BAL) and lung tissue, via measuring expression of surface and intracellular 
molecules, some of which represent an activated status.   
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3.2. Hypotheses &  Aims 
3.2.1. Hypotheses 
 
i. RV-1B infection increases IL-15 and IL-15Rα expression in the lungs and this is 
associated with RV-induced type I IFN expression.  
ii. RV-induced IL-15 expression is associated with recruitment/expansion and 
activation of NK cells in the airway and lungs and precedes T cell responses. 
 
3.2.2. Aims 
To investigate IL-15 expression and the NK cell response in BALB/c mice during infection 
with a minor group RV (RV-1B). 
 
i. To determine the virus load in the lungs using Taqman qPCR.  
ii. To determine the magnitude, kinetics and cellular source(s) of IL-15 and IL-15Rα in 
the airway and lungs using Taqman qPCR, ELISAs and immunohistochemistry.  
iii. To determine expression of IFNs, ISGs, and proinflammatory cytokines and 
chemokines using Taqman qPCR and ELISAs.    
iv. To determine the magnitude, kinetics and activation status of the NK cell response 
in the airway and lungs using flow cytometry. 
v. To examine the acquired T cell response in the airway and lungs using flow 
cytometry. 
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3.3. Results 
3.3.1. Virus Load 
BALB/c mice were infected i.n. with RV-1B (5.0x106 TCID50) or UV-irradiated RV-1B (UV-RV-
1B). Virus load in the lungs was determined at various time points post-infection (p.i.), by 
detecting viral RNA in lung homogenate via qPCR. Here, we demonstrated persistence of the 
virus in the lungs between d1-2 p.i. in RV-1B treated mice, after which levels declined 
though virus remained detectable at d7 p.i., consistent with previous findings [255] (Fig 3.1). 
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Figure 3.1 Virus load in the lungs during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock). Lungs were harvested at the 
indicated timepoints p.i., and processed for RNA extraction and cDNA was made by reverse 
transcription as described. RV-1B viral RNA copies were quantified by qPCR, data was normalised 
against 18s rRNA expression and presented as RNA copies/μl of sample. Data are expressed as means 
± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is for RV-1B compared with UV-RV-1B or PBS treatments at the indicated times 
(***p<0.001). Only statistically significant differences are shown. 
 
3.3.2. Differential BAL Cell Counts 
Total BAL cell counts demonstrated a significant and rapid influx of cells into the airways by 
d1 p.i. with RV-1B infection, with numbers peaking at d2 and declining thereafter (Fig 3.2a). 
The airways cellular inflammatory profile was determined by differential cell counts based 
on cellular morphology from cytospin slides of BAL cells. As previously reported by Bartlett 
et al. [255], RV-1B induced a peak of neutrophilia at d1 p.i. (p<0.001 compared to controls), 
at which neutrophils made up to ~80% of the total BAL cells (Fig 3.2 b&c); neutrophilia was 
resolved between d4-7. Lymphocyte numbers also increased in the BAL at d2 p.i. with RV-1B 
and peaked at d4, at which they comprised ~35% of the total BAL cells (p<0.001 compared 
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to controls) (Fig 3.2 d&e); an elevated percentage of BAL lymphocytes was still detected at 
d7. These responses were virus-replication dependant as they were not observed in mice 
treated with UV-RV-1B. 
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Figure 3.2 Differential BAL cell counts during RV-1Binfection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock) and BAL was performed at the 
indicated timepoints p.i. Recovered live BAL cells were counted (a) and processed for cytospin slides. 
Slides were blinded to experimental conditions and cells differentially counted to give the percentage 
and absolute number of (b&c) neutrophils and (d&e) lymphocytes in the airway. Data are expressed 
as means ± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. 
Statistical significance is for RV-1B compared with UV-RV-1B and mock treated mice at the indicated 
times (***p<0.001, **p<0.01& *p<0.05). Only statistically significant differences are shown. 
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3.3.3. BAL Proinflammatory Mediators 
As previously reported by Bartlett et al. [255], RV-1B infection induced production of a range 
of mediators including the following as detected by ELISAs in the BAL fluid. Coinciding with 
the peak of neutrophilia, production of KC, a neutrophil chemoattractant, peaked at d1 p.i. 
infection (p<0.001) and declined thereafter, though levels at d2 were still significantly 
elevated (p<0.001) (Fig 3.3a). Proinflammatory cytokines IL-6 and IL-1β were both 
significantly induced at d1 p.i. with RV-1B (p<0.001), and though IL-6 levels rapidly 
decreased thereafter, IL-1β remained elevated at d2 p.i. (p<0.01) (Fig 3.3 b&c). Lastly, TNF-α 
was induced at d2-4 p.i. (p<0.01), after which levels declined (Fig 3.3d).  
 
1 2 4 7
0
250
500
750
1000 RV-1B
UV-RV-1B
Mock
***
***
***
***
Days Post Infection
B
A
L
 K
C
 P
ro
te
in
 L
e
v
e
ls
(p
g
/m
L
)
1 2 4 7
0
50
100
150
200 RV-1B
UV-RV-1B
***
Mock
***
Days Post Infection
B
A
L
 I
L
-6
 P
ro
te
in
 L
e
v
e
ls
(p
g
/m
L
)
1 2 4 7
0
25
50
75
100 RV-1B
UV-RV-1B
** Mock
***
***
**
Days Post Infection
B
A
L
 I
L
-1

 P
ro
te
in
 L
e
v
e
ls
(p
g
/m
L
)
1 2 4 7
0
50
100
150
200
250
300
350
400
450 RV-1B
UV-RV-1B
Mock
**
**
**
**
Days Post Infection
B
A
L
 T
N
F
- 
 P
ro
te
in
 L
e
v
e
ls
(p
g
/m
L
)
(a) (b)
(c) (d)
 
Figure 3.3 BAL cytokines and chemokines produced in response to RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (d0), and BAL was performed at the 
indicated timepoints p.i. Protein levels of (a) KC, (b) IL-6, (c) IL-1β and (d) TNF-α were quantified by 
ELISA in the BAL fluid and expressed as pg/ml. Data are expressed as means ± SEM of4-6 mice per 
group and is representative of at least 2 independent experiments. Statistical significance is for RV-1B 
compared with UV-RV-1B treated animals at the indicated times (***p<0.001, **p<0.01 & *p<0.05). 
Only statistically significant differences are shown. 
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3.3.4. Expression of IL-15 and IL-15Rα 
3.3.4.1. BAL and Lung IL-15 and IL-15Rα Gene Expression 
IL-15 is reported to be expressed by monocytes, macrophages and DCs [254]. qPCR analysis 
of BAL cells demonstrated a sharp peak of IL-15 and IL-15Rα mRNA expression with RV-1B 
infection at d1 p.i. (p<0.001 compared to controls), after which levels rapidly declined (Fig 
3.4 a&b). Analysis of lung homogenate demonstrated a significant upregulation of IL-15 
mRNA by ~3-fold in RV-1B treated mice at d1 p.i. (p<0.001 vs UV-RV-1B; p<0.01 vs mock), 
and levels declined thereafter though remained elevated over mock controls at d2 (p<0.01) 
(Fig 3.4c). Expression of IL-15Rα in the lungs during RV-1B infection mirrored that of IL-15, 
with a 2-fold increase of mRNA levels at d1 p.i. (p<0.001) (Fig 3.4d). Comparison of the two 
sources demonstrates that BAL cells expressed much higher levels of both genes at d1 p.i. 
compared to lung tissue, suggesting that they may be a more important source of IL-15/IL-
15Rα signalling. 
 
3.3.4.2. Lung IL-15 and IL-15Rα Protein Expression 
 
To detect IL-15 and IL-15Rα protein in lung homogenate that was either intracellular or 
attached to the cell surface, lungs were homogenised and the clarified supernatant analysed 
by ELISA. In coordination with mRNA expression, we detected upregulation of both IL-15 
protein and soluble IL-15/IL-15Rα complexes (sIL-15/IL-15Rα) at d1 p.i. with RV-1B infection 
(p<0.001 vs UV-RV-1B; p<0.01 vs mock) (Fig 3.4 e&f). Extremely high levels of protein were 
detected suggesting a high degree of background associated with this method, though 
previously reported constitutive expression of IL-15 by lung epithelium [257] explains 
detection of protein in control groups. To further confirm IL-15 protein expression using a 
different technique, immunohistochemistry was performed on lung sections to illustrate 
increased expression of IL-15 protein at d1 and d2 p.i. with RV-1B (Fig 3.5). 
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Figure 3.4 RV-1B infection induces IL-15 and IL-15Rα expression in BAL cells and lung tissue. 
 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and lungs were harvested after 
BAL was performed at the indicated timepoints p.i. Lungs and BAL cells were processed for RNA 
extraction and cDNA made by reverse transcription as described. Gene expression levels of (a & c) IL-
15 and (b& d) IL-15Rαwere quantified by qPCR in lung and BAL cells. Data was normalised against 18s 
rRNA expression and presented as copies of mRNA/μl of sample. Protein expression of (e) IL-15 and 
(f) soluble IL-15/IL-15Rα complexes were analysed by ELISA using lung homogenate, and expressed as 
pg/ml. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 
independent experiments. Statistical significance is for RV-1B compared with UV-RV-1B or PBS 
treatments at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant 
differences are shown. 
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Figure 3.5 Immunohistochemistry staining for IL-15 expression in the lungs of BALB/c mice in 
response to RV-1B infection. 
IL-15 expression in (a&b) RV-1B, (c&d) UV-RV-1B and (e&f) mock treated mice at d1 and d2 p.i. 
respectively. (g) Negative control. Total magnification x400.    
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3.3.5. Expression of Type I and III Interferons 
Previous studies have reported that IFN-β is required for IL-15 expression, thus we 
hypothesised that RV-induced IFN regulates IL-15 expression. IFN-α mRNA was not tested by 
qPCR as 13 subtypes exist; however, IFN-α protein was detected in the BAL fluid by ELISA at 
d1 p.i. with RV-1B (p<0.001 vs controls) and levels rapidly declined thereafter (Fig 3.6a). IFN-
β expression was analysed by qPCR and ELISA. Very low mRNA levels were detected in lung 
homogenate (data not shown) but significant expression in BAL cells at 10h and d1 p.i. with 
RV-1B was observed (p<0.01 and p<0.001 vs controls) (Fig 3.6b). Protein was detected in 
both the BAL fluid and lung homogenate at d1 p.i. with RV-1B (p<0.001 and p<0.05 vs 
controls) (Fig 3.6 c&d). Thus, we showed that RV-mediated IL-15 expression was associated 
with expression of type I IFNs at d1 p.i. and both responses were virus-replication 
dependent. 
 
Type III IFNs are known to be virally induced and their expression is also an indication of IFN-
α/β signalling. In the lungs, IFN-λ2/3 mRNA levels peaked at d1 p.i. with RV-1B (p<0.001 
compared to controls) and declined thereafter, though mRNA remained detectable at d2-4 
p.i. (ns) (Fig 3.6e). Protein levels peaked in the BAL fluid at d1 p.i. with RV-1B, remained 
significantly elevated over controls at d2 and decreased thereafter however, protein was still 
detectable in RV-1B treated mice at d7 (p<0.05) (Fig 3.6f). 
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Figure 3.6 RV-1B infection induces expression of type I and III IFNs in BAL cells and lung tissue.  
BALB/c mice were dosed i.n. with RV-1B, UV-RV-1B or PBS (mock), and lungs were harvested after BAL 
was performed at the indicated times after infection. Protein levels of (a) IFN-α, (c) IFN-β and (f) IFN-λ 
in the BAL fluid and (d) IFN-β in lung homogenate were analysed by ELISA and data expressed as 
pg/ml. Lung and BAL cells were processed for RNA extraction and  gene expression levels of (b) IFN-β 
in BAL cells and (e) IFN-λ2/3 in lung tissue were quantified by qPCR. Data was normalised against 18s 
rRNA expression and presented as copies of mRNA/μl of sample. Data are expressed as means ± SEM 
of 4-6 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is for RV-1B compared with UV-RV-1B or PBS treatments at the indicated times 
(***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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3.3.6. NK Cell Response to RV-1B Infection 
Flow cytometry was used to assess the magnitude, kinetics and activation status of the NK 
cell response to RV-1B infection in BALB/c mice. Recovered BAL and lung cells were stained 
for surface expression of CD3, NKp46 and CD69, and for intracellular cytokines IFN-γ and 
GranzymeB.  
 
3.3.6.1. BAL NK Cells 
NK cells are defined as CD3- and NKp46+ in BALB/c mice, and in the absence of infection 
there were virtually no NK cells in the BAL. In response to RV-1B infection, there was a large 
increase in NK cell numbers in the airway at d1 p.i., which peaked at d2 (p<0.001 vs controls) 
(Fig 3.7b), at which they comprised ~30% of total BAL lymphocytes (Fig 3.7a) and levels 
declined thereafter. To define the populations of activated NK cells, CD3- live lymphocytes 
were gated on, from which the percentage and absolute numbers of NKp46+/CD69+, 
NKp46+/IFN-γ+ and NKp46+/GranzymeB+ cells were analysed. Correspondingly, the 
percentage and absolute numbers of activated NK cells positive for the above markers, 
peaked at d2 p.i. in the airway (p<0.001 vs controls), after which levels rapidly declined (Fig 
3.7 c-h). Thus, we showed that this RV-mediated influx of activated NK cells into the airway 
was temporally or in time associated with expression of IL-15 and IL-15Rα at d1 p.i. 
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Figure 3.7 BAL NK cell response during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and BAL was performed at the 
indicated timepoints p.i. 1x10
5
BAL cells were stained for surface markers CD3, CD69 and NKp46, 
intracellular cytokines IFN-γ and GranzymeB and a dead cell marker; staining was analysed on a BD 
LSR II flow cytometer as described. Data are presented as percentage and absolute numbers of BAL 
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(a&b) CD3-/NKp46+, (c&d) CD3- gated, NKp46+/CD69+, (e&f) NKp46+/IFN-γ+ and (g&h) 
NKp46+/GranzymeB+ NK cells. Data are expressed as means ± SEM of4-6 mice per group and is 
representative of at least 3 independent experiments. Statistical significance is for RV-1B compared 
with UV-RV-1B or PBS treatments at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
 
3.3.6.2. Lung NK Cells 
In the lungs, the percentage of CD3-/NKp46+ NK cells was elevated in RV-1B treated mice 
compared to controls at d1-4 p.i., though significance was not reached (Fig 3.9a). However, 
upon translation of percentages using total lung cell counts (Fig 3.8), a significant increase in 
absolute numbers of NK cells was observed at d2-4 p.i. with RV-1B (Fig 3.9b), and numbers 
returned to baseline levels by d7.  
 
Despite total numbers being significantly elevated only by d2 p.i., NK cells in the lungs had 
already upregulated expression of CD69, IFN-γ and GranzymeB by d1 p.i. with RV-1B 
compared to controls (Fig 3.9 c-h). However, the peak of expression of these activation 
markers on NK cells was on d2 p.i. with RV-1B, demonstrated by both percentage and 
absolute cell numbers (p<0.001 vs controls). Percentage of IFN-γ+ and GranzymeB+ NK cells 
peaked at d2 p.i. with RV-1B compared to controls (p<0.001)  and levels remained elevated 
at d4 over controls (Fig 3.9 e&g); this trend was similarly mirrored by the total number of NK 
cells positive for IFN-γ or Granzyme B (Fig 3.9 f&h). Resolution of the NK cell response in the 
lungs was observed by d7.  
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Figure 3.8 Total lung leukocyte count during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and the left lung lobe excised 
after BAL was performed at the indicated time points p.i. Lungs were digested as described, and the 
resultant single-cell suspension counted to give the total number of live cells. Data are expressed as 
means ± SEM of 4-6 mice per group and is representative of at least 3 independent experiments. 
Statistical significance is for RV-1B compared with UV-RV-1B or PBS treatments at the indicated times 
(***p<0.001). Only statistically significant differences are shown. 
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Figure 3.9 Lung NK cell response during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 
cells were stained for surface markers CD3, CD69 and NKp46, intracellular cytokines IFN-γ and 
GranzymeB and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. 
Data are presented as percentage of lymphocytes and absolute numbers of (a &b) CD3-/NKp46+ NK 
cells, CD3- gated double positive (c&d) NKp46+/CD69+, (e&f) NKp46+/IFN-γ+ and (g&h) 
  82 
 
NKp46+/GranzymeB+ NK cells. Data are expressed as means ± SEM of 4-6 mice per group and is 
representative of at least 3 independent experiments. Statistical significance is for RV-1B compared 
with UV-RV-1B or PBS treatments at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
 
3.3.7. T Cell Response to RV-1B Infection 
3.3.7.1. BAL T Cells 
CD4+ T cells were recruited/expanded in the airway from d2 p.i. with RV-1B compared to 
controls, with the percentage and absolute number peaking at d7, at which point they 
comprised ~40% of BAL lymphocytes (Fig 3.10 a&b). The percentage of CD69+ and IFN-γ+ 
CD4+ T cells were consistently elevated in RV-1B treated mice compared to controls at d1-7 
p.i. (Fig 3.10 c&e), however absolute numbers increased progressively between d2-7 (Fig 
3.10 d&f). 
 
Similarly, the number of CD8+ T cells in the airway incrementally increased from d2 p.i. with 
RV-1B until d7 (Fig 3.11b), at which point they comprised ~10% of BAL lymphocytes (Fig 
3.11a). The percentages of CD69+ and IFN-γ+ CD8+ T cells were elevated by d1 p.i., however 
significant increases in cell numbers were observed only from d2 until d7 (Fig 3.11 d&f).  
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Figure 3.10 BAL CD4+ T cell response during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and BAL was performed at the 
indicated timepoints p.i. 1x10
5
 BAL cells were stained for surface markers CD3, CD4 and CD69, 
intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow 
cytometer as described. Data are presented as percentage of BAL lymphocytes and absolute numbers 
of (a &b) CD3+/CD4+ T cells, and CD3+ gated double positive (c&d) CD4+/CD69+ and (e&f) CD4+/IFN-
γ+ T cells. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 3 
independent experiments. Statistical significance is for RV-1B compared with UV-RV-1B or PBS 
treatments at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant 
differences are shown. 
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Figure 3.11 BAL CD8+ T cell response during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and BAL was performed at the 
indicated timepoints p.i. 1x10
5
 BAL cells were stained for surface markers CD3, CD8 and CD69, 
intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow 
cytometer as described. Data are presented as percentage of BAL lymphocytes and absolute numbers 
of (a &b) CD3+/CD8+ T cells and CD3+ gated double positive (c&d) CD8+/CD69+ and (e&f) CD8+/IFN-
γ+ T cells. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 3 
independent experiments. Statistical significance is for RV-1B compared with UV-RV-1B or PBS 
treatments at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant 
differences are shown. 
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3.3.7.2. Lung T Cells 
The percentage of CD4+ T cells in the lungs was elevated in RV-1B treated mice over controls 
between d4-7 p.i., however we observed the absolute number of CD4+ T cells increase from 
d2 (Fig 3.12 a&b). Both percentage and number of CD69+ CD4+ T cells increased 
incrementally in the lungs from d1 p.i. with RV-1B until d7. The percentage of IFN-γ+ CD4+ T 
cells was elevated in RV-1B treated mice over controls at d4-7 p.i, however the total number 
of cells had increased significantly from d2 and remained similarly elevated by d7 (Fig 3.12 
e&f).  
 
In contrast, the percentage of CD8+ T cells did not significantly change upon RV-1B infection, 
but a sharp increase in cell number was observed at d2 p.i. with RV-1B, and numbers 
decreased thereafter (Fig 3.13 a&b). The percentage of CD69+ CD8+ T cells was consistently 
elevated in RV-1B treated mice from d1-7 p.i., though numbers peaked significantly at d2 
and declined thereafter though remaining elevated over controls until d7 (Fig 3.13 c&d). The 
number of IFN-γ+ CD8+ T cells also peaked at d2 p.i. with RV-1B but was not significantly 
elevated over controls by d4 (Fig 3.13 e&f).   
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Figure 3.12 Lung CD4+ T cell response during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 
cells were stained for surface markers CD3, CD4 and CD69, intracellular cytokine IFN-γ and a dead cell 
marker; staining was analysed on a BD LSR II flow cytometer as described. Data are presented as 
percentage of lung lymphocytes and absolute numbers of (a &b) CD3+/CD4+ T cells and CD3+ gated 
double positive (c&d) CD4+/CD69+ and (e& f) CD4+/IFN-γ+ T cells. Data are expressed as means ± 
SEM of 4-6 mice per group and is representative of at least 3 independent experiments. Statistical 
significance is for RV-1B compared with UV-RV-1B or PBS treatments at the indicated times 
(***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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Figure 3.13 Lung CD8+ T cell response during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B, UV-RV-1B or PBS (mock), and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 
cells were stained for surface markers CD3, CD8 and CD69, intracellular cytokine IFN-γ and a dead cell 
marker; staining was analysed on a BD LSR II flow cytometer as described. Data are presented as 
percentage of lung lymphocytes and absolute numbers of (a&b) CD3+/CD8+ T cells and CD3+ gated 
(c&d) CD8+/CD69+ and (e&f) CD8+/IFN-γ+ T cells. Data are expressed as means ± SEM of 4-6 mice per 
group and is representative of at least 3 independent experiments. Statistical significance is for RV-1B 
compared with UV-RV-1B or PBS treatments at the indicated times (***p<0.001, **p<0.01 & *p<0.05). 
Only statistically significant differences are shown. 
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3.4. Chapter Summary 
In BALB/c mice, IL-15 was upregulated in BAL cells and lung tissue at days 1-2 after RV-1B 
infection. Immunohistochemistry analysis of lung sections indicated expression of IL-15 
protein on the apical surface of epithelial cells lining the airway, supporting the trans-
presentation signalling mechanism. Additionally, the high levels of IL-15 mRNA detected in 
BAL cells also suggests that they are important sources of IL-15, with macrophages a likely 
source as demonstrated in humans [256].  
 
We show that IL-15 expression is associated with expression of type I IFNs early after 
infection; IFN-β mRNA was detected as early at 10h after infection in BAL cells, followed by 
expression of IL-15 mRNA at day 1 in both BAL cells and lung tissue. Therefore, we suspect 
that IFN-β plays a role in regulating RV-mediated IL-15 expression. IFN-λ has not been 
previously reported to induce IL-15 expression, and we found IFN-λ protein levels to persist 
in the BAL fluid as late as day 7 after infection, whereas IL-15 protein levels decline after day 
1. 
 
The airway/lung leukocyte response to RV-1B infection in BALB/c mice initially comprised of 
airway neutrophilia early after infection, accompanied by an activated NK cell response at 
days 1-2, which was followed by T cell mediated inflammation at days 2-7 after infection. 
Thus, IL-15 and type I IFN expression was associated with the recruitment/expansion of NK 
cells in both the airway and lungs. The NK cells exhibited an activated phenotype due to 
increased expression of surface CD69 and intracellular GranzymeB and IFN-γ. NK cells are 
capable of producing TNF-α and detection of elevated levels in the BAL fluid at days 2-4 after 
infection may be at least in part attributed to the NK cell response to RV-1B infection. 
Clearance of virus as detected by reduction in viral RNA levels in lung homogenate occurred 
after the peak of the NK cell response at day 2 after infection. 
 
In the airway and lungs, CD4+ and CD8+ T cells were activated, with respect to CD69 and 
IFN-γ expression, from day 1 after infection. Recruitment/expansion of BAL CD4+ and CD8+ T 
cells and lung CD4+ T cells was observed from day 2 after infection, with numbers increasing 
until day 7, with greater numbers of CD4+ T cells compared to CD8+ T cells. The lung CD8+ T 
cells response peaked at day 2 after infection and declined thereafter, suggesting the 
response may be associated with IL-15 signalling.  
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The data presented constitutes the first in vivo evidence of RV-induced IL-15 and its 
association with type I IFN expression and the NK cell response in a mouse model of 
infection. These data provide a basis for further investigating the specific roles that IL-15 
signalling plays during RV infection, specifically addressing its necessity for the NK cell 
response.  
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4. Chapter 4: Results - Immune responses to RV infection in the absence of IL-
15 signalling in vivo. 
4.1. Introduction 
Understanding the roles of IL-15 in RV infections may be important for the development of 
more targeted therapeutics to promote key pathways of antiviral host defence. The role of 
IL-15 regulated NK cell responses in antiviral host defence has been well characterised for a 
number of viruses including the herpes group viruses, hepatitis B and C and HIV; however, in 
vivo evidence implicating the importance of this pathway for respiratory virus infections is 
lacking. Two models of deficient IL-15 signalling are employed in this chapter to highlight 
innate and adaptive responses that are affected by the absence of this signalling pathway 
during RV-1B infection.  
 
We established in the previous chapter that RV-induced IL-15 is expressed at day 1 after 
infection in mice and is followed by the recruitment/expansion and activation of NK cells in 
the airway and lung tissue. Therefore, we first aimed to investigate the dependency of the 
NK cell response to IL-15 signalling, through use of an IL-15 neutralising antibody (M96), 
which was administered intranasally at the time of infection in addition to 24h after 
infection, to transiently and locally block IL-15 signalling in the airway/lungs.  
 
Secondly, to further investigate other specific roles that IL-15 plays in the immune response 
to RV, we infected IL-15Rα ko mice that have a constitutive and systemic block to IL-15 
mediated responses. These mice have a severe deficiency in NK cells due to a developmental 
block in the absence of IL-15 signalling, therefore, this model also indirectly assesses the 
importance of NK cells for early control of RV-1B infection. 
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4.2. Hypotheses & Aims 
 
4.2.1. Hypotheses 
i. IL-15 signalling in the airway/lungs is required for the recruitment/expansion and 
activation of NK cells into the lungs during RV infection.  
ii. NK cell activation affects RV clearance. 
iii. NK cells are the major source of IFN-γ production during RV infection.  
iv. Deficient NK cell IFN-γ production during RV infection is associated with 
development of a Th2 response.  
 
4.2.2. Aims 
We aimed to explore these hypotheses using 2 different models of IL-15 deficiency, which 
differ in transient and local vs constitutive and systemic blocks to IL-15 signalling. 
 
Part 1: To investigate the dependency of the NK cell response during RV-1B infection to IL-15 
signalling in the airway/lungs, via co-administration of an IL-15 neutralising antibody (M96) 
at the time of infection in BALB/c mice to transiently inhibit IL-15. 
 
Part 2: To investigate the immune responses to RV-1B infection in the absence of systemic 
and constitutive IL-15 signalling, and indirectly assess the importance of NK cells during RV-
1B infection using IL-15Rα ko mice. 
 
i. To determine the virus load in the lungs using Taqman qPCR.  
ii. To determine the expression of IFNs, ISGs, proinflammatory cytokines and 
chemokines and Th2-associated mediators in the BAL and lungs using Taqman qPCR 
and ELISAs. 
iii. To examine the NK cell response in the airway and lungs using flow cytometry. 
iv. To examine the acquired T cell response in the airway and lungs using flow 
cytometry. 
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4.3. Results – Part 1: Transient and Local Neutralisation of IL-15 During RV Infection 
In this study, BALB/c mice were treated i.n. with 50μl RV-1B (5x106 TCID50) at 0h in addition 
to either 20μg M96 IL-15 neutralising antibody (‘RV-M96’), 20μg mIgG2a isotype control 
(‘RV-ISO’) or PBS (‘RV-PBS) at 0h and 24h p.i. Mock-infected mice were treated with PBS 
alone. The nomenclature for the different treatment groups in this model are summarised 
again in Table 4.1.  
 
 
Experimental Groups RV-1B Infection 
0h – i.n 
M96 
0h & 24h – i.n. 
Isotype Control 
0h & 24h – i.n. 
RV-PBS YES NO NO 
RV-M96 YES YES NO 
RV-ISO YES NO YES 
Mock (PBS) NO NO YES 
 
Table 4.1 Experimental groups of the RV infection model with neutralisation of airway/lung IL-15. 
 
 
4.3.1. Virus Load 
To determine if IL-15 neutralisation in the airway/lungs affects the lung viral load, we 
measured the level of RV vRNA via qPCR in lung homogenate. However, we found that 
treatment with M96 during RV-1B infection had no significant effect on virus load at 24h and 
48h p.i. (Fig 4.1).  
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Figure 4.1 Effect of IL-15 neutralisation in the airway/lungs on lung virus load during RV-1B 
infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. Lungs were harvested at 24h and 48h p.i. and processed for RNA extraction, and cDNA made 
by reverse transcription as described. RV-1B viral RNA copies were quantified by qPCR. Data was 
normalised against 18s rRNA expression and expressed as viral RNA copies/μl of sample. Data are 
expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 independent 
experiments. Statistical significance is shown between mice of specific treatment groups, at the 
indicated times (***p<0.001 & *p<0.05). Only statistically significant differences are shown. 
 
 
4.3.2. Differential BAL Cell Counts 
To determine if IL-15 signalling affects the inflammatory cell profile in the airway during RV 
infection we assessed the differential BAL cell counts of cytospins. As shown in chapter 3, 
RV-1B infection results in an increase in total BAL cell counts, however we found that the 
presence of M96 did not affect this (Fig 4.2a). Additionally, IL-15 neutralisation did not affect 
the degree of neutrophilia in the airway during RV-1B infection (Fig 4.2 b&c). We have also 
previously shown that BAL lymphocyte numbers increase at 48h p.i. with RV-1B; however, 
here we demonstrate that the presence of M96 significantly reduces the percentage and 
number of lymphocytes detected at 48h p.i. with RV-1B (Fig 4.2 d&e). 
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Figure 4.2 Effect of IL-15 neutralisation in the airway/lungs on total and differential BAL cell counts 
during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. BAL was performed at 24h and 48h p.i. and recovered live BAL cells were counted (a) and 
processed for cytospin slides. Slides were blinded to experimental conditions and cells differentially 
counted to give the percentage and total number of (b&c) neutrophils and (d&e) lymphocytes in the 
airway. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between mice of specific treatment groups, 
at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are 
shown. 
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4.3.3. Expression of Lung IL-15 and IL-15Rα 
Expression of IL-15 and sIL-15/IL-15Rα complexes in response to RV-1B infection was shown 
in chapter 3. To determine if M96 affects expression of IL-15/IL-15Rα we analysed 
expression of these molecules by ELISA using lung homogenate. We found that 
neutralisation with M96 did not affect RV-mediated IL-15 expression (Fig 4.3 a&b).  
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Figure 4.3 IL-15 neutralisation in the airway/lungs does not affect RV-induced IL-15 and IL-15Rα. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. Lungs were harvested at 24h and 48h p.i. and processed for protein detection as described. 
The level of (a) IL-15 and (b) sIL-15/IL-15Rα complexes were quantified by ELISA and expressed as 
pg/ml. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between mice of specific treatment groups, 
at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are 
shown. 
 
 
4.3.4. BAL Proinflammatory Mediators 
To assess if neutralisation of IL-15 in the airway/lungs effects production of proinflammatory 
cytokines and chemokines during RV-1B infection, we analysed the BAL fluid by ELISAs. We 
found that M96 did not affect production of KC, IL-6, IL-1β or RANTES during RV-1B infection 
(Fig 4.4 a-d). However, RV-M96 treated mice expressed almost 2-fold more TNF-α than RV-
PBS and RV-ISO controls at 24h p.i. (***p<0.001), after which levels returned to baseline (Fig 
4.4e). 
 
4.3.5. Expression of Type I IFNs, Type III IFNs and Interferon Stimulated Genes 
To investigate if IL-15 signalling in the airway/lungs effects expression of type I and III IFNs 
and thus ISGs during RV-1B infection, we analysed expression by qPCR and ELISAs. We found 
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RV-induced IFN-α, IFN-β and IFN-λ expression to be unaltered in the presence of M96, and 
consequentially the ISGs Viperin, PKR, IP-10 and I-TAC were also unaffected during RV-1B 
infection (Fig 4.5). 
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Figure 4.4 Effect of IL-15 neutralisation in the airway/lungs on expression of BAL proinflammatory 
cytokines and chemokines during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. BAL was performed at 24h and 48h p.i., and the concentration of (a) KC, (b) IL-6, (c) IL-1β, (d) 
RANTES and (e) TNF-α were detected in the BAL fluid by ELISA and expressed as pg/ml. Data are 
expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 independent 
experiments. Statistical significance is shown between mice of specific treatment groups, at the 
indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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Figure 4.5 Effect of IL-15 neutralisation in the airway/lungs on expression of BAL and lung type I 
IFNs, type III IFNs and ISGs during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. BAL was performed and lungs harvested at 24h and 48h p.i. Concentration of (a) IFN-α, (c) IFN-
λ2/3, (f) IP-10 and (g) I-TAC in the BAL fluid were quantified by ELISA and expressed as pg/ml. Lungs 
were processed for RNA extraction and cDNA made by reverse transcription as described. (b) IFN-β, 
(d) Viperin and (e) PKR mRNA were quantified by qPCR, data was normalised against 18s rRNA 
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expression and expressed as mRNA copies/μl of sample. Data are expressed as means ± SEM of 4-6 
mice per group and is representative of at least 2 independent experiments. Statistical significance is 
shown between mice of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
 
4.3.6. Expression of IFN-γ 
IFN-γ expression in the lungs was determined by qPCR (Fig 4.6). As expected we observed 
upregulation in control virus groups at 24h and 48h p.i. compared to mock-infected mice 
however, mice treated with both RV-1B and M96 demonstrated no upregulation of IFN-γ at 
either timepoint. Thus, transient neutralisation of IL-15 in the airway/lungs during RV-1B 
infection results in deficient IFN-γ expression. Production by specific lymphocyte populations 
is further explored by flow cytometry in sections 4.3.9 and 4.3.10. 
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Figure4.6 IL-15 neutralisation in the airway/lungs results in deficient IFN-γ expression in the lungs 
during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. Lungs were harvested at 24h and 48h p.i. and processed for RNA extraction and cDNA made by 
reverse transcription as described. IFN-γ mRNA was quantified by qPCR, data was normalised against 
18s rRNA expression and expressed as mRNA copies/μl of sample. Data are expressed as means ± 
SEM of 4-6 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is shown between mice of specific treatment groups, at the indicated times (***p<0.001 
& *p<0.05). Only statistically significant differences are shown. 
 
4.3.7. Expression of Th2 Mediators 
We hypothesized that in the absence IFN-γ expression, which helps drive development of a 
Th1 response against virus, a Th2 response may develop. Thus, we assessed expression of 
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molecules commonly associated with Th2 responses. Chemokines TARC and MDC have been 
reported to be pivotal in development of Th2-mediated responses [258]; analysis of BAL 
fluid by ELISA demonstrated greater production in RV-M96 compared to RV-PBS and RV-ISO 
treated mice early after infection at 24h but this was only statistically significant for TARC 
and not MDC, and by 48h levels had equalized between all virus treated groups (Fig 4.7 a&b). 
We also assessed expression of the classical Th2 cytokines by qPCR, and though we did not 
detect IL-4 and IL-5, a small increase in IL-13 mRNA levels in the lungs of RV-M96 treated 
mice was observed compared to RV-PBS and RV-ISO, but this was not statistically significant 
and levels were very low (Fig 4.7c). This data provides some indication of a weak Th2 
response in the absence of IL-15 and IFN-γ signalling in the airway and lungs during RV-1B 
infection of BALB/c mice. 
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Figure 4.7 IL-15 neutralisation in the airway/lungs resulst in increased expression of Th2 mediators 
in the BAL and lungs during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. BAL was performed and lungs were harvested at 24h and 48h p.i. The concentration of (a) 
TARC and (b) MDC in BAL fluid was measured by ELISA and expressed as pg/ml. Lungs were processed 
for RNA extraction and cDNA made by reverse transcription as described. (c) IL-13 mRNA was 
quantified by qPCR, data was normalised against 18s rRNA expression and presented as mRNA 
copies/μl of sample. Data are expressed as means ± SEM of 4-6 mice per group, representative of at 
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least 2 independent experiments. Statistical significance is shown between mice of specific treatment 
groups, at the indicated times (***p<0.001 & **p<0.01). Only statistically significant differences are 
shown. 
 
4.3.8. Effect of M96 Antibody Treatment on Splenic and Lung Lymphocytes 
We used flow cytometry to determine if i.n. administration of M96 antibody affects 
lymphocytes in the lungs and spleen in the absence of RV-1B infection. We show that splenic 
and lung CD4+ and CD8+ T cell frequencies are not altered 48h post antibody treatment (Fig 
4.8 c-f). However, the frequency of NK cells in the lungs had decreased by ~2.5% at 24h and 
by ~4% at 48h post antibody treatment compared to mock and isotype control treated mice 
(Fig 4.8h). Additionally, the frequency of splenic NK cells at 48h post treatment had 
decreased by ~2% in M96 treated mice compared to controls (Fig 4.8g). Thus, we 
demonstrate that 20μg of M96 given i.n. results in depletion of NK cells as early as 24h post 
treatment in the lungs, and the decrease in splenic NK cell frequency implies that the 
antibody is acting systemically by 48h despite the specific local administration.  
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Figure 4.8 Intranasal administration of M96 IL-15 neutralising antibody does not affect T cell 
populations but reduces the frequency of lung and slpenic NK cells by 48h after adminstration.  
BALB/c mice were treated i.n. with M96 (IL-15 neutralising antibody), mIgG2a isotype control (ISO)or 
PBS (Mock) at 0h and 24h. The spleen and left lung lobe was excised after BAL was performed at 24h 
and 48h post-treatment, and the tissues digested as described. The resultant live single cell 
suspension was counted to give the total number of (a) spleen and (b) lung cells. 1x10
6
 cells were 
stained for surface markers CD3, CD4, CD8 and NKp46 and a dead cell marker; staining was analysed 
on a BD LSR II flow cytometer as described. Data are presented as the percentage of (c&d) 
CD3+/CD4+ T cells, (e&f) CD3+/CD8+ T cells and (g&h) CD3-/NKp46+ NK cells of the lymphocyte gate 
in the spleen and lung respectively. Data are expressed as means ± SEM of 4 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is shown between mice 
of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only 
statistically significant differences are shown.  
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4.3.9. NK Cell Response 
Flow cytometry was employed to assess the dependency of the NK cell response in both the 
airway and lungs to IL-15 signalling during RV infection. Cells were stained for surface 
markers CD3, NKp46 and CD69, in addition to intracellular cytokines GranzymeB and IFN-γ. 
NK cells were defined as CD3-/NKp46+ cells within the lymphocyte population.  
 
4.3.9.1. BAL NK Cells 
As established in chapter 3, NK cells entered the airway at 24h and peaked at 48h p.i. with 
RV-1B infection, which was observed in this study with RV-PBS and RV-ISO treated mice to 
equal extents. However, we demonstrate that in RV-M96 treated mice, there was a 
significant block to the proliferation/expansion of NK cells in the airway compared to the 
virus controls (Fig 4.9a). Consequentially, there was a deficiency in the number of activated 
CD69+, GranzymeB+ and IFN-γ+ NK cells in RV-M96 compared to RV-PBS and RV-ISO treated 
mice at both 24h and 48h p.i. (Fig 4.9 b-d). Therefore, this data clearly demonstrates the 
ability of M96 antibody, via neutralisation of IL-15 signalling, to block the 
recruitment/expansion of NK cells in the airway during RV-1B infection.  
  
  103 
 
24 48
0
5.0×10 2
1.0×10 3
1.5×10 3
2.0×10 3
2.5×10 3
3.0×10 3
3.5×10 3
4.0×10 3
RV-M96
RV-PBS
Mock
RV-ISO
**
***
***
***
*
***
***
*
Hours Post Infection
B
A
L
 N
K
 C
e
ll
s
24 48
0
5.0×10 2
1.0×10 3
1.5×10 3
2.0×10 3
2.5×10 3
3.0×10 3
3.5×10 3
RV-M96
RV-PBS
Mock
RV-ISO
**
**
*
*
***
***
***
***
Hours Post Infection
B
A
L
 C
D
6
9
+
 N
K
 C
e
ll
s
24 48
0
2.5×10 2
5.0×10 2
7.5×10 2
1.0×10 3
1.3×10 3
1.5×10 3
1.8×10 3
2.0×10 3
RV-M96
RV-PBS
Mock
RV-ISO
**
**
*
*
***
***
***
***
Hours Post Infection
B
A
L
 G
ra
n
z
y
m
e
B
+
 N
K
 C
e
ll
s
24 48
0
2.5×10 2
5.0×10 2
7.5×10 2
1.0×10 3
1.3×10 3
1.5×10 3
RV-M96
RV-PBS
Mock
RV-ISO
***
***
***
***
***
***
**
**
Hours Post Infection
B
A
L
 I
F
N
- 
+
 N
K
 C
e
ll
s
(a)
(c)
(b)
(d)
 
 
Figure 4.9 IL-15 neutralisation in the airway/lungs results in deficient BAL NK cell resposnes during 
RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. BAL was performed at 24h and 48h p.i., and 1x10
5
 cells were stained for surface markers CD3, 
CD69 and NKp46, intracellular cytokines GranzymeB and IFN-γ and a dead cell marker; staining was 
analysed on a BD LSR II flow cytometer as described. Data are presented as the absolute number of 
BAL (a) CD3-/NKp46+ NK cells, CD3- gated double positive (b) NKp46+/CD69+, (c) 
NKp46+/GranzymeB+ and (c) NKp46+/IFN-γ+ NK cells. Data are expressed as means ± SEM of 4-5 mice 
per group and is representative of at least 2 independent experiments. Statistical significance is 
shown between mice of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
 
4.3.9.2. Lung NK Cells 
The total lung cell counts did not differ between the groups at 24h p.i. however, total 
numbers were increased in RV infected groups compared to mock-treated mice at 48h (Fig 
4.10). Additionally, at 48h p.i. there was a slight reduction in the total number of lung cells in 
RV-M96 compared to RV-PBS and RV-ISO treated mice, but this was not statistically 
significant.  
 
We found the percentage of lung NK cells to be ~2-fold lower in RV-M96 compared to mock-
treated mice at 24h and 48h p.i. (p<0.05) (Fig 4.11a), suggesting depletion of NK cells due to 
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treatment with M96; however, due to increased total lung cell counts in virus treated groups 
(regardless of M96 treatment), no significant difference was observed in the absolute 
number of NK cells between RV-M96 compared to mock treated mice at 24h and 48h p.i. 
(Fig 4.11b).  
 
Upon comparison of virus treated groups, we show that RV-M96 treated mice had reduced 
frequencies of NK cells compared to RV-PBS and RV-ISO treated mice at 24h and 48h p.i., 
which translated into ~2.5-3-fold fewer numbers of NK cells in M96 treated mice at both 
time points. Additionally, the percentage and absolute numbers of CD69+, GranzymeB+ and 
IFN-γ+ NK cells at 24h and 48h p.i. was increased in both RV-PBS and RV-ISO groups 
compared to mock treated mice, but was not in RV-M96 treated mice (Figure 4.11 c-h). Thus, 
we demonstrate that IL-15 neutralisation in the airway/lungs by M96 antibody resulted in a 
severely deficient NK cell response to RV-1B infection. 
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Figure 4.10 Effect of IL-15 neutralisation in the airway/lungs on the total lung leukocyte count 
during RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. The left lung lobe was excised after BAL was performed at 24h and 48h p.i. Lungs were 
digested as described and the resultant live single-cell suspension counted to give the total number 
lung cells. Data are expressed as means ± SEM of 4-5 mice per group and is representative of at least 
2 independent experiments. Statistical significance is shown between mice of specific treatment 
groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant 
differences are shown. 
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Figure 4.11 IL-15 neutralisation in the airway/lungs results in deficient lung NK cell responses during 
RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. The left lung lobe was excised after BAL was performed at 24h and 48h p.i. and digested as 
described. 1x10
6
 cells were stained for surface markers CD3, CD69 and NKp46, intracellular cytokines 
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GranzymeB and IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as 
described. Data are presented as the percentage and absolute number of lung (a&b) CD3-/NKp46+ NK 
cells, CD3- gated double positive (c&d) NKp46+/CD69+, (e&f) NKp46+/GranzymeB+ and (g&h) 
NKp46+/IFN-γ+ NK cells. Data are expressed as means ± SEM of 4-5 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is shown between mice 
of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
 
4.3.10. T Cell Response 
4.3.10.1. BAL T Cells 
As expected, CD4+ T cell numbers rose in the airway at 48h p.i. in virus treated groups 
however, we observed a small reduction in number in RV-M96 compared to RV-PBS and RV-
ISO groups, but this was not found to be significant (Fig 4.12a). Similarly, a decrease in 
numbers of CD69+ CD4+ T cells in RV-M6 compared to RV-PBS and RV-ISO groups at 48h p.i. 
was observed (p<0.05) (Fig 4.12c), though the decrease in number of IFN-γ+ CD4+ T cells was 
not significant (Fig 4.12e).  
 
The reduction in cell number in RV-M6 treated mice was more pronounced with CD8+ T cells, 
which were ~50% of those in RV-PBS treated mice at 48h p.i. (p<0.01) (Fig 4.12b). 
Correspondingly, numbers of CD69+ and IFN-γ+ CD8+ T cells were also reduced in RV-M96 
compared to RV-PBS and RV-ISO treated groups at 48h p.i. (p<0.01 for CD69+; p<0.05 for 
IFN-γ+) (Fig 4.12 d&f). This data suggests that neutralisation of IL-15 during RV-1B infection 
has a significant effect on the recruitment/expansion and activation of T cells in the airways, 
and this is more pronounced in CD8+ rather than in CD4+ T cells.  
4.3.10.2. Lung T Cells 
In the lungs, the percentage of CD4+ T cells did not vary between all groups at either 
timepoints (Fig 4.13a), though translation to cell numbers demonstrated a slightly impaired 
increase in total number of CD4+ T cells in RV-M96 compared to RV-PBS treated mice at 48h 
p.i. (p<0.05) (Fig 4.13b). The percentage of CD69+ and IFN-γ+ CD4+ T cells rose equally at 
24h and 48p.i. within virus treated groups compared to mock treated mice (Fig 4.13 c&e); 
however, cell number revealed a small reduction in total number of activated CD4+ T cells in 
RV-M96 compared to RV-PBS and RV-ISO treated mice at 48h p.i., though this was not 
statistically significant (Fig 4.13 d&f).  
 
Similar trends were seen for lung CD8+ T cells, though the deficiency in total number of 
CD8+ T cells in RV-M96 compared to RV-PBS and RV-ISO was slightly greater, but still not 
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statistically significant for CD69+ and IFN-γ+ CD8+ T cells (Fig 5.14). Thus, similar to the 
airway, neutralisation of IL-15 during RV-1B infection appears to affect the 
recruitment/expansion and activation of CD8+ T cells to the lungs, though the effect is not as 
great as the effect on the NK cell response. 
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Figure 4.12 Effect of IL-15 neutralisation in the airway/lungs on the BAL T cell response during RV-
1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. BAL was performed at 24h and 48h p.i. and 1x10
5
 cells were stained for surface markers CD3, 
CD4, CD8 and CD69, intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a BD 
LSR II flow cytometer as described. Data are presented as the absolute number of BAL (a) CD3+/CD4+, 
(b) CD3+/CD8+, CD3+ gated double positive (c) CD4+/CD69+, (d) CD8+/CD69+ (e) CD4+/IFN-γ+ and (f) 
CD8+/IFN-γ+ T cells. Data are expressed as means ± SEM of 4-5 mice per group and is representative 
of at least 2 independent experiments. Statistical significance is shown between mice of specific 
treatment groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). 
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Figure 4.13 Effect of IL-15 neutralisation in the airway/lungs on the lung CD4+ T cell response during 
RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. The left lung lobe was excised after BAL was performed at 24h and 48h p.i. and digested as 
described. 1x10
6
 cells were stained for surface markers CD3, CD4 and CD69, intracellular cytokine IFN-
γ and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. Data are 
presented as the percentage and absolute number of lung (a&b) CD3+/CD4+ T cells, CD3+ gated 
double positive (c&d) CD4+/CD69+ and (e&f) CD4+/IFN-γ+ T cells. Data are expressed as means ± SEM 
of 4 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is shown between mice of specific treatment groups, at the indicated times (***p<0.001, 
**p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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Figure 4.14 Effect of IL-15 neutralisation in the airway/lungs on the lung CD8+ T cell response during 
RV-1B infection. 
BALB/c mice were treated i.n. with RV-1B at 0h in addition to PBS, M96 (IL-15 neutralising antibody) 
or mIgG2a isotype control (IS0) at 0h and 24h p.i., and mock-infected mice were treated with PBS 
alone. The left lung lobe was excised after BAL was performed at 24h and 48h p.i. and digested as 
described. 1x10
6
 cells were stained for surface markers CD3, CD8 and CD69, intracellular cytokine IFN-
γ and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. Data are 
presented as the percentage and absolute number of lung (a&b) CD3+/CD8+ T cells, CD3+ gated 
double positive (c&d) CD8+/CD69+ and (e&f) CD8+/IFN-γ+ T cells. Data are expressed as means ± SEM 
of 4 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is shown between mice of specific treatment groups, at the indicated times (***p<0.001, 
**p<0.01 & *p<0.05). Only statistically significant differences are shown. 
 
 
  110 
 
4.4. Chapter Summary – Part 1 
Treatment of mice intranasally at the time of RV-1B infection and 24h later with IL-15 
neutralising antibody to block IL-15 signalling in the airway/lungs did not affect airway 
neutrophilia levels. However, the percentage and total number of BAL lymphocytes was 
decreased in the presence of M96 during infection. Levels of the proinflammatory cytokines 
IL-6, IL-1β and RANTES were not changed in the presence of M96, nor was the expression of 
IL-15, type I IFNs, IFN-λ and ISGs at 24h and 48h after infection. By looking at total IFN-γ 
mRNA levels in lung homogenate by qPCR, we found IFN-γ upregulation to be deficient in 
RV-M96 treated mice compared to controls, which was associated with increased expression 
of Th2-associated mediators TARC, MDC and IL-13.  
 
Intranasal administration of M96 alone without infection, at the same doses used for 
infection studies resulted in reduced NK cell frequencies in the lungs (from ~7.0% to 4.0%) 
and spleen (from ~5.5% to 3.5%) compared to PBS treated mice 48h after treatment. Thus, 
intranasally administered M96 can act systemically and IL-15 is important for 
survival/homeostasis of NK cells in the periphery. Despite depletion, at 48h post M96 
treatment a population of NK cells still exists in the mouse permitting a potential response 
to virus infection.  
 
RV-M96 treated mice demonstrated a block to recruitment/expansion of NK cells in both the 
airway and lungs at 24h and 48h after infection compared to controls – at both time points, 
RV-M96 and mock treated mice exhibited similar total numbers of NK cells. In addition, 
airway and lung NK cells in RV-M96 treated mice did not increase expression of CD69, 
GranzymeB and IFN-γ compared to virus controls. Thus, we show that transiently blocking IL-
15 in the airway/lungs during RV-1B infection in mice inhibits the recruitment/proliferation 
and activation of NK cells, even in the presence of type I IFN signalling. 
 
IL-15 neutralisation did not significantly affect the CD4+ T cell response to RV-1B infection in 
mice. However, we show reduced CD8+ T cell recruitment/expansion and activation (CD69 
and IFN-γ expression) in the airway and lung tissue of RV-M96 treated mice compared to 
controls at 48h after infection. The reduced number of IFN-γ+ CD8+ T cells in M96-RV 
treated mice was mild compared to the severely deficient expression in NK cells, and 
expression in CD4+ T cells was intact. Due to the large deficiency in total IFN-γ mRNA levels 
observed in lung tissue of RV-M96 treated mice compared to virus controls, we suggest that 
NK cells are the main producers of IFN-γ in BALB/c mice early after RV-1B infection. To 
  111 
 
further investigate the roles of IL-15 signalling and the importance of NK cells in the immune 
response to RV infection, we analysed the response in IL-15Rα ko mice.  
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4.5. Results – Part 2: RV-1B Infection in IL-15Rα ko Mice 
In this study, IL-15Rα ko and control B6.129 mice were infected i.n. with RV-1B (5x106 
TCID50) and ‘Mock’ mice (0h) were treated i.n. with PBS only. IL-15Rα ko mice have a 
constitutive and systemic block to IL-15 signalling and consequentially have a severe 
deficiency in NK cells.  
 
4.5.1. Virus Load 
To determine if the absence of IL-15 signalling and NK cells affects the lung virus laod, we 
measured the level of RV-1B viral RNA in the lungs. We found a higher and more sustained 
virus load in the lungs at both 8h (ns) and 24h p.i. (p<0.05) compared to B6.129 mice (Fig 
4.15), and virus was cleared by both groups by 96h.  
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Figure 4.15 IL-15Rα ko mice have an increased lung viral load after RV-1B  infection. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and lungs were harvested at the 
indicated timepoints p.i. Lungs were processed for RNA extraction and cDNA made by reverse 
transcription as described. RV-1B viral RNA copies were quantified by qPCR, and data was normalised 
against 18s rRNA expression and presented as vRNA copies/μl of sample. Data are expressed as 
means ± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. 
Statistical significance is for IL-15Rα ko compared with B6.129 mice treated with RV-1B, at the 
indicated times (*p<0.05). Only statistically significant differences are shown. 
 
4.5.2. Differential BAL Cell Counts 
Similar to infection with IL-15 neutralising antibody, there was no significant difference in 
the total number of BAL cells, nor in the degree of neutrophilia between IL-15Rα ko and 
B6.129 mice in response to RV-1B infection (Fig 4.16 a-c). Also, in agreement with the 
neutralising antibody study, we detected a deficient BAL lymphocyte response in IL-15Rα ko 
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compared to B6.129 mice, as determined by both percentage and total number at 48h and 
96h p.i. (Fig 4.16 d&e).  
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Figure 4.16 Total and differential BAL cell counts during RV-1B infection in IL-15Rα ko mice. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and BAL was performed at the 
indicated time points p.i. Recovered live BAL cells were (a) counted and processed for cytospin slides. 
Slides were blinded to experimental conditions and cells differentially counted to give the percentage 
and total number of (b&c) neutrophils and (d&e) lymphocytes in the airways. Data are expressed as 
means ± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. 
Statistical significance is for IL-15Rα ko compared with B6.129 mice treated with RV-1B, at the 
indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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4.5.3. BAL Proinflammatory Mediators 
Proinflammatory cytokines and chemokines produced in response to RV-1B were measured 
in the BAL fluid by ELISA. No differences were detected in the expression of KC and RANTES 
in response to virus in both groups (Fig 4.17 a&e). However, unlike the neutralising antibody 
study, higher levels of IL-6 at 24h p.i. (p<0.001) and IL-1β at 24h (p<0.01) and 48h (p<0.01) 
were observed in IL-15Rα ko compared to B6.129 mice (Fig 4.17 b&c). Additionally, levels of 
TNF-α were slightly elevated in IL-15Rα ko compared to B6.129 mice at 24h and 48h p.i., 
though the differences were not statistically significant (Fig 4.17d). 
 
4.5.4. Expression of Type I IFNs, Type III IFNs and Interferon Stimulated Genes 
Analysis of the BAL fluid by ELISA demonstrated that expression of IFN-α was deficient and 
short lived in IL-15Rα ko mice; levels peaked at 48h p.i. and had declined to baseline by 72h 
in IL-15Rα ko compared to B6.129 mice, which peaked at 72h p.i. and with ~2-fold more IFN-
α (Fig 4.18a). Lung IFN-β expression was detected by qPCR, and though higher levels of 
mRNA were detected in B6.129 compared to IL-15Rα ko mice at 24h p.i., the difference was 
not statistically significant (Fig 4.18b).  
 
Similarly, BAL IFN-λ2/3 was found to be deficient in IL-15Rα ko compared to B6.129 mice. A 
small peak of production was detected at 24h p.i. in IL-15Rα ko mice, however higher levels 
were detected in B6.129 mice at 24h, which was sustained at 48h (p<0.01) and declined 
thereafter (Fig 4.18c). Thus, these data suggests that during RV-1B infection, expression of 
type I and III IFNs is compromised in the absence of IL-15 signalling.  
 
However, despite detection of less type I and III IFN production in IL-15Rα ko mice, no 
significant differences were detected between IL-15Rα ko and B6.129 mice in expression of 
the ISGs PKR, OAS-1a, I-TAC and IP-10 in response to RV-1B infection (Fig 4.18 d-g). This is in 
agreement with data obtained from the IL-15 neutralising antibody study suggesting that 
absence of IL-15 signalling during RV-1B infection does not appear affect expression of ISGs.  
 
4.5.5. Expression of IFN-γ  
On the other hand, in response to RV-1B infection, expression of IFN-γ was found to be 
severely deficient in IL-15Rα ko compared to B6.129 mice as detected by qPCR in lung 
homogenate (p<0.01 at 24h p.i.) (Fig 4.19). Thus, in agreement with the IL-15 neutralising 
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antibody study, our data suggests that IL-15 signalling during RV-1B infection is necessary for 
IFN-γ expression. 
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Figure 4.17 Expression of BAL proinflammatory cytokines and chemokines in response to RV-1B 
infection in IL-15Rα ko mice. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and BAL was performed at the 
indicated time points p.i. The concentration of (a) KC, (b) IL-6, (c) IL-β, (d) TNF-α and (e) RANTES in the 
BAL fluid was determined by ELISA and expressed as pg/ml. Data are expressed as means ± SEM of 4-6 
mice per group and is representative of at least 2 independent experiments. Statistical significance is 
for IL-15Rα ko compared with B6.129 mice treated with RV-1B, at the indicated times (***p<0.001, 
**p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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Figure 4.18 Expression of BAL and lung type I and III IFNs and interferon stimulated genes in 
response to RV-1B infection in IL-15Rα ko mice. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and lungs were harvested after 
BAL was performed at the indicated timepoints p.i. (a) IFN-α, (c) IFN-λ2/3, (f) I-TAC and (g) IP-
10proteinswere detected in the BAL fluid by ELISA and expressed as pg/ml. Lungs were processed for 
RNA extraction and cDNA made by reverse transcription as described. (b) IFN-β, (d) PKR and (e) OAS-
1a mRNA was detected by qPCR, data normalised against 18s rRNA expression and presented as 
mRNA copies/μl of sample. Data are expressed as means ± SEM of 4-6 mice per group and is 
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representative of at least 2 independent experiments. Statistical significance is for IL-15Rα ko 
compared with B6.129 mice treated with RV-1B, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
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Figure 4.19 IL-15Rα ko mice have a deficeint IFN-γ response during RV-1B infection. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and lungs were harvested at the 
indicated timepoints p.i. Lungs were processed for RNA extraction and cDNA made by reverse 
transcription as described. IFN-γ mRNA copies/μl of sample were quantified by qPCR and data was 
normalised against 18s rRNA expression. Data are expressed as means ± SEM of 4-6 mice per group 
and is representative of at least 2 independent experiments. Statistical significance is for IL-15Rα ko 
compared with B6.129 mice treated with RV-1B, at the indicated times (**p<0.01). Only statistically 
significant differences are shown. 
 
4.5.6. Expression of Th2 Mediators 
We were also prompted to look for expression of Th2 mediators in this study based on the 
deficient expression of IFN-γ. MDC and TARC were detected in BAL fluid by ELISA and found 
to be induced during infection, and though higher levels were observed in IL-15Rα ko 
compared to B6.129 mice the differences were not statistically significant (Fig 4.20 a&b). We 
also investigated expression of classical Th2 cytokines in lung tissue by qPCR. Increased 
expression of IL-4 mRNA was detected in IL-15Rα ko mice during RV-1B infection, with 
significantly higher levels at 96h p.i. compared to B6.129 mice (p<0.01) (Fig 4.20c). IL-5 was 
found to be induced in response to RV-1B infection in IL-15Rα ko but not B6.129 mice;  levels 
peaked at 24h p.i. in IL-15Rα ko mice and declined thereafter however, differences between 
the groups were not statistically significant (Fig 4.20d). Lastly, expression of IL-13 was also 
significantly induced in IL-15Rα ko mice but not B6.129 mice; expression was detected by 8h 
p.i. in IL-15Rα ko mice (p<0.05) and peaked at 24h (ns) (Fig 4.20e). Therefore, in the absence 
of IL-15 signalling during RV-1B infection, characteristic traits of a Th2 response developed in 
IL-15Rα ko mice. 
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Figure 4.20 IL-15Rα ko mice demonstrate increased expression of Th2 cytokines and chemokines in 
BAL fluid and lung tissue during RV-1B infection.  
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and lungs were harvested after 
BAL was performed at the indicated timepoints p.i. (a) MDC and (b) TARC proteins were detected in 
the BAL fluid by ELISA and expressed as pg/ml. Lungs were processed for RNA extraction and cDNA 
made by reverse transcription as described. (c) IL-4, (d) IL-5 and (e) IL-13 mRNA were detected by 
qPCR, data normalised against 18s rRNA expression and presented as mRNA copies/μl of sample. Data 
are expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 independent 
experiments. Statistical significance is for IL-15Rα ko compared with B6.129 mice treated with RV-1B, 
at the indicated times (**p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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4.5.7. NK Cell Response 
As previously stated, IL-15Rα ko mice have a constitutive block to IL-15 signalling and 
therefore, NK cells are unable to develop. Flow cytometry was used to confirm this and 
analyse the response in B6.129 mice; BAL and lung cells were stained with monoclonal 
antibodies specific for CD3, NK1.1, CD69, GranzymeB and IFN-γ. NK cells were defined as 
CD3-/NK1.1+ cells within the lymphocyte gate, and the representative flow plots in Figure 
4.21 illustrate the absence of these cells in the BAL and lung of IL-15Rα ko mice in 
comparison to control B6.129 mice. 
 
 
 
 
Figure 4.21 Representative flow plots of BAL and lungs NK cells in B6.129 and IL-15Rα ko mice. 
Flow plots illustrate the presence of CD3-/NK1.1+ NK cells within the gate, in the airway and lungs of 
(a&c) B6.129 mice, and their absence in (b&d) IL-15Rα ko mice. Numbers indicated on plots represent 
the % of events falling within the indicated gate.  
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4.5.7.1. BAL NK Cells 
Figure 4.22 clearly demonstrates the total absence of an NK cell response to RV-1B infection 
in the airway of IL-15Rα ko mice. Similar to that seen with BALB/c mice in chapter 3, the 
total number of BAL NK cells in B6.129 mice peaked at 24h p.i. and remained elevated at 96h 
(Fig 4.22a), and these cells were shown to be activated based on their expression of CD69, 
GranzymeB and IFN-γ (Fig 4.22b-d). 
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Figure 4.22 The BAL NK cell response to RV-1B infection in IL-15Rα ko mice is absent. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and BAL was performed at the 
indicated time points p.i. 1x10
5
BAL cells were stained for surface markers CD3, CD69 and NK1.1, 
intracellular cytokines GranzymeB and IFN-γ and a dead cell marker; staining was analysed on a BD 
LSR II flow cytometer as described. Data are presented as the absolute number of BAL (a) CD3-
/NK1.1+ NK cells, CD3- gated double positive (b) NK1.1+/CD69+, (c) NK1.1+/GranzymeB and (d) 
NK1.1+/IFN-γ+ NK cells. Data are expressed as means ± SEM of 4-6 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is for IL-15Rα ko 
compared with B6.129 mice treated with RV-1B, at the indicated times (***p<0.001 & **p<0.01). 
Only statistically significant differences are shown. 
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4.5.7.2. Lung NK Cells 
The total number of lung cells was observed to increase in response to RV-1B infection in 
both groups; however, numbers in IL-15Rα ko mice were found to be lower than those in 
B6.129 mice at both 24h and 48h p.i. with RV-1B infection (p<0.05) (Fig 4.23). Regardless of 
RV-1B infection, NK cells were absent from the lungs of IL-15Rα ko mice, though an NK cell 
response was detected during RV-1B infection in B6.129 (Fig 4.24); compared to 0h, the 
number of NK cells increased and peaked at 24h p.i. with RV-1B and declined back to 
baseline by 96h, and similarly the numbers of CD69+, GranzymeB+ and IFN-γ+ NK cells also 
peaked at 24h and declined to baseline (0h) levels by 96h (Fig 4.24 d, f&h). 
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Figure 4.23 Total lung leukocyte count during RV-1B infection in IL-15Rα ko mice. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and the 
resultant live single-cell suspension counted. Data are expressed as means ± SEM of 4-6 mice per 
group and is representative of at least 2 independent experiments. Statistical significance is for IL-
15Rα ko compared with B6.129 mice treated with RV-1B, at the indicated times (*p<0.05). Only 
statistically significant differences are shown. 
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Figure 4.24 The lung NK cell response to RV-1B infection in IL-15Rα ko mice is absent. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 
cells were stained for surface markers CD3, CD69 and NK1.1, intracellular cytokines GranzymeB and 
IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. Data 
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are presented as the percentage and absolute number of lung (a&b) CD3-/NK1.1+ NK cells, CD3- 
gated double positive (c&d) NK1.1+/CD69+, (e&f) NK1.1+/GranzymeB and (g&h) NK1.1+/IFN-γ+ NK 
cells. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 
independent experiments. Statistical significance is for IL-15Rα ko compared with B6.129 mice 
treated with RV-1B, at the indicated times (***p<0.001 & **p<0.01). Only statistically significant 
differences are shown. 
 
4.5.8. T Cell Response 
4.5.8.1. BAL T Cells 
In the airway, CD4+ T cell numbers increased after infection with RV-1B in both IL-15Rα ko 
and B6.129 mice; no differences in numbers were detected between the groups and 
numbers were greatest at 96h p.i. (Fig 4.25a). The number of CD69+ T cells increased at 24h 
and 48h p.i. equally in both groups however, at 96h p.i. B6.129 mice had ~1.5-fold more 
CD69+ CD4+ T cells compared to IL-15Rα ko mice (p<0.01) (Fig 4.25c). However, no 
significant differences in the number of IFN-γ+ CD4+ T cells were detected between the 
groups during RV-1B infection (Fig 4.25e). 
 
On the other hand, there was a striking deficiency of CD8+ T cells in the airway in IL-15Rα ko 
compared to B6.129 mice in response to RV-1B infection. In B6.129 mice, CD8+ T cells were 
recruited into the airway by 24h p.i., numbers peaked at 48h (p<0.001) and remained 
significantly elevated at 96h (p<0.001) compared to IL-15Rα ko mice (Fig 4.25b). Similarly, 
there was a lack of activated CD69+ and IFN-γ+ CD8+ T cells in the airway of IL-15Rα ko mice 
compared to B6.129 mice, which demonstrated a significant increase in the number of 
activated CD8+ T cells, peaking at 48h p.i. (p<0.001) and declining thereafter (Fig 4.25 d&f). 
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Figure 4.25 The BAL CD8+ T cell but not CD4+ T cell resposne during RV-1B infection in IL-15Rα ko 
mice is deficient. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and BAL was performed at the 
indicated time points p.i. 1x10
5
 BAL cells were stained for surface markers CD3, CD4, CD8, and CD69, 
intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow 
cytometer as described. Data are presented as the absolute number of BAL (a) CD3+/CD4+ T cells, (b) 
CD3+/CD8+ T cells, CD3+ gated double positive (c) CD4+/CD69+, (d) CD8+/CD69+, (e) CD4+/IFN-γ+ and 
(f) CD8+/IFN-γ+ T cells. Data are expressed as means ± SEM of 4-6 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is for IL-15Rα ko 
compared with B6.129 mice treated with RV-1B, at the indicated times (***p<0.001, **p<0.01& 
*p<0.05). Only statistically significant differences are shown. 
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4.5.8.2. Lung T Cells 
As no differences were detected in percentage of lung CD4+ T cells during RV-1B infection 
between IL-15Rα and B6.129 mice (Fig 4.26a), the total number was lower in IL-15Rα ko 
mice at 24h and 48h p.i. compared to B6.129 mice (p<0.01 & p<0.001) (Fig 4.26b) due to the 
total lung cell count profile (Fig 4.23). However, the percentage of CD69+ and IFN-γ+ CD4+ T 
cells was higher at 24h-48h and 24h-96h p.i. respectively in IL-15Rα ko compared to B6.129 
mice (Fig 4.23 c&e); upon translation into cell number, we observed only slightly lower total 
numbers of CD69+ and IFN-γ+ CD4+ T cells within the lungs of IL-15Rα ko compared to 
B6.129 mice at 24h and 48h p.i., and the differences were not statistically significant (Fig 
4.23 d&f).  
 
The lung CD8+ T cell response to RV-1B infection in IL-15Rα ko mice mirrors that in the 
airway. Firstly, the baseline percentage of CD8+ T cells in the lungs is ~2-fold lower in IL-
15Rα ko mice, and there was little/no increase in percentage with RV-1B infection compared 
to B6.129 mice (Fig 4.27a). Thus, no noticeable increase in the total number of lung CD8+ T 
cells was detected at any time point p.i. compared to B6.129 mice, which demonstrated 
recruitment/expansion of CD8+ T cells in the lungs at 24h and 48h p.i. (P<0.001), and 
numbers declined thereafter (Fig 4.27b). Additionally, lung CD8+ T cells in IL-15Rα ko mice 
demonstrated deficient upregulation of CD69 and IFN-γ in response to RV-1B infection, 
compared to B6.129 mice, of which the later demonstrated increased numbers of activated 
lung CD8+ T cells at 24h and 48h p.i. (p<0.001) (Fig 4.27 c-f). Thus, in the absence of IL-15 
signalling, IL-15Rα ko mice had significantly fewer lung CD8+ T cells at baseline, which failed 
to increase in numbers and activate upon RV-1B infection. 
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Figure 4.26 Lung CD4+ T cell response to RV-1B infection in IL-15Rα ko mice. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 
cells were stained for surface markers CD3, CD4 and CD69, intracellular cytokine IFN-γ and a dead cell 
marker; staining was analysed on a BD LSR II flow cytometer as described. Data are presented as the 
percentage and absolute number of lung (a&b) CD3+/CD4+ T cells, CD3+ gated double positive (c&d) 
CD4+/CD69+ and (e&f) CD4+/IFN-γ+ T cells. Data are expressed as means ± SEM of 4-6 mice per group 
and is representative of at least 2 independent experiments. Statistical significance is for IL-15Rα ko 
compared with B6.129 mice treated with RV-1B, at the indicated times (**p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
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Figure 4.27 The lung CD8+ T cell response to RV-1B infection in IL-15Rα ko mice is deficient. 
IL-15Rα ko and B6.129 mice were treated i.n. with RV-1B or PBS (0h), and left lung lobe excised after 
BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 cells 
were stained for surface markers CD3, CD8 and CD69, intracellular cytokine IFN-γ and a dead cell 
marker; staining was analysed on a BD LSR II flow cytometer as described. Data are presented as the 
percentage and absolute number of lung (a&b) CD3+/CD8+ T cells, CD3+ gated double positive (c&d) 
CD8+/CD69+ and (e&f) CD8+/IFN-γ+ T cells. Data are expressed as means ± SEM of 4-6 mice per group 
and is representative of at least 2 independent experiments. Statistical significance is for IL-15Rα ko 
compared with B6.129 mice treated with RV-1B, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
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4.6. Chapter Summary – Part 2 
IL-15Rα ko mice have a systemic and constitutive block to IL-15 signalling, and in response to 
RV-1B infection no difference in the degree of neutrophilia was detected but significantly 
fewer BAL lymphocytes in comparison to wild type mice was observed. Additionally, IL-15Rα 
ko mice demonstrated increased expression of the proinflammatory cytokines IL-6, IL-1β and 
TNF-α.  
 
During RV-1B infection in the absence of IL-15 signalling, analysis of lung tissue mRNA 
showed a severe deficiency in IFN-γ expression. This was associated with increased 
expression of the Th2-associated chemokines TARC and MDC. Moreover, mRNA expression 
of the classical Th2 cytokines IL-4, IL-5 and IL-13 was detected in lung tissue of IL-15Rα ko 
mice after infection. Thus, IL-15 signalling appears to be important for induction of an IFN-γ 
response, the absence of which is associated with development of a Th2-type response to 
primary RV infection in mice.  
 
A deficient lymphocytic response to RV-1B infection was observed in IL-15Rα ko mice, which 
was associated with an increased viral load in lung tissue at 8h and 24h after infection. 
Unlike wild type mice, due to the severe lack of NK cells there was no activated NK cell 
response to RV-1B infection in IL-15Rα ko mice. Moreover, IL-15Rα ko mice exhibited a 
lower frequency and absolute number of CD8+ T cells in the lungs at baseline, and a severely 
impaired CD8+ T cell response in both the airway and lungs was detected after RV infection. 
In contrast, the absence of IL-15 signalling did not substantially affect the CD4+ T cell 
response to RV.  
 
In addition to the necessity for IL-15 signalling for the NK cell response demonstrated in Part 
1 of Chapter 4, we show in Part 2 that IL-15 signalling is also important for the generation of 
an activated CD8+ T cell response to RV-1B infection in mice. These results also highlight the 
pleiotropic nature of IL-15 during virus infection, and how its absence can influence the Th1 
vs Th2 balance of the antiviral immune response.  
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5. Chapter 5: Results - IL-15 expression and the NK cell responses in the 
absence of type I IFN signalling 
5.1. Introduction 
Most if not all nucleated cells are able to produce type I IFNs early after viral infection, a 
response which represents an early and central regulator of antiviral immune responses. 
Secreted type I IFNs bind a common heterodimeric receptor composed of type I IFN-α-
receptor subunits 1 and 2 (IFNAR1 and IFNAR2), inducing a series of signalling pathways to 
mediate an antiviral state in infected and surrounding cells, in addition to activating key 
innate and adaptive immune response via induction of >300 ISGs. Type I IFNs are capable of 
inducing direct effects on cells to promote antiviral resistance, such as expression of OAS 
and PKR, and they also stimulate expression of various cytokines and chemokines that act as 
immunomodulators to direct the antiviral response.   
 
In chapter 3, we demonstrated expression of IL-15 in BAL cells and lung tissue in response to 
RV infection, which was associated with expression of type I IFNs. Previous reports have 
demonstrated induction of IL-15 upon in vitro stimulation of macrophages, DCs and 
epithelial cells with IFN-β [118, 256]. Therefore, in this chapter we employed the use of 
IFNAR1 ko mice to examine the role of type I IFN signalling on RV-induced IL-15 in vivo.   
 
The importance of type I IFNs for activation of NK cell responses has been well documented 
for viral infections including vaccinia virus, herpes viruses and HIV however, the role of type I 
IFNs on the NK cell response during RV infection is unknown. Additionally, whether type I 
IFNs regulate NK cell activity via direct or indirect pathways is unclear. As IL-15 has been 
shown to be induced by type I IFNs and regulates NK cell activities, we suggest that IL-15 is 
the main intermediary factor that mediates the effects of type I IFNs on NK cells. Therefore 
in this chapter, we aim to explore the relationships between type I IFNs, IL-15 and NK cells 
during the immune response to RV infection, and their importance for control of virus 
replication/infection.  
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5.2. Hypotheses & Aims 
5.2.1. Hypotheses 
 
i. Type I IFN signalling is necessary for induction of IL-15 in the lungs during RV-1B 
infection.  
ii. Type I IFN signalling is necessary for the recruitment/expansion and activation of NK 
cells in the airway and lungs during RV-1B infection.  
iii. A deficient NK cell response results in deficient IFN-γ production, which is associated 
with increased viral load and development of a Th2 response to virus.  
 
5.2.2. Aims 
To investigate the dependency of IL-15 expression and the NK cell response on type I IFN 
signalling during RV-1B infection, by using type I IFN receptor knockout mice (IFNAR1 ko).  
 
i. To determine the virus load in the lungs using qPCR.  
ii. To determine gene expression levels of IL-15 in the lungs using qPCR.  
iii. To determine expression of IFNs, ISGs, proinflammatory cytokines and chemokines 
and Th2-associated mediators using qPCR and ELISAs. 
iv. To examine the magnitude, kinetics and activation status of the NK cell and acquired 
T cell responses in the airway and lungs using flow cytometry. 
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5.3. Results 
5.3.1. Virus Load 
IFNAR1 ko and wild type C57BL/6 mice were infected i.n. with RV-1B (5x106 TCID50) or PBS 
(0h baseline). qPCR analysis of lung homogenate demonstrated a signficantly higher virus 
load in the lungs of IFNAR1 ko mice at 8h p.i. with RV-1B compared to C57BL/6 (p<0.001) 
(Fig 5.1). vRNA levels declined thereafter in IFNAR1 ko mice and no significant difference was 
observed between the groups at 24h and 48h p.i. Thus, we found that absence of type I IFN 
signalling does affect the rate of virus replication and/or clearance from the lungs early after 
infection.  
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Figure 5.1 IFNAR1 ko mice demonstrate an increased lung viral load after RV-1B infection. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h), and lungs were harvested at 
the indicated timepoints p.i. Lungs were processed for RNA extraction and cDNA made by reverse 
transcription as described. RV-1B viral RNA copies were quantified by qPCR and data was normalised 
against 18s rRNA expression and presented as viral RNA copies/μl of sample. Data are expressed as 
means ± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. 
Statistical significance is for IFNAR1 ko compared with C67BL/6 mice treated with RV-1B, at the 
indicated times (***p<0.001). Only statistically significant differences are shown. 
 
5.3.2. Differential BAL Cell Counts 
Cytospin assays using BAL cells demonstrated the degree of leukocyte inflammation in the 
airway in the absence of type I IFN signalling during RV-1B infection. Firstly, no differences in 
the total number of BAL cells between IFNAR1 ko and C57BL/6 mice were observed during 
the timecourse (Fig 5.2a). However, neutrophilia was significantly greater in IFNAR1 ko mice, 
in which neutrophils comprised ~60% and ~55% of total BAL cells at 24h and 48h p.i. 
respectively, compared to ~40% and ~25% in C57BL/6 mice (Fig 5.2 b&c). 
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In contrast, the lymphocyte response in the airway was severely deficient in IFNAR1 ko mice. 
At 48h p.i. the percentage of total BAL lymphocytes in IFNAR1 ko mice was ~5% compared to 
~25% in C57BL/6 mice, and this deficiency was similarly translated into lymphocyte numbers 
(Fig 5.2 d&e). We observed the peak of lymphocytes at 48h p.i., our final timepoint, though 
it is likely that the percentage/number may increase between d2-7 p.i. as seen with BALB/c 
mice (chapter 3).  
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Figure 5.2 Differential BAL cell counts during RV-1B infection of IFNAR1 ko mice. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and BAL was performed at the 
indicated timepoints p.i. Recovered live BAL cells were counted (a) and processed for cytospin slides. 
Slides were blinded to experimental conditions and cells differentially counted to give the percentage 
and total number (b&c) neutrophils and (d&e) lymphocytes in the airway. Data are expressed as 
means ± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. 
Statistical significance is for IFNAR1 ko compared with C67BL/6 mice treated with RV-1B, at the 
indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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5.3.3. BAL Proinflammatory Mediators 
To determine if absent type I IFN signalling during RV-1B infection affected production of 
proinflammatory mediators, we analysed the BAL fluid by ELISA. Firstly, significantly higher 
levels of KC were produced at 8h p.i. in IFNAR1 ko compared to C57BL/6 mice (p<0.001), 
after which levels rapidly decreased in both groups (Fig 5.3a). Equal quantities of IL-6 were 
produced in both groups at 8h p.i. and though levels declined thereafter, the rate was much 
quicker in IFNAR1 ko mice (Fig 5.3b). No significant differences in expression of IL-12 was 
detected between both groups (Fig 5.3c). Conversely, deficient production of RANTES, IL-1β 
and TNF-α was observed in IFNAR1 ko mice compared to C57BL/6 mice at the peak of 
expression at 24h p.i. (p<0.001 for RANTES; p<0.05 for IL-1β and TNF-α) (Fig 5.3 d, e &f).  
 
5.3.4. Expression of Type I and III Interferons  
Amplification of IFN-α/β production occurs via autocrine and paracrine signalling through 
the type I IFN receptor, thus we measured expression to confirm deficient signalling. No BAL 
IFN-α protein was detected in IFNAR1 ko mice in contrast to C57BL/6 mice which 
demonstrated increasing levels between 8-48h p.i. with RV-1B (Fig 5.4a). Similarly, 
expression of IFN-β mRNA in the lungs was detected only in C57BL/6 mice at 8h p.i. with RV-
1B, followed by a peak of protein in the BAL fluid at 24h (Fig. 5.4 b&c).  
 
Additionally, levels of IFN-λ2/3 mRNA in the lungs were ~2-fold higher in C57BL/6 mice at 8h 
p.i. with RV-1B compared to IFNAR1 ko mice (p<0.05), and elevated mRNA levels persisted in 
C57BL/6 mice between 8-48h; levels had diminished rapidly in IFNAR1 ko mice by 24h p.i. 
(Fig 5.4d). Thus, production of type I and III IFNs in IFNAR1 ko mice was deficient in response 
to RV-1B infection. 
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Figure 5.3 BAL cytokines and chemokines produced in response to RV-1B infection in IFNAR1 ko 
mice. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and BAL was performed at the 
indicated timepoints p.i. Protein levels of (a) KC, (b) IL-6, (c) RANTES, (d) IL-12, (e) IL-1β and (f) TNF-α 
were analysed by ELISA in BAL fluid and expressed as pg/ml. Data are expressed as means ± SEM of4-
6 mice per group and is representative of at least 2 independent experiments. Statistical significance 
is for IFNAR1 ko compared with C67BL/6 mice treated with RV-1B, at the indicated times (***p<0.001, 
**p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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Figure 5.4 Expression of type I and III IFNs in response to RV-1B infection in IFNAR1 ko mice is 
deficient. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h), and BAL was performed and 
lungs harvested at the indicated timepoints p.i. Protein levels of (a) IFN-α and (c) IFN-β in BAL fluid 
were analysed by ELISA and expressed as pg/ml. Lung tissue was processed for RNA extraction and 
cDNA made by reverse transcription as described, and the level of (b) IFN-β and (d) IFN-λ2/3 gene 
expression was quantified by qPCR. Data was normalised against 18s rRNA expression and presented 
as copies of mRNA/μl of sample. Data are expressed as means ± SEM of 4-6 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is for IFNAR1 ko 
compared with C67BL/6 mice treated with RV-1B, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
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5.3.5. Expression of Interferon Stimulated Genes 
To further confirm absent type I IFN signalling in IFNAR1 ko mice, we analysed expression of 
various ISGs. BAL IP-10 protein was observed by ELISA at 24h p.i. with RV-1B in C57BL/6 but 
not IFNAR1 ko mice (p<0.001) (Fig 5.5a). Likewise, upregulation of OAS-1a, Viperin and PKR 
mRNA in the lungs was detected by qPCR in C57BL/6 but not IFNAR1 ko mice from 8h p.i. 
with RV-1B (Fig 5.5 b-d).  
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Figure 5.5 Expression of interferon stimulated genes in response to RV-1B infection in IFNAR1 ko 
mice is deficient. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h), and BAL was performed and 
lungs harvested at the indicated timepoints p.i. Protein levels of (a) IP-10 in BAL fluid was analysed by 
ELISA and expressed as pg/ml. Lung tissue was processed for RNA extraction and cDNA made by 
reverse transcription as described, and the level of gene expression of (b) Viperin, (c) OAS and (d) PKR 
were quantified by qPCR. Data was normalised against 18s rRNA expression and presented as copies 
of mRNA/μl of sample. Data was expressed as means ± SEM of 4-6 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is for IFNAR1 ko 
compared with C67BL/6 mice treated with RV-1B, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
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5.3.6. Expression of IL-15 and IL-15Rα  
We analysed expression of IL-15 by qPCR to determine if its production is dependent on IFN-
α/β signalling during RV-1B infection. Agreeably, we found deficient mRNA expression in 
IFNAR1 ko mice compared to C57BL/6 mice, which demonstrated a peak of IL-15 mRNA in 
the lungs at 8h p.i. with RV-1B (Fig 5.6a). IL-15Rα mRNA was upregulated in both groups at 
8h p.i., though levels were~2-fold higher in C57BL/6 compared to IFNAR1 ko mice (Fig 5.6b).  
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Figure 5.6 Expression of IL-15 and IL-15Rα in response to RV-1B infection in IFNAR1 ko mice is 
deficient. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and lungs harvested at the 
indicated timepoints p.i. Lung tissue was processed for RNA extraction and cDNA made by reverse 
transcription as described, and the level of gene expression of (a) IL-15 and (b) IL-15Rα were 
quantified by qPCR. Data was normalised against 18s rRNA expression and presented as copies of 
mRNA/μl of sample. Data are expressed as means ± SEM of 4-6 mice per group and is representative 
of at least 2 independent experiments. Statistical significance is for IFNAR1 ko compared with 
C67BL/6 mice treated with RV-1B, at the indicated times (**p<0.01 & *p<0.05). Only statistically 
significant differences are shown. 
 
 
5.3.7. Expression of IFN-γ  
We also analysed total IFN-γ mRNA expression in the lungs by qPCR. We found the peak of 
expression at 8h p.i. with RV-1B in both groups, though the quantity in C57BL/6 mice was 
~2-fold higher than in IFNAR1 ko mice (p<0.001) (Fig 5.7). By 24h and 48h p.i., levels had 
declined though remained higher in C57BL/6 compared to IFNAR1 ko mice (ns). Lymphocyte 
specific expression of IFN-γ in the airway and lungs is presented in sections 5.3.9 and 5.3.10 
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Figure 5.7 Expression of IFN-γ in response to RV-1B infection in IFNAR1 ko mice is deficient. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and lungs harvested at the 
indicated timepoints p.i. Lung tissue was processed for RNA extraction and cDNA made by reverse 
transcription as described, and the level of IFN-γ gene expression was quantified by qPCR. Data was 
normalised against 18s rRNA expression and presented as copies of mRNA/μl of sample. Data are 
expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 independent 
experiments. Statistical significance is for IFNAR1 ko compared with C67BL/6 mice treated with RV-1B, 
at the indicated times (***p<0.001). Only statistically significant differences are shown. 
 
 
5.3.8. Expression of Th2 Mediators 
Production of Th2 cytokines and chemokines in the airway and lungs is characteristic of 
allergy and asthma. IFN-γ strongly potentiates development of Th1-mediated responses 
however, we suggest that its deficiency in IFNAR1 ko mice may allow development of a Th2 
response to RV-1B infection. Firstly, MDC and TARC in BAL fluid were measured by ELISA. 
Both groups of mice upregulated these proteins in response to RV-1B infection, though 
levels were significantly higher in IFNAR1 ko mice at 8h p.i. for MDC, and at 24h and 48h p.i. 
for TARC compared to C57BL/6 mice (Fig 5.8 a&b).  
 
Secondly, expression of the classical Th2 cytokines IL-4, IL-5 and IL-13 in the lungs were 
analysed by qPCR. A sharp peak of IL-4 and IL-5 mRNA expression was detected in IFNAR1 ko 
mice compared to C57BL/6 mice at 8h p.i. (p<0.001), after which levels rapidly declined (Fig 
5.8 c&d); however, mRNA copy numbers detected at the peak of expression were low, 
particularly for IL-5. No differences in expression of IL-13 were detected between IFNAR1 ko 
and C57BL/6 mice with RV-1B infection. Overall, in the absence of type I IFN signalling, this 
data suggests the development of a weak Th2 response to RV-1B infection as observed in 
IFNAR1 ko mice. 
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Figure 5.8 IFNAR1 ko mice demonstrate increased expression of Th2-associated mediators in 
response to RV-1B infection. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and BAL was performed and 
lungs harvested at the indicated timepoints p.i. Protein levels of (a) MDC and (b) TARC in the BAL fluid 
were analysed by ELISA and expressed as pg/ml. Lung tissue was processed for RNA extraction and 
cDNA made by reverse transcription as described, and the level of gene expression of (c) IL-4, (d) IL-5 
and (e) IL-13 were quantified by qPCR. Data was normalised against 18s rRNA expression and 
presented as copies of mRNA/μl of sample. Data are expressed as means ± SEM of 4-6 mice per group 
and is representative of at least 2 independent experiments. Statistical significance is for IFNAR1 ko 
compared with C67BL/6 mice treated with RV-1B, at the indicated times (***p<0.001 & **p<0.01). 
Only statistically significant differences are shown. 
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5.3.9. NK Cell Response 
No previous studies have addressed the role of type I IFNs on the NK cell response during RV 
infection, thus we sought to investigate this in IFNAR1 ko mice. To determine the kinetics of 
NK cell recruitment/expansion and activation in the airway and lungs, leukocytes were 
stained with monoclonal antibodies specific for CD3, NK1.1, CD69, GranzymeB and IFN-γ and 
analysed by flow cytometry; NK cells were defined as CD3-/NK1.1+ within the lymphocyte 
gate. 
5.3.9.1. BAL NK Cells 
In response to RV-1B infection, there was a significantly deficient airway NK cell response in 
IFNAR1 ko mice, as demonstrated by the ~8-fold lower number of NK cells observed 
compared to C57BL/6 mice at 48h p.i. (p<0.001) (Fig. 5.9a). Consequently, almost no CD69+, 
GranzymeB+ and IFN-γ+ NK cells were observed in the airway of IFNAR1 ko mice compared 
to C57BL/6 mice, in which numbers of NK cells expressing these activation markers peaked 
at 48h p.i. (p<0.001) (Figure 5.9b-d). Figure 5.10 illustrates the deficient BAL NK cell response 
in IFNAR1 ko mice by way of representative flow plots. 
5.3.9.2. Lung NK Cells 
No differences were detected in the number of total lung cells between the groups at any 
time point (Fig 5.10a). Thus, as no significant differences were observed in the percentage of 
CD3-/NK1.1+ NK cells between the groups at any time point (data not shown), the total 
number of NK cells detected in the lungs was similar in both IFNAR1 ko and C57BL/6 mice all 
time points, and with respect to baseline levels (0h) both groups demonstrated an increase 
in numbers of NK cells at 48h p.i. (Fig 5.10b). 
 
Despite similar numbers of lung NK cells, those observed in IFNAR1 ko mice showed 
deficient expression of activation markers. IFNAR1 ko mice did not upregulate CD69 
significantly, unlike C57BL/6 mice which demonstrated an incremental increase in the 
number of CD69+ NK cells between 0h-48h p.i. with RV-1B (p<0.001) (Fig 5.11c). Intracellular 
staining demonstrated deficient numbers of GranzymeB+ NK cells in response to RV-1B 
infection in IFNAR1 ko mice, as numbers were greater in C57BL/6 compared to IFNAR1 ko 
mice at both 24h and 48h p.i. (p<0.01) (Fig 5.11d). Similarly, the absolute number of IFN-γ+ 
NK cells was greater in C57BL/6 compared to IFNAR1 ko mice at 24h p.i. (p<0.01) (Fig 5.11e). 
Figure 5.12 illustrates these differences between the groups as representative flow plots of 
lung NK cells at 48h p.i., demonstrating that in IFNAR1 ko compared to C57BL/6 mice, ~<5% 
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vs ~35%  of lung NK cells were CD69+, ~20% vs ~35% were GranzymeB+ and ~20% vs ~35% 
were IFN-γ+. 
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Figure 5.9 The BAL NK cell response to RV-1B infection in IFNAR1 ko mice is deficient. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and BAL was performed at the 
indicated timepoints p.i. 1x10
5
 BAL cells were stained for surface markers CD3, CD69 and NK1.1, 
intracellular cytokines IFN-γ and GranzymeB and a dead cell marker; staining was analysed on a BD 
LSR II flow cytometer as described. Data is presented as the absolute number of (a) CD3-/NK1.1+ NK 
cells and CD3- gated double positive (b) NK1.1+/CD69+, (c) NK1.1+/ GranzymeB+ and (d) and NK1.1+/ 
IFN-γ+ NK cells. Data are expressed as means ± SEM of 4-6 mice per group and is representative of at 
least 2 independent experiments. Statistical significance is for IFNAR1 ko compared with C67BL/6 
mice treated with RV-1B, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically 
significant differences are shown. 
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Figure 5.10 Representative flow plots demonstrating deficeint BAL NK cell responses at 48h after 
RV-1B in IFNAR1 ko mice. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B and BAL was performed at 48h p.i. 1x10
5
 
BAL cells were stained for surface markers CD3, CD69 and NK1.1, intracellular cytokines IFN-γ and 
GranzymeB and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. 
Data is presented as representative flow plots illustrating (a&b) CD3-/NK1.1+ NK cells and CD3- gated 
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double positive (c&d) NK1.1+/CD69+, (e&f) NK1.1+/ GranzymeB+ and (g&h) NK1.1+/ IFN-γ+ NK cells 
from IFNAR1 ko and C57BL/6 mice. Data are representative of at least 2 independent experiments. 
Numbers indicated on plots represent the % of events falling within the indicated gate. 
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Figure 5.11 The lung NK cell response to RV-1B infection in IFNAR1 ko mice is deficient. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and the 
resultant single-cell suspension was counted to give (a) the total live cell number. 1x10
6
 cells were 
stained for surface markers CD3, CD69 and NK1.1, intracellular cytokines IFN-γ and GranzymeB and a 
dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. Data are 
presented as the absolute number of (b) CD3-/NK1.1+ NK cells, and CD3- gated double positive (c) 
NK1.1+/CD69+, (d) NK1.1+/GranzymeB+ and (e) NK1.1+/IFN-γ+ NK cells. Data are expressed as means 
± SEM of 4-6 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is for IFNAR1 ko compared with C67BL/6 mice treated with RV-1B, at the indicated times 
(***p<0.001 & **p<0.01). Only statistically significant differences are shown. 
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Figure 5.12 Representative flow plots demonstrating deficient lung NK cell resposnes at 48h after 
RV-1B infection in IFNAR1 ko mice. 
IFNAR1 ko and control C57BL/6 mice were treated i.n. with RV-1B and the left lung lobe excised after 
BAL was performed at 48h p.i. Lungs were digested as described. 1x10
6
 cells were stained for surface 
markers CD3, CD69 and NK1.1, intracellular cytokines IFN-γ and GranzymeB and a dead cell marker; 
staining was analysed on a BD LSR II flow cytometer as described. Data is presented as representative 
flow plots illustrating (a&b) CD3-/NK1.1+ NK cells and CD3- gated double positive (c&d) 
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NK1.1+/CD69+, (e&f) NK1.1+/GranzymeB+ and (g&h) NK1.1+/IFN-γ+ NK cells from IFNAR1 ko and 
C57BL/6 mice. Data are representative of at least 2 independent experiments. Numbers indicated on 
plots represent the % of events falling within the indicated gate. Only statistically significant 
differences are shown. 
 
 
5.3.10. T Cell Response 
5.3.10.1. BAL T Cells 
Both IFNAR1 ko and C57BL/6 mice demonstrated an equal increase of ~5-fold in the total 
numbers of airway CD4+ T cell at 48h p.i. with RV-1B compared to baseline (0h) levels (Fig 
5.13a). However, the recruited/expanded CD4+ T cells in IFNAR1 ko mice were unable to 
upregulate CD69 and IFN-γ to the same extent as C57BL/6 mice; C57BL/6 mice 
demonstrated ~3-fold more CD69+ CD4+ T cells (p<0.001) and ~2-fold more IFN-γ+ CD4+ T 
cells(p<0.001) in the airway at 48h p.i. compared to IFNAR1 ko mice (Fig 5.13 c&e).  
 
On the other hand, during RV-1B infection we observed almost no recruitment/expansion of 
CD8+ T cells into the airway of IFNAR1 ko compared to C57BL/6 mice, which demonstrated a 
sharp increase in numbers at 48h p.i. (p<0.001) (Fig 5.13b). Consequently, there was a 
complete deficiency of CD69+ (p<0.001) and IFN-γ+ (p<0.001) CD8+ T cells in the airway of 
IFNAR1 ko mice compared to C57BL/6 mice at 48h p.i. (Fig 5.13d&f).  
 
5.3.10.2. Lung T Cells 
Similar to the airway, both IFNAR1 ko and C57BL/6 mice demonstrated similar numbers of 
lung CD4+ T cells at all time points investigated (Fig 5.14a). However, lung CD4+ T cells in 
IFNAR1 ko mice demonstrated deficient upregulation of CD69 and IFN-γ compared to 
C57BL/6 mice at 48h p.i. (p<0.01) (Fig 5.14 c&e).  
 
The absolute number of lung CD8+ T cells was similar at 0h and 24h p.i. in both groups 
however, there was deficient recruitment/expansion of CD8+ T cells in IFNAR1 ko compared 
to C57BL/6 mice at 48h p.i. (p<0.05) (Fig 5.14b). Furthermore, the CD8+ T cells in the lungs of 
IFNAR1 ko mice failed to upregulate expression of CD69 and IFN-γ in response to RV-1B, 
unlike C57BL/6 mice at 48h p.i. (Fig 5.14 d&f). Thus, in both the airway and lungs, in the 
absence of type I IFN signalling during RV-1B infection, there is deficient activation of CD4+ 
and CD8+ T cells. 
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Figure 5.13 BAL CD4 and CD8 T cell response during RV-1B infection of IFNAR1 ko mice. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and BAL was performed at the 
indicated timepoints p.i. 1x10
5
BAL cells were stained for surface markers CD3, CD4, CD8 and CD69, 
intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow 
cytometer as described. Data is presented as the absolute number of (a) CD3+/CD4+, CD3+ gated (b) 
CD4+/CD69+, (c)CD4+/IFN-γ+, (d) CD3+/ CD8+, CD3+ gated (e) CD8+/CD69+ and (f) CD8+/IFN-γ+ T cells. 
Data are expressed as means ± SEM of 4-6 mice per group and is representative of at least 2 
independent experiments. Statistical significance is for IFNAR1 ko compared with C67BL/6 mice 
treated with RV-1B, at the indicated times (***p<0.001 & *p<0.05). Only statistically significant 
differences are shown. 
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Figure 5.14 Lung CD4 and CD8 T cell response during RV-1B infection of IFNAR1 ko mice. 
IFNAR1 ko and C57BL/6 mice were treated i.n. with RV-1B or PBS (0h) and the left lung lobe excised 
after BAL was performed at the indicated timepoints p.i. Lungs were digested as described and 1x10
6
 
cells were stained for surface markers CD3, CD4, CD8 and CD69, intracellular cytokine IFN-γ and a 
dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. Data is presented 
as the absolute number of (a) CD3+/CD4+, CD3+ gated (b) CD4+/CD69+, (c) CD4+/IFN-γ+, (d) CD3+/ 
CD8+, CD3+ gated (e) CD8+/CD69+ and (f) CD8+/IFN-γ+ T cells. Data are expressed as means ± SEM of 
4-6 mice per group and is representative of at least 2 independent experiments. Statistical 
significance is for IFNAR1 ko compared with C67BL/6 mice treated with RV-1B, at the indicated times 
(***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
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5.4. Chapter Summary 
In the absence of type I IFN signalling in IFNAR1 ko mice, we observed an enhanced 
neutrophilic response to RV-1B infection compared to C57BL/6 mice. IFNAR1 ko mice had 
increased levels of IL-6, similar levels of IL-12 and reduced levels of RANTES and TNF-α 
compared to C57BL/6 mice. Moreover, we observed deficient upregulation of IL-15, IL-15Rα 
and IFN-γ mRNA in lung tissue at 8h p.i. in IFNAR1 ko mice. In association, expression of Th2 
associated chemokines and cytokines MDC, TARC, IL-4 and IL-5 were increased in the 
absence of type I IFN signalling during RV infection. Deficient expression of the ISGs IP-10, 
PKR, OAS and Viperin observed confirmed the lack of type I IFN signalling in IFNAR1 ko mice.  
 
The BAL NK cell response was absent in IFNAR1 ko mice compared to C57BL/6 mice, and the 
latter demonstrated accumulation in the airway and activation at 24h and 48h p.i. In the 
lungs, although IFNAR1 ko mice had similar total numbers of NK cells at the time points 
investigated, the NK cells failed to upregulate CD69 expression and demonstrated deficient 
upregulation of intracellular GranzymeB and IFN-γ compared to C57BL/6 after infection. 
Thus, in the absence of type I IFN signalling, the NK cell response to RV-1B infection is 
impaired. These results were associated with an increased virus load at 8h p.i. with RV in the 
absence of type I IFN signalling, suggesting that type I IFNs are important for the early 
control of virus infection/replication. 
 
In both the airway and lung tissue, CD4+ T cells were recruited to a similar extent in IFNAR1 
ko and control mice, but deficient upregulation of CD69 and IFN-γ expression in CD4+ T was 
observed in IFNAR1 ko mice after infection. In contrast, the CD8+ T cells response was 
absent in IFNAR1 ko mice compared to C57BL/6 mice, which demonstrated 
recruitment/accumulation and activation in to the airway and lungs at 48h p.i.  
 
These data show that IL-15 is an ISG in the mouse model of RV infection, and type I IFN 
signalling is critical for the NK cell and CD8+ T cell response. Association of these deficiencies 
in the absence of type I IFN signalling with an increased lung viral load suggests that these 
responses are important components of antiviral defence against RV infection. 
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6. Chapter 6: Results – IL-15 expression and the NK cell response during RV-
induced asthma exacerbation 
6.1. Introduction 
Asthma is a disease characterised by chronic airway inflammation with episodes of variable 
and reversible airway obstruction. Respiratory virus infections are the primary cause of 
asthma exacerbations, significantly contributing to asthma morbidity, mortality and health 
care costs. RVs are the most common etiological agents of exacerbations and the 
mechanisms by which RVs mediate asthma exacerbations are unclear. Therefore, further 
research is necessary to explore more targeted therapeutic options to prevent and/or treat 
virus-induced asthma exacerbations.  
 
We have established from the previous chapters using mouse models that RV infection 
upregulates IL-15 expression in the airway and lungs, which is dependent on type I IFN 
signalling. We showed that the ensuing NK cell response, which is an important source of 
early IFN-γ after RV infection, is dependent on IL-15. These responses are associated with 
the decline of virus load in the lungs. However, the pre-existence of a dominant Th2 
environment in the lungs of asthmatics results in a somewhat altered immune response to 
RV infection compared to healthy individuals [27]. 
 
Asthmatic bronchial epithelial cells (BECs) infected with RV ex vivo demonstrated deficient 
IFN-β production, which was associated with increased viral replication and deficient 
induction of apoptosis compared to BECs from healthy individuals [108]. In addition, IL-15 
levels in the BAL fluid of asthmatics has been shown to be lower than that found in non-
asthmatics at baseline, and RV infection of BAL macrophages from asthmatics demonstrated 
deficient induction of IL-15; these results inversely correlated with AHR and virus load during 
in vivo human experimental RV infection [256]. Furthermore, immunohistochemistry data 
from bronchial biopsies has illustrated deficient IL-15 upregulation in asthmatics infected 
with RV compared to non-asthmatics (data not published – biopsies taken from Message et 
al. [27] study). Therefore, we suggest that deficient IFN-β expression in response to RV 
infection in asthmatics impairs the IL-15-NK cell antiviral pathway, resulting in increased 
virus load and prolonged infection due to impaired innate antiviral immunity. It is possible 
that this mechanism contributes to the development of RV-induced asthma exacerbations. 
In this chapter, we have employed a mouse model of RV-induced allergic airways 
inflammation to specifically investigate IL-15 expression and the NK cell response, to gain 
further knowledge of the contribution of this pathway to asthma exacerbation pathogenesis.  
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6.2. Hypotheses &  Aims 
6.2.1. Hypotheses 
 
i. RV-induced IL-15 is deficient in OVA sensitized and challenged mice.  
ii. Deficient IL-15 signalling results in a deficient NK cell response to RV infection in 
OVA sensitized and challenged mice, resulting in increased virus load.  
 
6.2.2. Aims 
To investigate the interaction between allergic inflammation and RV infection and the effect 
this has on IL-15 expression and NK cell resposens.  
 
To compare the following responses in allergen challenged and non-challenged mice: 
i. To determine virus load in the lungs using qPCR.  
ii. To determine expression of IL-15, IL-15Rα, Th2 cytokines, IFN-γ and IP-10 in the 
airway and lungs using qPCR and ELISAs. 
iii. To determine the magnitude, kinetics and activation status of the NK cell response 
in the airway and lungs using flow cytometry. 
vi. To examine the acquired T cell response in the airway and lungs using flow 
cytometry. 
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6.3. Results 
In this chapter, all mice were treated as described in Section 2.33/Figure 2.2. The 
nomenclature for the treatment groups for this model are summarised again in Table 6.1 
below.  
 
 
Experimental Groups Sensitization 
(Day -13) 
OVA/Alum i.p. 
Challenges 
(Days -2, -1 & 0) 
OVA or PBS i.n. 
RV-1B  Infection 
(Day 0) 
RV-1B or UV-RV-1B i.n. 
RV-OVA YES OVA RV-1B 
UV-OVA YES OVA UV-RV-1B 
RV-PBS YES PBS RV-1B 
UV-PBS YES PBS UV-RV-1B 
 
Table 6.1 Experimental groups of the RV-induced asthma exacerbation model, and the breakdown 
of treatments received by mice in each group. 
 
6.3.1. Virus Load 
Increased RV replication has been observed in ex vivo infected asthmatic bronchial epithelial 
cells in comparison to non-asthmatic cells [109], and it is suggested that deficient type I and 
III IFN production as well as a skewed Th2 response to virus infection are potential causes 
[27, 108, 109]. Thus, we analysed the virus load in the lungs by qPCR to determine the effect 
of allergic airways inflammation on RV replication/infection efficiency in the mouse model. 
We observed ~2-fold more RV viral RNA in RV-OVA compared to RV-PBS treated mice at d1 
p.i. (p<0.001), after which levels rapidly declined in both groups.  
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Figure 6.1 RV-1B infected mice with allergic airways inflammation demonstrated an increased virus 
load compared to non-allergic mice. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
Lungs were harvested at the indicated time points p.i., processed for RNA extraction and cDNA made 
by reverse transcription as described. RV-1B viral RNA copies were quantified by qPCR, data was 
normalised against 18s rRNA expression and presented as viral RNA copies/μl of sample. Data are 
expressed as means ± SEM of 4 mice per group and is representative of at least 2 independent 
experiments. Statistical significance is shown between mice of specific treatment groups, at the 
indicated times (***p<0.001). Only statistically significant differences are shown. 
 
6.3.2. Differential BAL Cell Counts 
Airway cellular inflammation was initially determined by differential staining of BAL cell 
cytospins. Firstly, BAL cell counts demonstrated significantly greater numbers of cells in the 
airway in OVA sensitized and challenged mice regardless of infection at all time points 
compare to PBS challenged mice (Fig 6.2a). In agreement with published data by Bartlett et 
al. [255] we found enhanced neutrophilia in RV infected OVA sensitized and challenged mice 
at d1 p.i. (p<0.001) (Fig 6.2b), at which neutrophils comprised ~60% of the total BAL cells in 
RV-OVA treated mice, compared to ~30% in RV-PBS treated mice (data not shown). 
Eosinophilia was seen only in OVA-challenged mice, and no significant differences in 
numbers were detected between RV-OVA and UV-OVA treated mice (Fig 6.2c). Numbers of 
lymphocytes were hugely elevated in OVA compared to PBS-challenged mice, demonstrating 
more than a 30-fold increase in numbers as early as d1 post-challenge, which increased 
between d2-7 (Fig 6.2d). However, no differences in the number of BAL lymphocytes were 
seen between RV-OVA and UV-OVA treated mice.     
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Figure 6.2 RV-1B infected mice with allergic airays inflammation demosntrated enhanced airway 
neutrophilia compared to non-allergic mice. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
BAL was performed at the indicated time points p.i. and recovered live BAL cells were (a) counted and 
processed for cytospin slides. Slides were blinded to experimental conditions and cells differentially 
counted to give the total number of (b) neutrophils, (c) eosinophils and (d) lymphocytes in the airway. 
Data are expressed as means ± SEM of 4 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between mice of specific treatment groups, 
at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are 
shown. 
 
6.3.3. Expression of Th2 Mediators 
IL-4, IL-5 and IL-13 are the classical Th2 cytokines known to be associated with atopic 
asthmatic airway inflammation. Secretion of these cytokines into the airway during the RV-
induced asthma exacerbation mouse model was previously demonstrated (and confirmed in 
these studies – data not shown), with enhanced levels of IL-4 and IL-5 detected in the BAL 
fluid of RV-OVA compared to UV-OVA treated mice at d1 p.i. [255]. Here, we confirmed 
increased expression of these Th2 cytokines through detection in lung homogenate by ELISA. 
Higher levels of IL-4, IL-5 and IL-13 were found in the lung tissue of RV-OVA compared to UV-
OVA treated mice at d1 p.i. (p<0.001 for IL-4 and IL-5; p<0.01 for IL-13) (Fig6.3 a-c), and 
though the same trend was observed at d2, it was not statistically significant. Levels of IL-4 
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and IL-13 declined after d2 post challenge with OVA however, IL-5 remained detectable in 
the lungs as late as d7 post challenge.  
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Figure 6.3 Expression of lung Th2 cytokines during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
Lungs were harvested after BAL was performed at the indicated time points p.i. Lungs were processed 
for protein detection as described, and the concentration of (a) IL-4, (b) IL-5 and (c) IL-13 was 
determined by ELISA and presented as pg/ml. Data are expressed as means ± SEM of 4 mice per group 
and is representative of at least 2 independent experiments. Statistical significance is shown between 
mice of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
 
 
6.3.4. Airway Hyperreactivity 
Expression of the above Th2 cytokines has previously been associated with increased airway 
hyperreactivity (AHR) in both human disease and mouse models of RV-induced asthma 
exacerbation. In human disease models, exacerbation is measured in terms of decreased 
lung function (changes in FEV1 and PEF) in addition to increased bronchial hyperreactivity to 
methacholine or histamine challenges [27, 95]. Here, we used whole body plethysmography 
at d1 post challenge/infection to confirm exacerbation; AHR was measured in response to 
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increasing doses of aerosolised methacholine via detecting changes in PenH and airways 
resistance. We confirmed published findings [255] demonstrating enhanced PenH in RV-OVA 
compared to UV-OVA treated mice upon challenge with 10 and 30mg/ml methacholine 
(p<0.05 & p<0.01 respectively), and PBS challenged mice demonstrated no response to any 
dose of methacholine tested regardless of infection (Fig 6.4). Thus, RV-1B infection resulted 
in enhanced AHR in mice with allergic airways inflammation. 
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Figure 6.4 RV-1B infection in allergic mice enhanced airway hyperreactivity.  
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
At d1 post-challenge/infection, PenH was measured in response to challenge with increasing doses of 
aerosolised methacholine. PenH is expressed as area under the curve over a 5 minute log period post 
challenge. Data are expressed as means ± SEM of 4 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between RV-OVA and UV-OVA treated 
mice, at the indicated concentrations of methacholine treatment (**p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
 
 
6.3.5. Expression of IL-15 and IL-15Rα  
Deficient upregulation of IL-15 and IL-15Rα in asthmatics has been observed in lung biopsies 
after experimental RV infection compared to non-asthmatic subjects [256](Laza-Stanca, 
2011). Thus, we investigated expression in BAL cells and lung tissue in the mouse model of 
RV-induced asthma exacerbation via qPCR and ELISA. Contrary to human studies, we found 
significantly enhanced IL-15 and IL-15Rα mRNA expression in lung tissue at d1 p.i. in RV-OVA 
compared to UV-OVA, RV-PBS and UV-PBS treated mice (p<0.001 for IL-15; p<0.05 for IL-
15Rα) (Fig 6.5 a&b). However, protein detection in lung homogenate demonstrated 
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enhanced expression of IL-15 and sIL-15/IL-15Rα complexes in both RV-OVA and UV-OVA 
treated mice compared to PBS challenged mice at d1 and d2 p.i., and though a higher level 
of protein was detected in RV-OVA compared to UV-OVA treated mice, the differences were 
not statistically significant (Fig 6.5 e&f). This suggests a degree of OVA-specific induction of 
IL-15 and IL-15Rα protein in lung tissue. 
 
Chapter 3 demonstrated significant induction of IL-15 expression in BAL cells with RV-1B 
infection however, here we demonstrate enhanced levels of IL-15 and IL-15Rα mRNA 
expression in BAL cells in RV-OVA treated mice at 10h and d1 p.i. compared to RV-PBS 
treated mice (Fig 5.5 c&d). Additionally, no induction was detected in UV-RV-1B infected 
mice, regardless of OVA challenge.  
 
6.3.6. Expression of IFN-γ  
Previous chapters demonstrated the importance of IFN-γ production for the immune 
response against RV infection and its association with IL-15 signalling and the NK cell 
response. Thus, we analysed its expression in lung tissue by qPCR to determine if allergic 
inflammation affects its expression in response to RV-1B infection. We found ~3-fold more 
IFN-γ mRNA in the lungs of RV-OVA compared to RV-PBS treated mice at d1 p.i. (p<0.001), 
with levels equalizing between the two groups at d2 (Fig 6.6a). Additionally, UV-OVA treated 
mice also had elevated levels of IFN-γ mRNA compared to RV-PBS treated mice at d1 p.i. 
(p<0.05), however the trend had reversed by d2 p.i. as levels increased in RV-PBS treated 
mice (p<0.05). By d4 p.i., levels had declined to baseline in all groups except RV-PBS treated 
mice, though this was not significant.  
 
Additionally, IP-10 is an IFN-γ inducible protein and an NK cell activating chemokine, 
therefore we analysed its secretion in to the airway by ELISA to confirm presence of IFN-γ 
signalling. Consistent with IFN-γ expression, we observed a sharp peak of IP-10 protein in 
RV-OVA treated mice at d1 p.i. (p<0.001) that had diminished by d2, at which we then 
detected a smaller peak of IP-10 in RV-PBS treated mice (Fig 6.6b).  
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Figure 6.5 Expression of RV-induced IL-15 in BAL cells and lung tissue was enhanced in mice with 
allergic airways inflammation compared to non-allergic mice. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
Lungs were harvested after BAL was performed at the indicated time points p.i. Lungs and BAL cells 
were processed for RNA extraction and cDNA made as described. (a&c) IL-15 and (b&d) IL-15Rα gene 
expression was quantified by qPCR in lung and BAL cells. Lungs were processed for protein detection 
as described, and the concentration of (e) IL-15 and (f) sIL-15/IL-15Rα complex was determined by 
ELISA and presented as pg/ml. Data are expressed as means ± SEM of 4 mice per group and is 
representative of at least 2 independent experiments. Statistical significance is shown between mice 
of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only 
statistically significant differences are shown. 
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Figure 6.6 Expression of lung IFN-γ and BAL IP-10 during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
Lungs were harvested after BAL was performed at the indicated time points p.i. Lungs were processed 
for RNA extraction and cDNA made as described, and (a) IFN-γ gene expression was quantified by 
qPCR. Data was normalised against 18s rRNA expression and presented as mRNA copies/μl of sample. 
The concentration of (b)IP-10 in BAL fluid was determined by ELISA and presented as pg/ml. Data are 
expressed as means ± SEM of 4 mice per group and is representative of at least 2 independent 
experiments. Statistical significance is shown between mice of specific treatment groups, at the 
indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
 
6.3.7. NK Cell Response 
No previous studies have characterised the BAL and lung NK cell response during RV-induced 
exacerbation in mice, and published data from human experimental RV-induced asthma 
exacerbations is elementary. Thus, we analysed the responses by flow cytometry after BAL 
and lung cells were stained for surface markers CD3, CD69 and NKp46, and intracellular 
cytokines IFN-γ, GranzymeB and IL-4. 
6.3.7.1. BAL NK Cells 
Contrary to our hypothesis, we observed a greatly enhanced NK cell response in RV-OVA 
compared to RV-PBS treated mice at d1 and d2 p.i. (p<0.001 ) with respect to both 
percentage and total NK cell numbers (Fig 6.7 a&b); at d1 NK cells comprised ~25% of the 
total BAL lymphocytes in RV-OVA treated mice, compared to <5% in RV-PBS treated mice 
(p<0.001), and levels had declined back to baseline on days 4 and 7. Additionally, elevated 
percentages and numbers of NK cells was detected in UV-OVA compared to RV-PBS treated 
mice at d1 and d2 p.i. suggesting the presence of an OVA-specific NK cell response; however, 
the percentage and number of NK cells in UV-OVA treated mice was still ~2-fold lower than 
in RV-OVA treated mice at both d1 and d2 p.i. (p<0.001). 
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Similarly, the percentage and number of CD69+ and GranzymeB+ BAL NK cells were elevated 
in OVA compared to PBS challenged mice, with significantly higher levels in RV-OVA 
compared to UV-OVA treated mice at d1 and d2 p.i. (Fig 6.7 c, d, g & h). However, only RV-
OVA treated mice demonstrated a significant increase in number of IFN-γ+ BAL NK cells at d1 
p.i. (p<0.001) (Fig 6.7). By d2 p.i., RV-OVA and RV-PBS treated mice had upregulated IFN-γ 
expression to an equal extent with respect to percentage of IFN-γ+ NK cells, though the total 
number was still significantly higher in RV-OVA treated mice (p<0.001) due to the much 
higher total BAL cell count (Figure 6.2a). 
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Figure 6.7 The BAL NK cell response to RV-1B infection was enhanced in mice with allergic airways 
inflammation compared to non-allergic mice.  
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BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
BAL was performed at the indicated time points p.i. and 1x10
5
 cells were stained for surface markers 
CD3, CD69 and NKp46, intracellular cytokines IFN-γ and GranzymeB and a dead cell marker; staining 
was analysed on a BD LSR II flow cytometer as described. Data is presented as the percentage and 
absolute number of (a&b) CD3-/NKp46+ NK cells, and CD3- gated double positive (c&d) 
NKp46+/CD69+, (e&f) NKp46+/GranzymeB+ and (g&h) NKp46+/IFN-γ+ NK cells. Data are expressed as 
means ± SEM of 4 mice per group and is representative of at least 2 independent experiments. 
Statistical significance is shown between mice of specific treatment groups, at the indicated times 
(***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are shown. 
 
6.3.7.2. Lung NK Cells 
The total number of lung cells was greatest in mice treated with RV-OVA at both d1 and d2, 
demonstrating ~2-fold more cells than RV-PBS and UV-PBS treated mice at d1 (p<0.001) (Fig 
6.8). Total numbers in UV-OVA treated mice was increased over RV-PBS (ns) and UV-PBS 
(p<0.05) treated groups at d1 p.i. however, numbers were similar between UV-OVA and RV-
PBS treated mice at d2 p.i. The total number of lung cells had declined in OVA challenged 
mice by d4 p.i. resulting in similar numbers detected in all groups at d4 and d7 p.i.  
 
The kinetics of NK cell recruitment/expansion in the lungs was similar to that in the airway. 
Percentage and number of NK cells was significantly increased in OVA compared to PBS 
challenged mice at d1 and d2 p.i., with ~2-fold more NK cells in RV-OVA compared to UV-
OVA treated mice at d1 p.i. (p<0.001), after which levels declined but remained higher in RV-
OVA treated mice at d2 (Fig 6.9 a&b).  
 
Similarly, percentages and numbers of activated CD69+ and GranzymeB+ NK cells were 
elevated only in OVA challenged groups, with ~3-fold greater numbers in RV-OVA compared 
to UV-OVA treated mice at d1 and d2 p.i. (p<0.001), after which levels returned to baseline 
(Fig 6.9 c-f). However, a significant increase in total number of IFN-γ+ NK cells was only 
detected in RV-OVA treated mice at d1 p.i. (p<0.001), despite elevated percentages in UV-
OVA treated mice at d1 and d2 p.i. (Fig 6.9g&h). 
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Figure 6.8 Total lung leukocyte counts during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
The left lung lobe was excised after BAL was performed at the indicated time points p.i. Lungs were 
digested as described, and the resultant single-cell suspension was counted to give the total number 
of live cells. Data are expressed as means ± SEM of 4 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between mice of specific treatment groups, 
at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are 
shown. 
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Figure 6.9 The Lung NK cell response to RV-1B infection was enhanced in mice with allergic airways 
inflammation compared to non-allergic mice. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
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The left lung lobe was excised after BAL was performed at the indicated time points p.i., and lungs 
were digested as described. 1x10
6
 cells were stained for surface markers CD3, CD69 and NKp46, 
intracellular cytokines IFN-γ and GranzymeB and a dead cell marker; staining was analysed on a BD 
LSR II flow cytometer as described. Data are presented as the percentage and absolute number of 
(a&b) CD3-/NKp46+ NK cells, and CD3- gated double positive (c&d) NKp46+/CD69+, (e&f) 
NKp46+/GranzymeB+ and (g&h) NKp46+/IFN-γ+ NK cells. Data are expressed as means ± SEM of 4 
mice per group and is representative of at least 2 independent experiments. Statistical significance is 
shown between mice of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & 
*p<0.05). Only statistically significant differences are shown. 
 
6.3.7.3. IL-4 Expression in NK Cells 
Previous reports have suggested that NK cells can develop a Th2 polarity, thus we 
investigated expression of IL-4 by BAL and lung NK cells during the RV-induced asthma 
exacerbation model. Unsorted lung and BAL leukocytes were stimulated with PMA, 
ionomycin and GolgiStop for 3h or left unstimulated, prior to staining with antibodies 
specific for CD3, NKp46 and intracellular IL-4 and analysed by flow cytometry.  
 
IL-4+ NK cells were detected only with stimulation, and increases in total number were 
observed with OVA compared to PBS challenged mice in both BAL and lungs. Despite low 
numbers detected in the airway, both OVA-challenged groups had increased levels of IL-4+ 
NK cells at d2-7 p.i. however, significantly more IL-4+ NK cells were detected in RV-OVA 
compared to UV-OVA treated mice at d2 and d4 p.i. (p<0.01) (Fig 6.10a). In the lungs, only 
RV-OVA treated mice demonstrated an increase in IL-4+ NK cells at d1 and d2 p.i. (Fig 6.10b). 
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Figure 6.10 BAL and lung NK cells expressed IL-4 in resposne to RV-1B infection in mice with allergic 
airways inflamation. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
The left lung lobe was excised after BAL was performed at the indicated time points p.i. 1x10
5
 BAL 
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cells and 1x10
6
 lung cells were stained for surface markers CD3 and NKp46, intracellular cytokine IL-4 
and a dead cell marker; staining was analysed on a BD LSR II flow cytometer as described. Data are 
presented as the absolute number CD3- gated double positive NKp46+/IL-4+ NK cells in the (a) airway 
and (b) lungs. Data are expressed as means ± SEM of 4 mice per group and is representative of at 
least 2 independent experiments. Statistical significance is shown between mice of specific treatment 
groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant 
differences are shown. 
 
6.3.8. T Cell Response 
6.3.8.1. BAL T Cells 
In the airway, the total number of CD4+ T cells significantly increased in OVA compared to 
PBS challenged mice from d1 p.i. and peaked between d4-7, and no significant differences 
were detected between RV-OVA and UV-OVA treated mice at any time point (Fig 6.11b). A 
similar trend was observed for the number of BAL CD69+ CD4+ T cells (Fig 6.11d). In contrast, 
the percentage of IFN-γ+ CD4+ T cells was increased and ~2.5-fold greater in RV-PBS 
compared to RV-OVA and UV-OVA treated mice at d2-7 p.i. (p<0.001) (Fig 6.11c); however, 
due to the much higher total number of cells in the airway of RV-OVA treated mice (Fig 6.2a), 
the number of BAL IFN-γ+ CD4+ T cells were equally elevated in RV-PBS and RV-OVA treated 
mice at d4 p.i., and by d7 numbers had declined in RV-PBS compared to RV-OVA and UV-
OVA treated mice (Fig 6.11f). Additionally, only RV-OVA treated mice demonstrated a 
significant increase in number of IL-4+ CD4+ T cells at d4 and d7 p.i. (p<0.001) (Fig 6.11h).  
 
Likewise, the total number of BAL CD8+ T cells was also elevated in OVA compared to PBS 
challenged groups, and no significant differences were detected between RV-OVA and UV-
OVA treated mice, in which numbers peaked at d2 p.i. and declined thereafter (Fig 6.12b). 
Numbers of CD69+ CD8+ T cells were significantly increased at d2 p.i. in OVA compared to 
PBS challenged groups, and in RV-OVA compared to UV-OVA treated mice (p<0.001) (Fig 
6.12d). Lastly, the percentage of IFN-γ+ CD8+ T cells was greater in RV-OVA compared to RV-
PBS treated mice on d1 p.i. and the relationship was reversed on d2 and d7 p.i.; despite this, 
the total number of IFN-γ+ CD8+ T cells remained significantly greater in RV-OVA compared 
to RV-PBS treated mice on days 2-7 due to the much higher total number of cells in the 
airway (Fig 6.12f). 
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Figure 6.11 BAL CD4+ T cell response during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
BAL was performed at the indicated time points p.i., and 1x10
5
 cells were stained for surface markers 
CD3, CD4, and CD69, intracellular cytokines IFN-γ and IL-4 and a dead cell marker; staining was 
analysed on a BD LSR II flow cytometer as described. Data are presented as the percentage and 
absolute number of (a&b) CD3+/CD4+ T cells, and CD3+ gated double positive (c&d) CD4+/CD69+, 
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(e&f) CD4+/IFN-γ+ and (g&h) CD4+/IL-4+ T cells. Data are expressed as means ± SEM of 4 mice per 
group and is representative of at least 2 independent experiments. Statistical significance is shown 
between mice of specific treatment groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). 
Only statistically significant differences are shown. 
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Figure 6.12 BAL CD8+ T cell response during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
BAL was performed at the indicated time points p.i., and 1x10
5
 cells were stained for surface markers 
CD3, CD8, and CD69, intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a 
BD LSR II flow cytometer as described. Data are presented as the percentage and absolute number of 
(a&b) CD3+/CD8+ T cells, and CD3+ gated double positive (c&d) CD8+/CD69+ and (e&f) CD8+/IFN-γ+ T 
cells. Data are expressed as means ± SEM of 4 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between mice of specific treatment groups, 
at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are 
shown. 
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6.3.8.2. Lung T Cells 
 
In the lungs, the percentage of CD4+ T cells was consistently and equally elevated in OVA 
compared to PBS challenged groups at d1-7 p.i. (Fig 6.13a). However, the total number of 
CD4+ T cells was greater in RV-OVA compared to UV-OVA treated mice, and greater in UV-
OVA compared to RV-PBS and UV-PBS treated mice at d1 and d2 p.i. (Fig 6.13b). After d2 
numbers declined but were still elevated in OVA compared to PBS challenged groups at d7 
p.i. Similarly, the percentage and total number of lung CD69+ CD4+ T cells was significantly 
elevated in OVA compared to PBS challenged groups, with similar levels observed between 
RV-OVA and UV-OVA treated mice (Fig 6.13 c&d).  
 
Despite variations in the percentage of IFN-γ+ CD4+ T cells between the groups at each time 
point, translation into cell numbers demonstrated equally elevated numbers of IFN-γ+ CD4+ 
T in RV-OVA and UV-OVA treated mice between d1-7 p.i. compared to RV-PBS treated mice, 
except for d4 at which numbers in RV-PBS treated mice increased to similar levels (Fig 6.13f). 
Expression of IL-4 in CD4+ T cells was only increased in OVA challenged groups, with no 
significant differences detected between RV-OVA and UV-OVA treated mice; percentage and 
numbers increased from d1 p.i., peaked at d4 and were still significantly elevated at d7 p.i. 
compared to RV-PBS and UV-PBS treated mice (Fig 6.13 g&h). 
 
With respect to CD8+ T cells in the lungs, the percentage was greatest in RV-OVA treated 
mice at d1 p.i., after which it decreased to similar levels detected in the other groups at days 
2-7; however, numbers of CD8+ T cells were significantly elevated in RV-OVA compared to 
UV-OVA, RV-PBS and UV-PBS treated mice at d1 and d2 p.i., after which levels declined to 
baseline (Fig 6.14b). Additionally, numbers were slightly elevated in UV-OVA compared to 
RV-PBS (ns) and UV-PBS treated mice (p<0.05) at d1 and d2 p.i. (Fig 6.14a). The percentage 
and total number of CD69+ CD8+ T cells was significantly elevated only in OVA compared to 
PBS challenged mice at d1 and d2 p.i., however the total number was ~2-fold greater in RV-
OVA compared to UV-OVA treated mice on both days (p<0.001), after which levels declined 
(Fig 6.14 c&d).  
 
The percentage of lung IFN-γ+ CD8+ T cells was greater in OVA compared to PBS challenged 
mice on d1 p.i., and this difference was resolved by d4. However, despite similar 
percentages detected in RV-OVA and UV-OVA treated mice on d1 and d2 p.i., numbers were 
significantly greater in RV-OVA treated mice (Fig 6.14f). On d1 p.i. numbers were ~2-fold and 
~3-fold greater in RV-OVA compared to UV-OVA and RV-PBS treated mice respectively 
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(p<0.001). Additionally, UV-OVA treated mice demonstrated elevated numbers over RV-PBS 
and UV-PBS treated mice on d1 p.i. (p<0.001) and remained elevated over UV-PBS treated 
mice on d2 (p<0.05).  
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Figure 6.13 Lung CD4+ T cell response during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
The left lung lobe was excised after BAL was performed at the indicated time points p.i., and lungs 
were digested as described. 1x10
6
 cells were stained for surface markers CD3, CD4, and CD69, 
intracellular cytokines IFN-γ and IL-4 and a dead cell marker; staining was analysed on a BD LSR II flow 
cytometer as described. Data are presented as the percentage and absolute number of (a&b) 
CD3+/CD4+ T cells, and CD3+ gated double positive (c&d) CD4+/CD69+, (e&f) CD4+/IFN-γ+ and (g&h) 
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CD4+/IL-4+ T cells. Data are expressed as means ± SEM of 4 mice per group and is representative of at 
least 2 independent experiments. Statistical significance is shown between mice of specific treatment 
groups, at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant 
differences are shown. 
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Figure 6.14 Lung CD8+ T cell response during an RV-induced allergic exacerbation model. 
BALB/c mice were sensitized i.p. with OVA/Alum at d-13 and challenged i.n. with OVA/PBS at d-2, -1 
and 0; mice were immediately infected with RV-1B or UV-RV-1B following the 3
rd
 OVA challenge on d0. 
The left lung lobe was excised after BAL was performed at the indicated time points p.i., and lungs 
were digested as described. 1x10
6
 cells were stained for surface markers CD3, CD8, and CD69, 
intracellular cytokine IFN-γ and a dead cell marker; staining was analysed on a BD LSR II flow 
cytometer as described. Data are presented as the percentage and absolute number of (a&b) 
CD3+/CD8+ T cells, and CD3+ gated double positive (c&d) CD8+/CD69+ and (e&f) CD8+/IFN-γ+ T cells. 
Data are expressed as means ± SEM of 4 mice per group and is representative of at least 2 
independent experiments. Statistical significance is shown between mice of specific treatment groups, 
at the indicated times (***p<0.001, **p<0.01 & *p<0.05). Only statistically significant differences are 
shown. 
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6.4. Chapter Summary 
In this chapter we have demonstrated that RV infection in airways with allergic inflammation 
(RV-OVA) exacerbated airway neutrophilia compared to control mice (RV-PBS). Within the 
OVA sensitized and challenged groups, similar levels of eosinophils and lymphocytes were 
detected in airway regardless of infection with live or inactivated virus. As previously shown 
in BAL fluid by Bartlett et al. [255], we demonstrated using lung homogenate that only OVA 
sensitized and challenged mice expressed IL-4, IL-5 and IL-13, and levels were greater in RV-
OVA compared to UV-OVA treated mice at days 1-2 p.i.  
 
In contrast to our hypothesis, we detected a dramatic upregulation of IL-15 mRNA in the 
lungs of RV-OVA treated mice compared to all other groups at day 1 p.i. Similarly, IL-15 
mRNA levels in BAL cells was much higher in RV-OVA treated mice compared to controls at 
10h p.i., but similar levels were detected in RV-PBS and RV-OVA treated mice at day 1 p.i 
However, enhanced levels of IL-15Rα mRNA in lung homogenate and BAL cells was only 
detected in RV-OVA treated mice, suggesting increased IL-15 signalling potential specific to 
this group based on the special trans-presentation mechanism for IL-15 signalling. In 
association with this, enhanced levels of total IFN-γ mRNA in the lungs of RV-OVA treated 
mice was detected at day 1 p.i. compared to other treatment groups, but by day 2 p.i. 
similar levels were observed between RV-OVA and RV-PBS treated mice and levels declined 
thereafter. IFN-γ induces expression of IP-10, and increased levels of BAL IP-10 protein was 
detected only in RV-OVA treated mice at day 1 and only in RV-PBS treated mice at day 2 p.i. 
 
As shown by flow cytometry, RV-OVA treated mice demonstrated the greatest increase in 
total NK cells numbers and CD69+, IFN-γ+ and GranzymeB+ NK cells at day 1-2 p.i. in the 
airway and lungs. Only a small increase in numbers of BAL IFN-γ+ NK cells was observed in 
RV-PBS treated mice at day 2 p.i. and levels were still significantly less than that observed in 
RV-OVA treated mice. These results are also in disagreement with our hypotheses. 
Furthermore, increased numbers of NK cells positive for intracellular IL-4 were detected in 
RV-OVA treated mice in the BAL at days 2-4 and in the lungs at days 1-2 p.i. compared to 
control groups. 
 
Numbers of BAL CD4+ T cells were greater in OVA compared to PBS challenged groups, and 
similar levels of BAL IFN-γ+ CD4+ T cells were detected in RV-OVA and RV-PBS treated mice 
at day 4 p.i. Only RV-OVA treated mice demonstrated increased numbers of BAL IL-4+ CD4+ 
T cells at days 4-7 p.i. Similarly, higher levels of BAL CD8+ T cells were observed in OVA 
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compared to PBS challenged mice, and numbers of BAL CD69+ and IFN-γ+ CD8+ T cells were 
greatest in RV-OVA compared to control groups.  
 
In the lungs, numbers of CD4+ T cells were significantly greater in OVA compared to PBS 
challenged mice, and although there were slightly greater total numbers in RV-OVA treated 
mice, there were similar levels of CD69+, IFN-γ+ and IL-4+ CD4+ T cells in both OVA 
challenged groups. However, significantly greater numbers of total and activated lung CD8+ 
T cells were observed in RV-OVA compared to control groups.  
 
All of these exacerbated immune responses observed in RV-OVA treated mice were 
associated with enhanced AHR compared to controls, in which no increased airway 
sensitivity was detected in PBS challenged mice. This was associated with an increased virus 
load in RV-OVA compared to RV-PBS treated mice at day 1 after infection. Thus, it appears 
that RV infection in airways with allergic inflammation results in both enhanced Th1 and Th2 
immune responses, which contributes to poor early virus control and increased AHR. 
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7. Chapter 7: Discussion & Future Work 
 
RV infections are amongst the most common viral infections encountered and the most 
frequent cause of the common cold; they are self-limiting and a mere inconvenience to a 
healthy host. In asthma, the effects of RV infection can be very different. RV infections cause 
significant morbidity and mortality in asthmatics as they trigger approximately two thirds of 
asthma exacerbations, which often results in hospitalisation. Few treatment options for 
acute exacerbations exist and their efficacy is limited, highlighting the urgent need for 
studies into the immune mechanisms of disease, particularly focusing on antiviral immunity. 
IL-15 expression and NK cell functions are key for defence against a number of viral 
infections however, their role in the immune response to RV infections and in asthma are 
unknown. 
 
We have used mouse models to examine RV-mediated IL-15 expression and the NK cell 
responses. We initially examined these responses in a model of RV infection in BALB/c mice. 
Following detection of RV-induced IL-15, we used two models of deficient IL-15 signalling to 
determine the role of IL-15 during infection; we employed an IL-15 neutralising antibody to 
transiently block IL-15 signalling in the airway/lungs of BALB/c mice and IL-15Rα knockout 
mice that have a constitutive block to IL-15 signalling. IL-15Rα ko mice have an intrinsic NK 
cell deficiency, allowing us to indirectly assess the importance of NK cells during RV infection. 
RV induces type I IFNs and IL-15 is a reported ISG, so we next determined if type I IFN 
signalling is necessary for RV-induced IL-15 and the NK cell responses using IFNAR1 ko mice. 
Lastly, given the importance of RV in asthma exacerbations, we used a mouse model of this 
condition to determine how RV and allergen interaction affects IL-15 expression and the NK 
cell responses.  
 
7.1. RV-Induced IL-15 Expression 
BALB/c mice were infected with a minor group RV (RV-1B), which resulted in airway 
neutrophilia followed by lymphocyte infiltration, and expression of proinflammatory 
mediators including KC, IL-1β, IL-6, TNF-α, type I IFNs and IFN-λ. These responses were 
dependant on virus replication as determined by infection with UV-irradiated RV. In UV-RV-
1B treated mice, a small degree of neutrophilia was detected at day 1 after infection (though 
this was not statistically significant compared to PBS or RV-1B treated mice) and is likely 
induced by immune recognition of viral proteins. Alternatives to this control are PBS 
treatment alone, or using HeLa cell lysate (cells used to propagate RV-1B) from uninfected 
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cells, prepared using the same purification method for RV-1B. Having confirmed the 
expected immune responses previously published for this model by Bartlett et al. [255], we 
then assessed IL-15 and IL-15Rα expression.  
 
IL-15 is a pleiotropic cytokine that is upregulated after a number of viral infections [116], 
suggesting the cytokine plays a role in generating an effective antiviral immune response, 
particularly through activation of NK cell responses; IL-15 is critical for NK cell development 
and functions, and NK cells are well known to be important for the innate antiviral immune 
response. This study is the first in vivo report of RV-mediated IL-15 upregulation. Expression 
was analysed in lung tissue to primarily address production in epithelial cells, previously 
reported to constitutively express IL-15. Expression was also analysed in BAL cells as 
macrophages are known sources of IL-15. As trans-presentation of IL-15 to other cells 
requires co-expression of IL-15Rα, we analysed levels of the receptor. We found that both 
IL-15 and IL-15Rα expression peaked at day 1 after infection in BAL cells (mRNA) and lung 
tissue (mRNA and protein). IL-15 staining of lung sections by immunohistochemistry was 
localised to the apical surface of epithelial cells lining the airway; we suggest this is spatially 
optimised for interaction of effector cells in the airway with virus-infected epithelial cells, to 
stimulate proliferation and activation of IL-15 responsive cells at the site of infection. Thus, 
early induction of IL-15 in the airway and lungs after RV infection potentially plays a role in 
developing the antiviral immune response.  
 
In support of this data, we have previously observed IL-15 upregulation in primary human 
BECs infected with RV in vitro (data not published), and Laza-Stanca et al. [256] 
demonstrated RV-induced upregulation in human monocyte derived macrophages in vitro. 
Fawaz et al. [116] conducted a comparative study infecting PMBCs in vitro with different 
viruses including influenza, RSV, HSV-1, EBV, reovirus, vesicular stomatitis virus and Sendai 
virus demonstrating early upregulation of IL-15 mRNA. Upregulation after in vivo infection 
has been observed with herpes group viruses, HIV, vaccinia virus and influenza [123, 259, 
260]. 
 
Numerous studies have documented the difficulty in detecting secreted IL-15 protein in 
biological fluids. Accumulating evidence in the last few years has identified trans-
presentation as the primary mechanism for IL-15 signalling, whereby IL-15 is stabilised upon 
binding IL-15Rα in the ER, and the complex is transported via the secretory pathway for 
presentation on the cell surface. Thus, we directed our efforts towards detecting cell-
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associated IL-15 protein by immunohistochemistry and ELISAs using lung homogenate rather 
than BAL fluid. The lung homogenate ELISA protocol was also recently used to demonstrate 
influenza induced expression of IL-15 protein in lung tissue [260]. This study showed via DC 
depletion experiments that plasmacytoid (pDCs) and CD8α+ DCs are the important sources 
of pulmonary IL-15 trans-presentation during influenza infection, and the level of IL-15 
mRNA expressed in alveolar macrophages was approximately 60% of that detected in 
pDCs/CD8α+ DCs. In our study, we found that BAL cells expressed higher levels of IL-15 
mRNA than lung tissue at day 1 after infection, suggesting they may be a more important 
source of IL-15 signalling however, our detection methods did not allow us to attribute 
expression to specific cell types. As neutrophils comprised approximately 80% of BAL cells at 
day 1 after infection and the remaining cells were macrophages, we suggest that these two 
cell types are potential important sources of IL-15 during RV infection.  
 
7.2. NK Cell Responses During RV Infection 
NK cells are innate large granular lymphocytes that act in the early phase of virus infection 
to eliminate infected cells whilst sparing uninfected cells, in addition to producing cytokines 
and chemokines that can affect other arms of the innate and adaptive immune responses 
[261]. IL-15 is widely reported to be important for development, differentiation, survival and 
activation of NK cells, thus we were interested in the relationship between IL-15 and NK cells 
during RV infection. We initially assessed the NK cell response to RV infection in BALB/c mice. 
To identify the role of IL-15 in the NK cell response during RV infection, IL-15 neutralising 
antibody was administered intranasally at the time of infection in BALB/c mice to transiently 
block pulmonary IL-15 signalling. IL-15Rα ko mice were used to assess the role of IL-15 and 
indirectly assess the importance of NK cells during RV infection as these mice lack NK cells.  
 
Little is known about NK cell responses during RV infection. Levandowski et al. [262] 
observed a decrease in PBMC levels during the acute symptomatic phase of experimental RV 
infection in humans, which included leukocytes expressing NK cell surface markers, and an 
associated increase in mononuclear leukocytes in nasal secretions. Levandowski & Horohov 
[263] demonstrated augmented NK-like cellular cytotoxicity upon incubation of PMBCs with 
RV in vitro. Thus, existing evidence on the role of NK cells during RV infection is basic, 
warranting further investigation to determine the importance of this innate response during 
RV infections, in addition to their role in individuals with more severe RV infections including 
those with asthma and COPD. Understanding the roles of IL-15 and NK cells during RV 
infections could reveal potential therapeutic targets for better disease control. 
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In the BALB/c mouse model of RV infection, recruitment and/or expansion of NK cells in the 
airway by day 1 after infection was detected, with numbers peaking at day 2, comprising 
approximately 30% of the total BAL lymphocyte population. In the lungs, numbers were 
elevated above controls at days 2-4 after infection. These accumulating NK cell populations 
exhibited an activated phenotype, described by increased expression of the early activation 
marker CD69 and intracellular IFN-γ and GranzymeB. These data suggest that NK cells play a 
role in early defence against RV infection. Although the NK cell response was associated with 
the decline in virus titre, numerous other cellular responses were also associated with the 
decline of RV in this model. It is not clear which, if any, are important for clearance. Because 
virus replication is limited in this model and appears to be ‘passively’ cleared, it is difficult to 
determine if specific immune responses are involved in clearance. However, in support of 
the role of NK cells in antiviral responses, RV infection of IL-15Rα ko mice that lack NK cells 
demonstrated increased virus loads at 8h and 24h after infection compared to wild type 
mice, implying that NK cells are important for controlling early viral load. In our mouse 
models, we have not shown RV replication per se as our qPCR assay measures viral load via 
quantifying the amount of positive sense genomic viral RNA in lung tissue;  however, 
detection of increased viral loads in knockout mice over wild type control mice implicates 
increased viral replication and/or impaired clearance of virus. To demonstrate increased 
viral replication directly in the future, in situ hybridisation with a sense RNA probe detecting 
negative strand replicative viral RNA would have to be performed as done by Bartlett et al. 
[255]. In addition, as the duration of RV replication in the mouse is short, it would be 
advantageous to develop a model in which replication lasts for several days as observed in 
clinical and experimental human RV infections [22, 23]. 
 
Many studies have indicated the importance of NK cell responses for clearance of viral 
infections. The best evidence is described by the few reported cases of reduced or absent 
NK cell activity in human subjects suffering from multiple, recurrent and often persistent 
herpes virus infections including HSV, CMV and EBV [239, 264-266]. Numerous in vitro and in 
vivo murine herpes virus infection models (including HSV-1, HSV-2, HHV-6, HHV-7 and EBV) 
also support the role of NK cells for control of infection.  
 
Clinical observations have indicated an inverse relationship between an increasing 
magnitude of NK cell deficiency and more severe RSV-induced bronchiolitis in infants [267-
269]. The striking correlation between deficient NK cell numbers and severity of RSV induced 
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disease clearly indicates a significant role of NK cells in protection during RSV infection. In 
mice, the NK cell response to RSV is similar to that observed with RV, with recruitment of NK 
cells to the airway and lungs by 48h after RSV infection, at which time they represent the 
largest IFN-γ producing population prior to the CD8+ T cell response [270, 271]; depletion of 
NK cells in this model resulted in an increased viral load at day 5 [272]. TLR4 deficient mice 
infected with RSV demonstrated an impaired NK cell response, which was associated with 
impaired virus clearance [273]; it is possible that TLR4-mediated detection of RV may be 
involved in regulation of the NK cell response in our models. Boosting NK cell responses 
during RSV infection via co-expression of IL-18 in the lungs significantly attenuated the peak 
virus load, further supporting the beneficial role of NK cells [274]. The RSV-mediated NK cell 
response in vivo may be regulated by IL-15, induction of which has been shown in 
monocytes and respiratory epithelial cells infected with RSV in vitro [125].  
 
Influenza infection also results in accumulation of NK cells at days 1-2 after infection in mice 
[275], and NK cell depletion via administration of anti-asialo GM1 antibodies significantly 
increases influenza induced morbidity and mortality [276]. Absence of the NK cell activating 
receptor Natural Killer Cell Receptor 1 (NCR1) in mice increased susceptibility to influenza 
infection compared to wild type mice [277]. The notion that NK cells play a critical role in 
clearance of influenza is further supported by a number of reported NK cell evasion 
mechanisms employed by influenza, including direct infection of NK cells resulting in their 
functional impairment, facilitating rapid virus replication in respiratory epithelial cells [278]. 
These studies with RSV and influenza provide support for our data, indicating an important 
role for NK cells in the immune response to RV infection that is associated with IL-15 
expression.  
 
In contrast, a recent study has shown that NK cells contribute to early lung injury during RSV 
infection in mice [279]. Conflicting evidence suggesting both pathogenic and beneficial 
effects of NK cells during RSV infection raises the possibility of NK cell-mediated 
pathogenicity during RV infection, mediated by NK cell produced IFN-γ, release of cytotoxic 
granules and recruitment and/or activation of inflammatory cells via NK cell secreted 
proinflammatory cytokines and chemokines. Absent NK cell responses in our RV infection 
mouse models of deficient IL-15 signalling did not result in reduced levels of inflammatory 
responses including neutrophilia and BAL proinflammatory cytokine levels; histological 
analysis of lung sections would further allow us to address whether NK cells contribute to 
disease pathogenesis during RV infection in these models. It is more difficult to assess 
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pathogenicity of immune responses in the mouse models of RV infection, as more significant 
markers of disease severity such as weight loss or lethality observed with RSV and influenza 
respectively are not seen with RV infection.  
 
7.3. Regulation of NK Cell Responses by IL-15  
IL-15 signals via the constitutively expressed IL-2Rβ/γc (CD122) heterodimeric receptor on 
NK cells. In BALB/c mice, the peak of IL-15 expression in lung and BAL cells at day 1 after RV 
infection precedes the NK cell responses in the airway and lungs, suggesting that IL-15 
potentially regulates NK cell responses during infection. To address the role of IL-15 on NK 
cell responses, we administered an IL-15 neutralising antibody intranasally at the time of RV 
infection to transiently block IL-15 signalling in the airway and lungs. Intranasal delivery was 
chosen to specifically block IL-15 at the site of infection to investigate the effects of RV-
induced IL-15 in the airway/lungs on local NK cell accumulation and activation; systemic 
delivery results in rapid systemic depletion of NK cells and may affect other immune 
populations in the periphery such as CD8+ T cells, making results upon infection in the lungs 
difficult to interpret. In this model, we observed a deficient NK cell response indicating that 
RV-induced IL-15 is necessary for the recruitment/expansion and activation of NK cells in the 
airway and lungs during RV infection.  
 
RV-induced IL-15 may act as a chemotactic signal in addition to promoting the survival and 
proliferation of NK cells, resulting in their accumulation during the early phase of infection. 
Allavena et al. [280] demonstrated the chemotactic effects of IL-15 on NK cells in vitro, and 
showed that IL-15 enhances LFA-1-dependant NK cell adhesion to vascular endothelial cells, 
promoting recruitment into tissues. However, IL-15 mediated NK cell recruitment into the 
airway and lungs during infection has not yet been investigated.   
 
The constitutive expression of IL-15 on a wide range of cells including respiratory epithelial 
cells and bone marrow stromal cells, in addition to constitutive IL-2Rβ/γc expression on NK 
cells suggests that IL-15 plays a role in NK cell survival. Carson et al. [281] demonstrated the 
survival of human NK cells cultured in the presence of IL-15 alone, at concentrations as low 
as 0.1ng/ml, for up to 8 days, compared to no survival in serum free media alone; this was 
attributed to IL-15 regulated expression of the anti-apoptotic molecule Bcl-2 preventing or 
delaying apoptosis of NK cells. Our results support the role of IL-15 in NK cell survival, as 
administration of IL-15 neutralising antibody resulted in decreased numbers of lung and 
splenic NK cells 48h after intranasal administration. Proliferation can also contribute to 
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increased NK cell numbers, previously shown to be IL-15 dependant [193]. IL-15 over-
expression in transgenic mice increases NK cell numbers, which could be attributed to 
increased survival and/or proliferation. Thus, IL-15 may act by a number of mechanisms to 
promote the accumulation of NK cells in the airway/lungs during RV infection, although the 
precise mechanism(s) at play were not examined in our studies. It would be valuable to 
investigate these pathways to further define the roles of IL-15 on NK cell functions during RV 
infection, with potential implications for therapeutic targets in individuals experiencing 
more severe RV-mediated disease.   
 
Activated NK cells can modulate immune responses via production of cytokines, specifically 
IFN-γ, TNF-α, GM-CSF and MIP-1α/CCL3 [282]. NK cell IFN-γ production is important for 
activation of host monocytes/macrophages after infection and development of appropriate 
and effective innate and adaptive immune responses [283]. Our model of deficient IL-15 
signalling using an IL-15 neutralising antibody demonstrated IL-15-depedant NK cell IFN-γ 
production in response to RV infection. In our infection models using IL-15Rα ko and IFNAR1 
ko mice, we could not attribute deficient expression of IFN-γ detected by total mRNA levels 
in lung tissue solely to the absent NK cell response as deficient CD8+ T cell responses were 
also observed, but the data in these models supports the neutralising antibody study i.e. 
deficient NK cell response associated with deficient IFN-γ response.   
 
These data are in accord with previous reports of IL-15 induced NK cell IFN-γ production. 
Carson et al. [284] demonstrated that IL-15 produced by LPS activated monocytes in vitro 
was necessary for optimal NK cell IFN-γ production; however, neutralisation of IL-15 did not 
completely abrogate IFN-γ expression suggesting that other monocyte-derived cytokines, 
including IL-12, are able to induce sub-optimal IFN-γ production by NK cells. Buunsgaard et 
al. [285] showed that neutralisation of endogenous IL-15 in PBMC cultures from HIV infected 
patients resulted in reduced IFN-γ production. Gosselin et al. [286] reported IFN-γ secretion 
by PMBCs upon stimulation with IL-15, which was synergistically enhanced in the presence 
of EBV or HSV-1. Furthermore, increased NK cell derived IFN-γ production is observed in IL-
15 transgenic mice [287]. The importance of NK cell produced IFN-γ for defence against virus 
infections in vivo has been demonstrated by other studies [230, 234].  
 
IL-15 stimulation of NK cell cytolytic functions for elimination of virus infected cells has been 
reported [116, 284, 286], but no previous evidence exists documenting the necessity of this 
pathway for RV clearance. Despite observing upregulation of NK cell GranzymeB during RV 
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infection, it is unclear how important the cytolytic pathway is as NK cell cytolytic activity was 
not directly measured. However, in our infection model with neutralising antibody, absence 
of NK cell responses did not affect the lung virus titre, suggesting that cytolytic activity of NK 
cells is not important for clearance of virus via destroying RV-infected epithelial cells. This is 
further supported by the limited cytopathic effect seen with RV infection compared to RSV 
and influenza [288-290]. It is more likely that NK cells, as an important source of IFN-γ, are 
key for directing development of Th1 responses to drive the appropriate antiviral immune 
responses (further discussed in Section 7.7).  
 
7.4. Type I IFN Signalling is Necessary for RV-induced IL-15 and the NK Cell Response 
Most if not all nucleated host cells are able to express type I IFNs early after viral infection, 
which stimulate expression of hundreds of ISGs to promote development of an antiviral 
state in surrounding cells and to directly stimulate innate and adaptive immune cells. Type I 
IFNs have been demonstrated to induce IL-15 expression [118] and consistent with this, RV-
induced IL-15 in BALB/c mice was associated with IFN-β expression; in BAL cells, IFN-β mRNA 
was elevated by 10h after infection followed by upregulation of IL-15 mRNA at 24h. To 
investigate if RV-induced IL-15 (and thus the NK cell response) in this model is dependent on 
type I IFN signalling, we analysed these responses during infection of IFNAR1 ko mice. These 
mice lack the IFN-α-receptor subunit1 and cannot mediate type I IFN signalling.  
 
We found deficient upregulation of IL-15 in RV infected IFNAR1 ko mice, confirming that IL-
15 is an ISG in this model. Our results are supported by Laza-Stanca et al. [256] whom 
demonstrated in vitro using macrophages, dose-dependent IL-15 expression upon IFN-β 
stimulation and inhibition of RV-induced IL-15 in the presence of an IFN-α-receptor subunit2 
(IFNAR2) blocking antibody. Therefore, in vitro and in vivo RV infection models show that RV-
induced IL-15 is dependent on type I IFNs. Consistent with these data, Azimi et al. [121] 
reported the presence of a virus-inducible enhancer region in the IL-15 promoter, composed 
of an IFN regulatory factor element (IRF-E) adjacent to an NF-κB binding site. Nguyen et al. 
[193] demonstrated the necessity for IFN-α/β and STAT1 activity for induction of IL-15 
during MCMV infection in mice, and Mattei et al. [118] showed IL-15 and IL-15Rα expression 
by splenic DCs upon IFN-α/β treatment in vivo and in vitro. Taken together, these studies 
confirm the importance of type I IFN signalling for the induction of IL-15 in response to virus 
infections, and support our data indicating type I IFN-dependant RV-induced IL-15 
expression. 
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Type I IFNs play an important role in upregulation of NK cell cytoxicity and IFN-γ production 
during virus infections including LCMV, HSV-2 and vaccinia virus, which enhances antiviral 
immunity [192, 261, 291-293]. In agreement, we found the NK cell response to RV infection 
dependant on type I IFN signalling. NK cell accumulation in the airway was completely 
absent in RV infected IFNAR1 ko mice, suggesting a recruitment block in the absence of type 
I IFN signalling. In the lungs, similar numbers of NK cells were present in IFNAR1 ko and wild 
type mice, but lung NK cells in IFNAR1 ko mice failed to upregulate CD69, IFN-γ and 
GranzymeB expression indicating that type I IFN signalling is necessary for activation of NK 
cells during RV infection.  
 
The deficient NK cell responses in IFNAR1 ko mice were associated with an increased virus 
load in the lungs at 8h after infection, at which time we also observed deficient expression 
of IL-15 and IFN-γ. Although deficient NK cell responses were also observed in our infection 
models with deficient IL-15 signalling (IL-15 neutralising antibody and IL-15Rα ko mice), 
expression of ISGs were not affected in these models suggesting that type I IFN signalling 
was intact; this implies that NK cell responses during RV infections are not achieved by direct 
action of type I IFNs on NK cells, but is likely mediated through type I IFN-induced IL-15 
signalling.  
 
These data are supported by previous reports indicating that type I IFNs stimulate accessory 
cells to produce IL-15, which acts as the intermediary factor to activate NK cells. Lucas et al. 
[247] reported DCs as the accessory cell for this pathway in vivo. Boudreau et al. [294] 
supported these findings via demonstrating the necessity of type I IFN-induced IL-15 by DCs 
for NK cell activation and tumour protection, and that stimulation of NK cells directly by type 
I IFNs alone was insufficient for activation. During MCMV infection, NK cell proliferation was 
mediated by type I IFN-induced IL-15 however, enhanced NK cell cytotoxicity required direct 
stimulation by type I IFNs in this model [193]. Foong et al. [117] demonstrated reduced virus 
titres as early as day 1 after infection in mice with an IL-15 expressing recombinant vaccinia 
virus compared to wild type virus, the effect of which was dependant on the presence of 
IFNs and NK cells. Furthermore, DC-NK cell interactions are becoming more apparent with 
imaging studies, illustrating the importance of these brief encounters for activation of NK 
cells in response to pathogenic stimuli [295]. All of these studies support the necessity of 
type I IFN signalling for IL-15 induced NK cell responses, as we have shown during RV 
infection in mice. 
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Our observations are in contrast to that reported by Martinez et al. [293], whom report the 
necessity for direct type I IFN stimulation of NK cells for their activation and effector 
function in vitro and in vivo, for efficient clearance of vaccinia virus infection. Direct 
stimulation for elimination of adenovirus vectors in vivo was also observed by Zhu et al. 
[292]. Beuneu et al. [296] demonstrated the necessity of both direct type I IFN stimulation of 
NK cells and indirect stimulation via accessory cells for IL-15 trans-presentation for optimal 
stimulation of NK cell effector functions in response to poly I:C stimulation in mice. It is likely 
that both IL-15 and type I IFNs are required for optimal NK cell responses; type I IFNs have 
numerous roles either functioning through induction of ISGs that in turn regulate NK cells 
(such as IL-15) or by directly stimulating NK cells. The relative importance of direct vs 
indirect (via ISGs) effects of type I IFNs will vary depending on the model, though 
cooperation of the two pathways is likely to be optimal as deficiency of either impedes the 
NK cell response.  
 
Despite the well known importance of the above pathways, it is necessary to remember that 
activation of NK cells during virus infection is very complex, as illustrated by the large variety 
of activating and inhibitory receptors that govern NK cell responses, which not only respond 
to cytokine stimulation (type I IFNs, IFN-γ, IL-12, IL-15 and IL-18) but also pathogen-derived 
gene products [297]. Regardless of the mechanism used, consistent with previous findings 
[117, 291, 293], we show in this study that type I IFN signalling is critical for NK cell 
responses during RV infection, and to our knowledge, this is the first report of IFN-
dependant IL-15 mediated NK cell responses for defence against a respiratory viral infection. 
 
7.5. IL-15 is Required for CD8+ T Cell Responses During RV Infection 
IL-15 was first discovered by its ability to stimulate proliferation of an IL-2-dependant CTLL-2 
mouse CD8+ T cell line [112, 133]. T cells respond to IL-15 signalling via the intermediate 
affinity IL-2Rβ/γc, which is upregulated after activation [298]. The relationship between IL-15 
and CD4+ T cells is unclear, but most reports indicate that IL-15 is not important for CD4+ T 
cell functions. This supports our findings of minimal disruption to CD4+ T cell responses in 
our mouse models of deficient IL-15 signalling (IL-15 neutralising antibody and IL-15Rα ko 
mice) during RV infection. IL-15 is critically important for maintaining memory CD8+ T cell 
populations as demonstrated by the severely reduced numbers of CD44high CD8+ T cells in IL-
15 and IL-15Rα ko mice [157, 158]. IL-15 supports the survival of CD8+ T cells at all 
developmental stages, by stimulating increased expression of Bcl-2 [160]; this explains the 
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dramatically lower frequency and total number of CD8+ T cells observed in the lungs of 
naïve IL-15Rα ko compared to wild type mice.  
 
Respiratory viral infections elicit Tc1 CD8+ T cell responses that are generally defined as 
cytotoxic and IFN-γ producing, which promote clearance of the infection. Tc2 CD8+ T cells 
producing IL-5 have been described in asthma [299] and, CD8+ T cells are reported to 
contribute to the pathogenesis of virus-induced asthma exacerbations, particularly with RSV 
infection [300]. The Th2 environment in asthmatic lungs are thought to alter virus-specific 
CD8+ T cell responses from IFN-γ to IL-5 production (Tc2), further potentiating allergic 
inflammation and hampering antiviral immune responses [300]. The role of IL-15 in 
regulating Tc1 vs Tc2 CD8+ T cell responses during virus infection and/or asthma is unknown. 
 
In BALB/c mice, the number of airway and lung activated (CD69+ and IFN-γ+) CD8+ T cells 
was elevated by day 2 after RV infection however, the response was reduced in mice treated 
with IL-15 neutralising antibody and completely deficient in IL-15Rα ko mice. Our data 
suggests that IL-15 plays a role in the accumulation of CD8+ T cells in the airway/lungs 
during RV infection, in addition to their activation. These data are supported by findings 
from Verbist et al.  [301] whom demonstrated the role of influenza-induced IL-15 for 
migration of CD8+ effector T cells to the airway in vivo; intranasal delivery of soluble IL-
15/IL-15Rα complexes restored the respiratory CD8+ T cell response to influenza infection in 
IL-15 ko mice, and continuous administration during the contraction phase of the CD8+ T cell 
response amplified the resultant memory pool generated in wild type mice. Inflammation 
induced expression of IL-15 on the basolateral surface of airway epithelial cells revealed by 
Hocke at al. [257] presents an attractive mechanism for spatially optimised IL-15 signalling to 
attract CD8+ T cells from the vasculature. However, it  is unclear whether IL-15 acts directly 
or indirectly on T cells to induce chemotaxis, and indirect mechanisms such as IL-15 induced 
expression of LFA-1 (an adhesion molecule that promotes lung-specific trafficking) [302, 303] 
and chemokine receptors on T cells [302] may play a role during RV infection.  
 
The deficient CD8+ T cell response in IL-15Rα ko mice could result from a  combination of 
poor recruitment, local proliferation, activation and survival signals due to the absence of 
epithelial, DC and/or macrophage trans-presentation of IL-15 in the airway [249, 260, 304]. 
We suggest that the reduced but not absent CD8+ T cell response observed with IL-15 
neutralising antibody was because the short transient period of IL-15 deficiency did not have 
a severe impact on the survival of CD8+ T cells. We do not expect the differences in CD8+ T 
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cell responses between these models to be attributed to insufficient blocking of pulmonary 
IL-15 by neutralising antibody, as the dose, timing and route of administration resulted in 
complete inhibition of airway and lung NK cell responses and early NK cell depletion in the 
spleen, indicating systemic activity despite intranasal administration. However, the transient 
block with neutralising antibody may not have occurred fast enough to completely prevent 
IL-15 mediated indirect mechanisms of T cell chemotaxis after RV infection hence detection 
of some accumulation of CD8+ T cells in the airway and lungs.  
 
The lack of an activated CD8+ T response in both IL-15Rα ko and IFNAR1 ko mice could be 
due to absent IL-15 mediated survival signals, possibly from pDCs, which are also key 
producers of type I IFNs. McGill et al. [260] showed that pDCs and CD8α+ DCs in the 
airway/lungs are the largest source of IL-15, necessary for survival of influenza-specific CD8+ 
T cells; the absence of these cells despite the presence of other IL-15 producing cells such as 
epithelial cells and macrophages did not support the survival and accumulation of CD8+ T 
cells during influenza infection. McGill et al. [260] administered recombinant mouse IL-
15Rα/Fc fusion proteins intranasally to block IL-15 signalling resulting in increased apoptosis 
and thus reduced numbers of CD8+ T cells during influenza infection. Similar to our results 
which support the role of IL-15 in regulating the magnitude of lung CD8+ T cells after RV 
infection, they also detected reduced frequency and total number of lung CD8+ T cells in IL-
15 ko mice during influenza infection. In vitro, IL-15 supports the survival of naïve and 
effector CD8+ T cells in the absence of IL-2 via induction of Bcl-2 and Bcl-xL [159, 305, 306]. 
IL-15 also inhibits IL-2-mediated activation induced cell death, thus potentially enhancing 
and prolonging the T cell response, which could be associated with better viral resistance or 
immune-mediated pathology [161]. 
 
In contrast, a study of LCMV infection in mice suggests that IL-15 is not necessary for 
supporting primary CD8+ T cell responses, as similar responses in IL-15 ko mice, IL-15Rα ko 
mice and wild type mice were observed [307]. We suggest that the dependency for IL-15 by 
specific immune responses may depend on the particular infectious agent, and the specific 
tissue/site of infection could also play a role. The importance of IL-15 for stimulation of T cell 
responses is clearly illustrated by its emerging popularity for incorporation into vaccines, to 
utilise its immune enhancing properties as an adjuvant that stimulates generation of both 
primary and memory responses. Poon et al. [308] showed enhanced humoural and cellular 
responses against the poorly immunogenic H5N1 influenza antigens with an IL-15 expressing 
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vaccinia based vaccine. These studies support our observations that IL-15 signalling is 
important for the CD8+ T cell response to RV infection.  
 
Despite detecting accumulation and activation of CD8+ T cells in response to RV infection, it 
is unclear how important a cytolytic CD8+ T cell response is during the anti-RV response, as 
similar to the argument for NK cells, minimal epithelial destruction is observed during RV 
infection. In contrast to a healthy host, a relationship between increased numbers of CD8+ T 
cells in asthmatics and severity of virus-induced asthma exacerbation has been reported 
[300]. It is possible that in a healthy host, CD8+ T cell responses are not critical for antiviral 
immunity during RV infection, but contributes to disease pathogenesis in asthma.   
 
7.6. Role of Type I IFNs on T cells During RV Infection 
Type I IFNs exert numerous effects on T cells via direct and indirect mechanisms, and their 
necessity for development of adaptive immune responses against virus infections has been 
well documented [309]. Similar levels of accumulating CD4+ T cells in the airway and lungs 
after RV infection in IFNAR1 ko and wild type mice were observed, indicating that type I IFN 
signalling during RV infection is not necessary for recruitment, proliferation or survival of 
CD4+ T cells. However, the recruited CD4+ T cells in IFNAR1 ko mice did not upregulate 
expression of CD69 and IFN-γ after infection indicating impaired activation in the absence of 
type I IFN signalling. Shiow et al. [310] demonstrated type I IFNs to be potent inducers of 
CD69 expression on CD4+ T cells, which in turn regulates T cell migration and production of 
TNF-α and IFN-γ by CD4+ T cells [311]. Previous in vitro and in vivo studies indicate the 
necessity of type I IFNs for T cell activation, but whether this occurs via direct or indirect 
mechanisms (e.g. via IL-12, IL-15 and/or IL-18 induction) during viral infections is unclear as 
conflicting evidence exists; the need for intrinsic type I IFN signalling for T cell activation 
appears to be specific to the infection model investigated [312-315].  
 
We have shown type I IFNs to be critical for accumulation and activation of airway and lung 
CD8+ T cells during RV infection, and this is associated with IL-15 upregulation. However, 
unaffected ISG expression and thus type I IFN signalling in IL-15Rα ko mice, despite deficient 
CD8+ T cell responses, suggests that type I IFNs regulate CD8+ T cell via indirect mechanisms 
during RV infection. Type I IFNs induce maturation of DCs, mediating upregulation of MHC 
class II molecules, co-stimulatory molecules (CD40, CD80 and CD86) and a number of 
cytokines, chemokines and chemokine receptors [316-318]; it is likely that impaired DC 
maturation and thus presentation of virus antigens for priming and stimulation of T cells 
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results in the deficient T cell responses observed in IFNAR1 ko mice during RV infection. 
Type I IFN stimulated expression of IL-15 by DCs [118] may be the indirect mechanism 
mediating proliferation and survival of activated T cells (as discussed above), previously 
attributed to type I IFNs during viral infections [319]. Work presented by Ruckert et al. [320] 
support the notion that DC-mediated IL-15 signalling regulates CD8+ T cell activation, 
necessary for development of Th1 immune responses in mice. The influenza-specific CD8+ T 
cell response was shown to be dependent on IL-15 signalling by Nakamura et al. [321]. In 
addition to IL-15, chemotaxis of T cells and efficient activation of naïve CD8+ T cells is also 
mediated by the ISG IP-10 [319], expression of which was deficient in IFNAR1 ko mice after 
RV infection.  
 
Although our studies suggest that type I IFNs act via indirect mechanisms to mediate T cell 
responses during RV infection, the necessity for direct stimulation of T cells via the type I IFN 
receptor was shown for activation of these responses during LCMV infection. Adoptively 
transferred IFNAR1 deficient T cells specific for LCMV into IFNAR1 sufficient mice resulted in 
significantly reduced proliferation and generation of memory populations compared to 
controls [313, 322]. Comparison of various reports suggest that direct action of type I IFNs 
for development of a functional T cell response is necessary for some but not all virus 
infections. Our data indicates that type I IFN signalling plays an important role in activation 
of Th1 effector responses during RV infection, though some mechanisms are likely to be 
mediated indirectly via IL-15 signalling. 
 
7.7. Deficient IFN-γ Responses & Associated Expression of Th2 Mediators  
Immune reactions to virus infections are typically mediated by Th1 responses, and early IFN-
γ production helps drive Th1 polarisation. Responses to RV infection in asthmatics is 
characterised by deficient IFN-γ production and augmented Th2 responses (increased BAL IL-
4, IL-5 and IL-13 levels), which are associated with more severe RV-mediated disease, virus 
load and asthma exacerbation severity [27]. IFN-γ is primarily produced by macrophages and 
NK cells in the innate response and by CD4+ and CD8+ T cells in the subsequent adaptive 
immune response. In vivo infection studies with measles, MCMV, vaccinia virus and West 
Nile Virus illustrate the necessity of IFN-γ production for effective antiviral defence, and 
deficient IFN-γ responses in these models is associated with increased susceptibility to 
infection and death [230, 323-326]. These studies indicate the importance of IFN-γ 
production to mediate a successful antiviral immune response, and deficiency is associated 
with pathogenic outcomes.  
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We have shown IFN-γ production early after RV infection, which was dependant on RV-
induced IL-15. During RV infection in mice, CD4+ and CD8+ T cells accumulate in the airway 
and lungs after 48h, therefore we suggest that NK cells are the dominant source of IFN-γ 
early after infection (prior to 48h). However, in the absence of upregulated IL-15 and thus 
IFN-γ production during RV infection in IL-15Rα ko and IFNAR1 ko mice, we observed 
increased expression of Th2-associated mediators TARC/CCL17, MDC/CCL22, IL-4, IL-5 and 
IL-13 in the lungs.  
 
TARC and MDC are Th2 cell attracting chemokines that bind chemokine receptor CCR4 highly 
expressed on Th2 cells. Recruitment of Th1 cells to inflammatory sites is mediated via 
predominant expression of CXCR3 and CCR5 on lymphocytes [327]. TARC and MDC are 
pivotal for development of Th2-dominated allergic disorders such as asthma and allergic 
rhinitis [328], via mediating recruitment of Th2 cells. Increased levels of TARC and MDC are 
expressed by the bronchial epithelium of asthmatics and by naïve T cells from asthmatic 
patients compared to healthy controls [258, 329]. Expression is also higher in Th2 compared 
to Th1 cell lines [258]. In a murine model of asthma, Kawasaki et al. [330] demonstrated 
blockade of TARC resulting in diminished AHR, reduced airway eosinophilia, CD4+ T cell 
infiltration and BAL Th2 cytokine levels, thus strongly implicating TARC in mediating Th2-
assocaited responses; similar results were observed upon neutralisation of MDC [331]. Other 
studies in mouse asthma models have reported reduced allergic airways inflammation 
following CCR4 blockade [332].  
 
Although they promote Th2 responses, expression of TARC and MDC were observed during 
RV infection in wild type mice that primarily exhibit a Th1 response. Others have also found 
expression of these chemokines during Th1 inflammatory responses, such as observed in 
atheroschlerotic and Crohn’s disease lesions [333, 334]. In contrast, it would be interesting 
to measure levels of Mig/CXCL9 (monokine induced by IFN-γ), important for enhancing 
recruitment and activation of Th1 cells, in our models of RV infection to further clarify the 
Th1/Th2 balance in the absence of IL-15 and type I IFN signalling. During RV infection, we 
suggest that absence of IFN-γ – the dominant Th1 polarising signal, likely generated by NK 
cells early after infection – permits Th2 responses to develop, facilitated by increased 
expression of TARC and MDC and possibly via activation of Th2 cytokine producing nuocytes 
(innate helper type 2 cells). This is in association with the well known mechanisms of 
reciprocally regulated Th1 and Th2 responses.  
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Increased expression of IL-4, IL-5 and IL-13 in the lungs, not normally associated with virus 
infections, suggests the accumulation of Th2 cells and/or activation of nuocytes in response 
to RV infection in the absence of an NK cell and IFN-γ response. Our data strongly 
complements observations by Kaiko et al. [335] whom demonstrated an RSV-induced Th2 
response to primary infection. They found that depletion of NK cells abrogated the primary 
source of IFN-γ early after RSV infection, which in turn resulted in upregulation of Th2 
cytokines, eosinophil infiltration and increased mucous production – hallmark features of 
allergic inflammation. IL-25 promotes development of Th2 responses in models of allergic 
asthma and helminth worm infections [189, 336-339] however, Kaiko et al. [335] were the 
first to demonstrate IL-25 mediated induction of virus-specific Th2 cells; they showed 
suppression of early IFN-γ production by epithelial-derived IL-25. Depleting NK cells resulting 
in reduced IFN-γ levels during RSV infection enhanced IL-25 production and lung Th2 
cytokine gene expression. Although we did not specifically prove NK cells as the early main 
source of IFN-γ after RV infection, deficiency of IFN-γ production associated with absent 
activated NK cells in our models of deficient IL-15 and type I IFN signalling indicates this; 
although deficient CD8+ T cell responses, which normally contribute to IFN-γ production, 
were also observed in these models, Kaiko et al. [335] showed that depletion of CD8+ T cells 
prior to RSV infection did not result in a Th2 response. Therefore, it is likely that NK cell 
produced IFN-γ-mediated regulation of IL-25 expression in the lungs also occurs during RV 
infection, as evident by the observed Th2 responses in the absence of activated NK cell 
responses observed in our studies.  
 
Clinical observations that RV and RSV infections during early life are linked to a greater risk 
of development of childhood asthma [340-343], and that defects in NK cell responses result 
in more severe RSV bronchiolitis [267-269], we suggest the above discussed mechanisms 
play a role in development of allergic asthma. Kaiko et al. [335] also demonstrated a casual 
relationship between deficient NK cell/IFN-γ responses during RSV infection and 
development of a Th2 response to an innocuous antigen during concomitant exposure, 
possibly via a mechanism of ‘collateral priming’. Why allergic sensitization rather than 
tolerance occurs to innocuous proteins early in life are unclear however, these data suggest 
that a Th2 polarised environment in the airway during virus infection observed with a 
deficient IFN-γ response, may be a possible mechanism for development of allergic 
sensitisation. In agreement, our data suggests that imbalances between Th1 and Th2 
responses during RV infection, via deficient IL-15 and/or type I IFN signalling and thus NK cell 
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activation and IFN-γ production, could possibly contribute to development of allergic asthma 
in early life. Our data also identify a potential mechanism for RV-induced asthma 
exacerbations. A number of studies have identified a deficiency in antiviral IFN production in 
asthma during RV infections [108, 109]. This could lead to deficient IL-15 production, NK cell 
activation and IFN-γ expression, which in turn could contribute to the increased Th2-driven 
allergic inflammation observed in the asthmatic lung. Figure 7.1 illustrates the 
interpretation/conclusions of our results on the role of IL-15 during RV infections in non-
allergic airways. 
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Figure 7.1 Role of IL-15 during RV infections. 
In response to RV infection, airway epithelial cells produce IFN-β which acts in an autocrine and 
paracrine fashion upon signalling via the type I IFN receptor complex on surrounding epithelial cells, 
neutrophils, DCs, and macrophages. Type I IFN stimulation of these cells induces upregulation of IL-15 
production and trans-presentation (surface expression of IL-15/IL-15Rα complexes). Trans-
presentation of IL-15 to resting NK cells results in their activation, which includes upregulation of the 
early activation marker CD69, GranzymeB and IFN-γ production. IL-15 signalling can also promote 
chemotaxis of NK cells into the airways and lungs, and stimulate proliferation and promote survival of 
NK cells, resulting in their accumulation after RV infection. NK cells are important producers of early 
IFN-γ after infection, key for driving the development of appropriate Th1 antiviral immune responses 
necessary for effective viral clearance, including Th1 priming of macrohpages and DCs, which in turn 
prime Th1 CD4+ T cells and Tc1 CD8+ T cells. In conditions of deficient IL-15 signalling, the NK cell 
response is impaired resulting in deficient IFN-γ production, which permits development of Th2 
responses that are not effective for antiviral defence resulting in increased lung viral loads.  
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7.8. RV-Induced IL-15 and the NK Cell Response in Allergic Airways 
Airway inflammation plays a central role in the immunopathology of asthma and is mediated 
by leukocyte infiltration, increased production of mucus and proinflammatory mediators, 
epithelial damage and airway remodelling processes. The cellular infiltrate of asthmatic 
airways is comprised of eosinophils, mast cells, basophils and importantly Th2 cytokine 
expressing T cells; enhanced neutrophilia is detected during respiratory virus infections, and 
in mice the degree of cellular infiltration correlates with AHR [81, 344, 345]. Asthma 
exacerbations are a major cause of asthma morbidity, mortality and high health care costs. 
Approximately two thirds of asthma exacerbations are associated with RV infections 
however, the mechanisms underlying this relationship are poorly understood. Having shown 
that deficient NK cell responses lead to enhanced RV-induced Th2 gene expression, we next 
investigated the relationship between RV infection and allergic airways inflammation to 
assess IL-15 expression and the NK cell response within allergic airways to model RV-induced 
asthma exacerbations [255].  
 
RV infection in allergic mice challenged with OVA (RV-OVA) resulted in enhanced airway 
neutrophilia, increased expression Th2 cytokines and greater AHR to increasing doses of 
methacholine compared to non-allergic mice (RV-PBS) and allergic mice infected with UV-
RV-1B (UV-OVA), confirming features of the model published by Bartlett et al. [255]. In RV-
OVA treated mice, we observed dramatically enhanced IL-15 expression at day 1 after 
infection, which was associated with a very large increase in number of activated IFN-γ and 
GranzymeB expressing NK cells in the airway and lungs also at day 1; both responses were 
much greater than in UV-OVA and RV-PBS treated mice. It is interesting that allergen alone 
induces NK cell responses, and BAL NK cells from UV-OVA treated mice express CD69 and 
GranzymeB, whereas RV-PBS treated mice exhibit IFN-γ producing NK cells.  
 
These results are in contrast to our hypothesis, in which we postulated deficient 
upregulation of IL-15 and thus impaired NK cell responses to RV infection in allergic airways, 
based on the following evidence from human studies. Deficient upregulation of IL-15 at day 
4 after experimental RV infection in asthmatics compared to non-asthmatics was observed 
in bronchial biopsies stained by IHC (data not published – bronchial biopsies obtained from 
Message et al. [27] study). In addition, Laza-Stanca et al. [256] demonstrated deficient IL-15 
expression in asthmatic BAL macrophages infected with RV ex vivo and lower levels of IL-15 
protein in the BAL fluid of asthmatics at baseline compared to non-asthmatics, and both 
results inversely correlated with AHR, virus load and disease severity during subsequent 
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experimental RV infection in vivo. The human data indicates that similar to IFNs, IL-15 
induction during RV infection is deficient in asthma. Furthermore, the previously discussed 
trend between NK cell impairment and severity of RSV-induced bronchiolitis in infants 
suggests that the degree of severity of RV-induced asthma exacerbations may be linked to a 
spectrum of deficient IFN-β, IL-15 and NK cell responses, all of which we have demonstrated 
to be interlinked.  
 
However, a comparative study of IL-15 expression in inflammatory pulmonary diseases by 
Muro et al. [346] demonstrated, by in situ hybridisation and immunohistochemistry using 
bronchial biopsies, no difference in the levels of IL-15 between asthmatics and non-
asthmatics. Much higher levels of IL-15 expression in bronchial biopsies of subjects with 
sarcoidosis and tuberculosis were observed, which are primarily Th1 chronic inflammatory 
diseases, and phenotyping of the IL-15-immunoreactive cells revealed the majority of cells to 
be neutrophils followed by macrophages. Therefore, we suggest that previous human 
studies demonstrating reduced or deficient IL-15 expression described above in asthma was 
due to the removal of many IL-15 expressing cells by method of BAL, and detection of 
soluble IL-15 in BAL fluid may not reflect the true situation as the majority if not all of IL-15 
protein would have been cell-associated. Deficient expression observed in bronchial biopsies 
at day 4 after infection in asthmatics mentioned above, may be misleading as an 
exacerbated peak of expression in the airway might have occurred earlier after infection in 
asthmatics, as seen in our mouse model.  
 
As Muro et al. [346] demonstrated neutrophils to be a significant population of IL-15 positive 
cells in Th1 pulmonary inflammatory diseases, we suggest that the exacerbated neutrophilia 
observed at day 1 after infection in RV-OVA compared to RV-PBS treated mice in our study 
contributes to the much higher levels of IL-15 observed in the airway, which in turn 
mediated the significantly larger influx of activated NK cells; this is consistent with increased 
IL-15 gene expression in lung tissue and BAL cells, and IL-15 protein in lung tissue found in 
RV-OVA treated mice. The dynamics of the NK cell response observed mirrors that of the 
neutrophil response, suggesting a strong association between the two, and previous studies 
have demonstrated cross-talk between neutrophils and NK cells resulting in reciprocal 
regulation of their functions [347]. Increased IL-15 expression in the lung tissue of RV-OVA 
compared to RV-PBS treated mice could also have contributed to NK cell response.  
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The increased virus load in RV-OVA compared to RV-PBS treated mice at day 1 after 
infection is in agreement with the increased virus replication detected during ex vivo RV 
infection of asthmatic compared to non-asthmatic bronchial epithelial cells [108], and 
increased disease severity (reduced lung function, increased symptom score) and higher 
virus loads in asthmatics experimentally infected with RV [27, 109]. This suggests that 
deficient innate responses, likely to arise from deficient antiviral responses in asthmatic 
airway epithelial cells, that control early virus replication exists in allergic asthmatic lungs as 
previously implied by Wark et al. [108]. However, detection of enhanced IL-15 expression 
and NK cell responses early after infection in allergic mice does not support this, and may be 
a discrepancy between mouse and human models, although these responses are yet to be 
characterised at early time points in humans. Despite increased virus replication in allergic 
mice at day 1 after infection, the virus load was driven down very quickly by day 2, which 
might at least in part result from enhanced NK cell responses that may act to limit virus 
replication/infection in mice via killing of virally infected cells and increased production of 
early IFN-γ. The quick decline in virus load in RV-OVA treated mice correlates with the swift 
resolution of the NK cell response, but we have no solid evidence proving NK cells to be 
important for virus clearance in this mouse model. It is also unknown if NK cell responses are 
deficient in human RV-induced asthma exacerbations. 
  
In contrast, NK cells could play a role in mediating increased AHR in RV-OVA treated mice by 
significantly contributing to enhanced cellular inflammation. Impairment of lung function 
and increased AHR in experimentally infected asthmatics compared to non-asthmatics was 
associated with increased cellular infiltration, primarily mediated by significant eosinophil 
and neutrophil recruitment to the airway [27]. As induction of IL-8/CXCL8, a potent 
neutrophil chemoattractant, is induced by IL-15 in T cells and monocytes [148, 302], it is 
logical to suggest that the increased expression of IL-15 in RV-OVA treated mice might 
contribute to the enhanced neutrophilia detected in these mice – another potential 
mechanism by which IL-15 could potentiate airway inflammation during RV-induced asthma 
exacerbations. 
 
Despite increased IFN-γ expression owing to the large activated NK cell response in RV-OVA 
treated mice, we observed enhanced expression of Th2 cytokines IL-4, IL-5 and IL-13 
compared to UV-OVA treated mice. This data is in contrast to that described by Kaiko et al. 
[335] of IFN-γ production suppressing Th2 responses. Although there is an NK cell-mediated 
Th1 signal, we suggest it is not great enough to suppress the allergen induced Th2 signal. 
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Whilst RV infection induces responses that could suppress Th2 pathways, RV also induces 
expression of many pro-Th2 molecules including CCL17/TARC, CCL22/MDC, IL-25 and STAT-6 
(unpublished data). Thus, the net effect of RV infection with allergen challenge is to 
exacerbate Th2 responses. We would then hypothesise that depletion of NK cells in RV-OVA 
treated mice would increase the exacerbation phenotype. It is also likely that a pre-existing 
allergic environment prior to virus infection outweighed the virus-induced Th2 suppressive 
effects of IFN-γ in our model. In humans, deficient IFN-γ and augmented IL-4, IL-5 and IL-13 
responses were detected during experimental RV infection in asthmatics compared to non-
asthmatics [27], though NK cell data to complement these findings are lacking. 
 
Whilst the majority of NK cells in lung and BAL expressed IFN-γ following allergen challenge 
and RV infection (RV-OVA), a small proportion instead expressed IL-4. To our knowledge, we 
show for the first time the appearance of IL-4 expressing NK cells in the airway and lungs 
after RV infection in an asthma model. These IL-4 expressing NK cells may potentially 
contribute to the enhanced IL-4 expression detected in these mice, further potentiating the 
allergic Th2 responses that contribute to increased AHR. Walker et al. [348] and Korsegren et 
al. [349] have also demonstrated contribution of NK cells to Th2 inflammation in mouse 
models. Walker et al. [348] showed NK cells produce IL-5, which significantly contributed to 
eosinophil infiltration in a mouse model of allergic inflammation using ragweed antigen. This 
lead to the identification of NK1 and NK2 cells [350, 351]. Increased NK2 cells have been 
observed in PBMCs from asthmatic subjects [351]. Thus, our data in conjunction with other 
studies suggests that NK cells could contribute to the augmentation of Th2 responses in vivo 
during RV infections in asthmatics, and further work into this mechanism would be very 
interesting.  
 
In this study, we demonstrated exacerbated IL-15 and NK cell responses after RV infection in 
mice with allergic airways. This is in contrast to the previously reported deficient IL-15 
responses observed in asthmatics and asthmatic cells infected ex vivo. Thus, more careful 
investigation of these responses, particularly in detection of cell-associated IL-15 rather than 
soluble IL-15, is necessary in human models of RV-induced asthma exacerbations. It is likely 
that increasing the ratio of NK1:NK2 would be therapeutically useful. The therapeutic 
potential of IL-15 to boost NK cell responses in asthmatics during RV infection to drive down 
virus load and help reduce the longevity of infection or increase IFN-γ production to 
suppress allergic inflammation exists; this potential can only be fully realised after carefully 
analysing the NK cell responses in human models. The observation of deficient IFN-β 
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responses in asthmatic cells has prompted development of inhaled IFN-β as therapy to 
prevent/treat exacerbations. However, as IL-15 is induced by IFN-β and promotes beneficial 
antiviral immune responses that help reduce virus load, IL-15 may serve as a more specific 
therapy for RV-induced asthma exacerbations, whilst avoiding potentially pathological side 
effects induced by the more global regulator of antiviral defence. From our mouse model of 
RV-induced asthma exacerbations it is unclear if the exacerbated IL-15 and NK cell responses 
are beneficial or contribute to immune-mediated pathology thus, further work blocking 
airway/lung IL-15 or depleting NK cells in this model would allow us to address this question. 
In addition, further studies characterising IL-15 production and the NK cell response in 
human models will provide more insight into the therapeutic potential of IL-15.  
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7.9. Summary of Conclusions 
 
 RV infection in mice induces IL-15 and IL-15Rα upregulation in lung tissue (primarily 
via epithelial cells) and BAL cells.  
 RV-induced IL-15 depends on type I IFN signalling, as demonstrated by the absence 
of induction in IFNAR1 ko mice. 
 RV infection results in the recruitment/expansion and activation (as determined by 
CD69, IFN-γ and GranzymeB expression) of NK cells in both the airway and lung 
tissue.  
 RV-mediated NK cell responses require pulmonary IL-15 signalling in mice, as 
demonstrated by the deficient NK cell responses in mice treated with IL-15 
neutralising antibody. 
 Absence of both RV-induced IL-15 upregulation and NK cell responses (observed in 
IFNAR1 ko and IL-15Rα ko mice) is associated with an increase in virus load, 
demonstrating the importance of these responses for control of early virus 
replication/infection. 
 Type I IFN and IL-15 signalling are also important for the recruitment/expansion and 
activation of CD8+ T cells during RV infection in mice. 
 IL-15 signalling is not important for CD4+ T cell response during RV infection in mice.  
 NK cell responses, potentially via IFN-γ production, are important negative 
regulators of Th2 immunity to RV infection.  
 RV-induced IL-15 and the associated NK cell responses in lung and BAL are 
significantly increased by RV infection in mice with exacerbated allergic airways 
inflammation.  
 The majority of accumulating NK cells express IFN-γ however, IL-4 expressing NK 
cells also arise in the airway and lungs in response to RV infection in mice with 
allergic airways inflammation, suggesting that a Th2 environment can polarise Th1 
innate components of the antiviral pathway, further potentiating allergic 
inflammation. 
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7.10. Future Work 
7.10.1. The Role of IL-15 and NK cells in RV Replication In Vivo 
Our BALB/c mouse model of RV infection is a good representation of human disease, as 
similar responses including airway neutrophilia and expression of Th1 proinflammatory 
cytokines are observed. This mouse model also demonstrates lower airway 
infection/replication [255], shown with cells of the lower airways in vitro and via detection 
of virus in the lower airways of asthmatics. It is clear that RV-1B does undergo some 
replication in the mouse. We have previously demonstrated RV replication (via detection of 
negative sense genomic RNA) in the mouse via in situ hybridisation in lung sections [255]. 
Here we report increased levels of viral RNA in IL-15Rα ko and IFNAR1 ko compared to wild 
type mice. However, it is apparent that the replicative ability of RV in this model is limited as 
there is not a significant increase in infectious virus in wild type mice. This makes it difficult 
to interpret results as the decline in virus load may be due to the poor replicative ability 
and/or the immune response in question. To better investigate the role of IL-15-induced NK 
cell activation for limiting RV replication/infection, it would be beneficial to try different 
serotypes other than RV-1B that may demonstrate improved replication that lasts for 
several days.  
 
7.10.2. Cellular Sources of IL-15 Protein in the Lungs 
Problems detecting IL-15 protein initially hampered efforts to investigate this specific 
pathway during RV infection. Having developed a method to confirm increased IL-15 protein 
levels in whole lung homogenate during RV infection, it would be beneficial to develop more 
sensitive methods to define the specific cellular sources of IL-15 trans-presentation in our 
mouse models of RV infection. Flow cytometry would be a useful tool to do so, allowing us 
to analyse which cells are particularly important for activation of NK cell responses during RV 
infection; a panel including antibodies to detect CD11b, CD11c, F4/80, Ly6, and IL-15 
(surface and intracellular) would facilitate identification of IL-15 expression by DCs, 
macrophages and neutrophils. As neutrophils are reported to express IL-15 in Th1 
inflammatory lung diseases [346], it may be likely that the dominant neutrophilic response 
in the airway early after RV infection is a significant source of IL-15, and cross-talk between 
neutrophils and NK cells might be critical for efficient antiviral responses.  
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7.10.3. Importance of IL-12 Expression for RV-induced NK Cell Responses 
As IL-12 is an important regulator of NK cells in many but not all viral infections, it would be 
useful to analyse expression of IL-12 in response to RV infection in mice, to confidently 
attribute the observed NK responses to IL-15 signalling. In particular, measure IL-12 
expression in our RV infection model with IL-15 neutralising antibody, to prove that the 
deficient NK cell responses were due to blocking IL-15 and not deficient IL-12 expression in 
this model.  
 
7.10.4. Role of IL-25 in Mediating Th2 Responses to RV infection 
Analysis of IL-25 expression in RV infected IL-15Rα ko and IFNAR1 ko mice would enable us 
to tease out the mechanism of primary RV infection induced Th2 responses observed in 
these mice, which exhibited deficient NK cell/IFN-γ production – similar to the responses 
detected by Kaiko at el. [335] with RSV. In addition, analysis of nuocytes in these mice, which 
respond to IL-25 and secrete Th2 cytokines as an innate response, would be very interesting 
as expression of Th2 cytokines in these models occurred at very early time points. 
 
7.10.5. Intranasal Administration of rmIL-15 in IFNAR1 ko Mice During RV Infection 
Other experiments to compliment our data include exogenous administration of 
recombinant mouse IL-15 into the airway during RV infection in IFNAR1 ko mice. If 
supplementation of IL-15 recovers the deficient NK cell response, we would be able to 
conclude that type I IFN signalling is not directly required on NK cells during RV infection, 
and likely acts indirectly on accessory cells to induce upregulation of IL-15, which in turn 
mediates the NK cell response. If IL-15-mediated rescue of NK cell responses in IFNAR1 ko 
mice results in reduction of virus load compared to IFNAR1 ko mice without exogenously 
administered IL-15, we could conclude that IL-15-mediated NK cell responses are important 
for limiting early virus replication/infection in mice. This would warrant further investigation 
of the IL-15-NK cell pathway in human models of RV-induced asthma exacerbations, in which 
virus load and prolonged infections correlates with disease severity and are potentially 
linked to deficient antiviral (IFN) responses [108, 109].  
 
7.10.6. Importance of NK Cell Cytotoxic Activity During RV Infection  
Analysis of the cytotoxic potential of the accumulating NK cell populations during RV 
infection in our mouse models would be helpful to demonstrate increased functional activity 
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of these cells in our mouse models. This would be done by incubating purified NK cell 
populations recovered from lungs and BAL with chromium labelled NK cell susceptible YAC-1 
cells, and the level of chromium released into the supernatant due to lysis of YAC-1 cells by 
NK cells reflects the degree of NK cell cytoxicity. Alternatively, flow cytometry analysis of 
CD107a/LAMP-1 (lysosome-associated membrane protein) surface expression on NK cells 
would serve as a marker of cytotoxic activity. CD107a is present on the surface of NK cells 
after exocytosis of cytotoxic granules that mediate lysis of target cells.  
 
7.10.7. Role of IL-15 in the Mouse Model of RV-Induced Asthma Exacerbation 
Our study using a mouse model of RV-induced allergic inflammation demonstrated 
associations between IL-15 expression, the NK cell response, virus load and AHR thus, 
manipulation of this system is necessary to assign causative effects. We suggest that 
administration of IL-15 neutralising antibody during RV infection in mice with allergic airway 
inflammation will allow us to further analyse the role of enhanced IL-15 expression on the 
exacerbated NK cell response. If the NK cell response is impaired as a result of blocking IL-15, 
analysis of lung virus load would provide valuable information as to whether the 
exacerbated NK cell response is beneficial for antiviral defence or not, in which case does it 
significantly contribute to AHR. Based on the results from our primary RV infection mouse 
model with IL-15 neutralising antibody, we suggest that blocking IL-15 in the airway/lungs 
during RV infection in mice with allergic airway inflammation will prevent the exacerbated 
NK cell response, and as a consequence early IFN-γ expression will be impaired; this removes 
the suppressive effects of IFN-γ on Th2 responses, permitting levels of epithelial-derived IL-
25 to increase, further driving expression of Th2 cytokines in allergic mice and greatly 
enhancing Th2 inflammation in the lungs, significantly contributing to greater AHR. This 
would support the role of NK cells in regulation of Th2 responses.  
 
7.10.8. IL-15 Expression and NK Cell Responses to RV Infection in Asthmatics and Non-
Asthmatics 
In humans, the role of IL-15 and NK cells in RV-induced asthma exacerbations remains 
unclear. Therefore, further work to more carefully analyse expression of cell-associated IL-15 
in BAL cells and lung tissue is necessary early after experimental RV infection in asthmatics 
and healthy volunteers. Similarly, characterisation of the NK cell response in the airway 
(BAL) by flow cytometry would provide valuable detailed information about this response in 
RV infected asthmatics, though the choice of time points for analysis would need to be 
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carefully determined to ensure the peak of NK cell responses were measured. Taken 
together, the potential of IL-15 as a therapeutic agent to prevent/treat RV-induced asthma 
exacerbations rests on further in-depth analysis of the above responses in human models.  
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